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ABSTRACT 
Autophagy is a vital catabolic process involved in the degradation of cellular components, which 
plays an important role in cancer and neurodegenerative disorders. Due to their high complexity, 
the pathways regulating autophagy have not been fully elucidated. The development of specific 
autophagy modulators and the identification of their cellular targets can provide valuable insight 
into the regulation of this process and, ultimately, its role in disease.  
 Herein, a potent inhibitor of starvation-induced autophagy (IC50 = 520 ± 550 nM) was 
identified using a phenotypic screen. In a series of secondary assays, the compound was validated 
as an autophagy inhibitor. The structure–activity relationship for this compound class was derived 
from a synthesized compound collection of structural analogs and used for the preparation of a 
chemical probe for affinity-based proteomics ("pull-down"). Glutamate dehydrogenase (GDH) and 
calpain-1 were isolated by means of affinity-based proteomics but devalidated as targets of the 
inhibitor in various biophysical and biochemical assays. The ATP-gated ionotropic receptor P2X4 
and the Ragulator component LAMTOR5 were the most promising targets determined by thermal 
proteome profiling and are currently under evaluation.  
 
 Targets predicted using a computational approach based on chemical similarity included 5-
hydroxytryptamine (5-HT) receptors and multiple kinases—rapidly accelerated fibrosarcoma 
(RAF1) and related kinases, pyruvate kinase (PK), and abelson murine leukemia viral oncogene 
homolog 1 (ABL1). Whereas no modulating effect on the predicted kinases was observed, the 
autophagy inhibitor was a potent antagonist of the G-protein-coupled serotonin receptor 5-HT6 (IC50 
= 1 µM). However, as known antagonists of the receptor did not inhibit autophagy, 5-HT6 was 
considered an off-target. Given the strong antagonistic effect seen, G-protein-coupled receptors 
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need to be further evaluated as potential targets of the identified inhibitor. The successful target 
identification of this potent inhibitor could help deliver further understanding of the complex 
mechanisms that regulate autophagy.  
 III 
KURZZUSAMMENFASSUNG 
Autophagie ist ein lebensnotwendiger katabolischer Prozess, der am Abbau zellulärer 
Komponenten beteiligt ist und eine wichtige Rolle bei Krebs und neurodegenerativen Krankheiten 
spielt. Aufgrund der hohen Komplexität der Autophagie-regulierenden Signalwege konnten diese 
noch nicht vollständig entschlüsselt werden. Die Entwicklung spezifischer Autophagie-
Modulatoren und die Identifizierung ihrer zellulären Zielproteine können einen wertvollen Einblick 
in die Regulierung von Autophagie und letztendlich ihre Rolle in Krankheiten gewähren. 
 Im Rahmen dieser Arbeit wurde mittels phänotypischem Screening ein potenter Inhibitor 
von durch Aushungern induzierter Autophagie identifiziert (IC50 = 520 ± 550 nM). In einer Reihe 
sekundärer Assays wurde diese Verbindung als echter Autophagie-Inhibitor validiert. Die Struktur-
Aktivitätsbeziehung für diese Verbindungsklasse wurde aus einer hergestellten Substanzkollektion 
abgeleitet, anhand derer eine chemische Sonde synthetisiert wurde. Glutamatdehydrogenase (GDH) 
und Calpain-1 wurden durch Affinitätschromatographie isoliert, allerdings anschließend in 
verschiedenen biophysikalischen und biochemischen Assays als Zielproteine des Autophagie-
Inhibitors devalidiert. Mittels thermischem Proteomprofiling wurden der ATP-abhängige 
Ionenkanal P2X4 und die Ragulator-Komponente LAMTOR5 als vielversprechendste Zielproteine 
identifiziert und werden derzeit untersucht.  
 
 5-Hydroxytryptaminrezeptoren und mehrere Kinasen—rapidly accelerated fibrosarcoma 
(RAF1) und verwandte Kinasen, Pyruvatkinase (PK) und abelson murine leukemia viral oncogene 
homolog 1 (ABL1)—waren unter den Zielproteinen, die durch rechnergestützte Ansätze anhand 
von strukturellen Ähnlichkeiten vorausgesagt wurden. Während kein Effekt auf die PK beobachtet 
wurde, war der Autophagie-Inhibitor ein potenter Antagonist des G-Protein-gekoppelten 
 IV 
Serotoninrezeptors 5-HT6 (IC50 = 1 µM). Da allerdings bekannte Antagonisten dieses Rezeptors 
Autophagie nicht inhibierten, wurde 5-HT6 als „Off-Target“ bezeichnet. Angesichts des 
beobachteten starken antagonistischen Effekts, müssen G-Protein-gekoppelte Rezeptoren genauer 
als mögliche Zielproteine des identifizierten Inhibitors untersucht werden. Die erfolgreiche 
Identifizierung des Zielproteins dieses Inhibitors könnte dazu beitragen, weitere Einsicht in die 
komplexen Autophagie-regulierenden Mechanismen zu ermöglichen.
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1. PREFACE 
Almost a century ago, Spemann and Mangold discovered what proved to be the foundation for 
understanding cell communication: When they transplanted a blastopore lip from an amphibian 
gastrula into the opposite side of another embryo, the authors noticed that gastrulation was induced 
in the surrounding tissue of the host, leading to the formation of a Siamese twin.[1]  
 Today we know that cell behavior is strongly influenced by external stimuli, which not only 
allow intercellular communication, but also regulate numerous processes throughout the life of a 
cell, e.g. division, differentiation, homeostasis, and programmed death. Extracellular signaling 
molecules (“ligands”) are, together with proteins and phospholipids, part of complex networks 
called signal transduction pathways, which are orchestrated in a tightly regulated fashion to 
maintain cellular function.  
 A signal transduction cascade generally starts with binding of an extracellular ligand to a 
transmembrane receptor. The bound receptor then triggers a series of activation events, resulting in 
the specific modulation of gene transcription and, ultimately, cellular response.[2] To date, numerous 
signaling pathways have been discovered, of which only few govern the vast majority of cellular 
processes.[3] Indeed, the induction or inhibition of such processes is also highly influenced by the 
cell competence, signal intensity, and cross-regulation between different pathways.[4]  
 Defects in cell signaling are responsible for various types of diseases, including 
immunodeficiency, neurodegenerative disorders, diabetes, and cancer.[5-6] The latter is a good 
example of how aberrant signaling pathways can have a major impact on health. A synergism of 
often more than one oncogene with abnormal expression causes uncontrolled proliferation, 
inhibition of tumor suppressor genes, and metastasis regardless of the nutrient levels or oxygen 
supply in the cell.  
 Recent work has shown that metabolic perturbations are a frequent cause for numerous 
human diseases.[7] Extensive research in this area has provided a large number of therapeutic targets 
and valuable insight into metabolic signaling pathways.[8] However, the complexity of cellular 
processes makes their study a significant challenge, posing many riddles, which can only be 
deciphered through an interdisciplinary approach. 
 6 
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2. INTRODUCTION 
Cell metabolism encompasses all the processes by which energy is converted inside a cell and is 
therefore involved in numerous key cellular functions. This strictly regulated equilibrium of 
constant synthesis and degradation of material allows for the proper functioning of cells.  
Before the 1950s, it was believed that proteins were stable in vivo and did not give catabolism the 
importance it has nowadays.[9] The understanding of metabolism only began with the discovery of 
protein degradation in lysosomes by de Duve et al.[10] Shortly after, irregularly shaped, double 
membraned vacuoles filled with cytoplasm and organelles were observed,[11-12] which were 
subsequently transformed into lysosomal-like structures.[13] It became evident that these vacuoles 
served for the degradation of cellular components and were hence named autophagosomes, Greek 
for “self-eating bodies.”[14]  
 
2.1. Autophagy 
Autophagy is a eukaryotic cellular process that mediates the degradation of cytosolic components 
to maintain homeostasis. This dynamic process acts primarily as a highly conserved response to 
nutrient deprivation—i.e., starved cells induce autophagy as a recycling mechanism to temporarily 
compensate for the lack of extracellular nutrients. Furthermore, autophagy is involved in the 
clearance of long-lived or unnecessary proteins and organelles.[15] For example, autophagy is 
responsible for the elimination of paternal mitochondria after fertilization.[15] The degradation of 
dysfunctional mitochondria is another important function of this process, as it prevents the release 
of reactive oxygen species and other toxic proteins to the cytosol.[15] The clearance of protein 
aggregates is also crucial to protect cells from toxic cellular waste. Apart from its role as a response 
to cellular stress, basal levels of autophagy are necessary for maintaining cellular homeostasis.[16] 
Autophagy is therefore a vital catabolic process in the development, differentiation, and survival of 
cells.[15, 17-19]  
 Three types of autophagy have been identified to date: chaperone-mediated autophagy, 
microautophagy, and macroautophagy. The former delivers soluble proteins containing a specific 
pentapeptide motif (i.e., KFERQ) to the lysosome using cytosolic chaperones.[20-22] Microautophagy 
refers to the direct engulfment of cytosolic components by invagination of lysosomal 
membranes.[21] The best characterized form of autophagy is macroautophagy, which, as 
microautophagy, involves the removal of cytosolic components. The difference lies in the 
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sequestration mode: in macroautophagy, double-membraned vesicles called autophagosomes are 
responsible for engulfing large cytosolic portions.[22] Macroautophagy and microautophagy can be 
both selective or non-selective. Selective modes are triggered by the recognition of autophagy 
substrates by specific receptors. One example is mitophagy, the degradation of unnecessary and 
damaged mitochondria.[22] Non-selective autophagy, on the other hand, is mainly responsible for 
the recycling of biomolecules for the production of nutrients and energy. Given that it is the main 
route to the lysosome and therefore the most prominent form of autophagy, this work focuses on 
the study of non-selective macroautophagy (hereafter autophagy).[9] 
 
2.1.1. Autophagy Process and Autophagic Machinery 
Autophagy starts with the formation of the autophagophore (or "pre-autophagosomal structures" in 
yeast), a double-membraned structure responsible for the sequestration of autophagic cargo. 
Autophagophores form in mammals predominantly at the contact sites between mitochondria and 
the endoplasmatic reticulum (ER).[22] However, the exact lipid source for membrane formation of 
autophagophores remains unclear. Autophagosomes are built upon the elongation and closure of 
autophagophores. These transient organelles have a diameter of approximately 1 µm and no 
hydrolytic activity.[22] For their maturation, autophagosomes are transported to the lysosomes along 
microtubules by dynein motor proteins. Once at the lysosome site, they fuse to endosomes and later 
lysosomes, generating autolysosomes, where the autophagic cargo is finally degraded (Figure 1).[21] 
This process requires a complex machinery acting in a coordinated fashion at each stage.  
 
Figure 1. Formation, elongation, and maturation of autophagosomes. Adaptation from Yang and Klionsky.[18]  
 
The identification of yeast autophagy-related (ATGs) genes in the early 1990s by Ohsumi 
and coworkers provided a breakthrough in the understanding of the molecular basis of autophagy. 
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With the discovery of the first mammalian ATG genes by Mizushima et al. it was demonstrated 
that this process is highly conserved from humans to yeast.[23]  
In mammals, the autophagic machinery comprises over 20 so-called autophagy-related 
(ATG) proteins, responsible for autophagosome formation and maturation. They can be divided in 
three functional units: the unc-51 like autophagy activating kinase 1 (ULK1) and its effectors and 
two ubiquitin-like conjugating systems (Figure 2).[24] ULK1 is the mammalian homolog of the yeast 
Atg1 protein and the most upstream ATG kinase. It activates class III phosphoinositide 3-kinase 
(PI3K, also named vacuolar protein sorting 34 [VPS34]) complex, which is essential in every step 
of autophagic flux. For example, VPS34 mediates the recruitment of the autophagic machinery to 
the growing autophagophore.  
The key protein of the first conjugating system is light chain 3 (LC3), the mammalian 
homolog of Atg8, which is responsible for the autophagophore elongation and closure. The cysteine 
protease ATG4 cleaves a C-terminal sequence of pro-LC3 to form LC3-I, which is then activated 
by the ubiquitin-like conjugating enzyme (E1-like) ATG7, and subsequently transferred to the E2-
like enzyme ATG3. LC3-I is then lipidated with phosphatidylethanolamine (PE) to form LC3-II, 
allowing its recruitment to the autophagophore. This last step is mediated by the ATG12 
conjugating system. ATG12 is activated by ATG7 and subsequently transferred to ATG10 to allow 
the formation of the ATG5–ATG12 conjugate. This conjugate forms a homodimer with ATG16L, 
which mediates the lipidation of LC3-I. Given the complexity of this process, upstream signaling 
is crucial for the regulation of the autophagic machinery at numerous stages. 
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Figure 2. Mechanism of the autophagic machinery. AMBRA = Activating molecule in BECN1-regulated 
autophagy protein 1; WIPI = WD repeat domain phosphoinositide-interacting protein; UVRAG = UV 
radiation resistance-associated gene protein; SH3GLB1 = endophilin-B1; GABARAP = Gamma-
aminobutyric acid receptor-associated protein. 
 
2.1.2. Regulation of Autophagy by Upstream Signaling  
Autophagosome formation is a multistep process, which is regulated by upstream signaling. Signal 
transduction can be triggered by nutrient levels, growth factors and amino acids. Though not yet 
fully elucidated, two main autophagy-regulating pathways have been discovered, referred to here 
as mammalian target of rapamycin (mTOR)-dependent pathway and phospholipase Cε (PLCε) 
pathway (Figure 3).[15] The mTOR-dependent pathway acts via class I PI3K, protein kinase B (PKB) 
and the mTOR complex 1 (mTORC1). The activation of mTORC1 blocks autophagy by inhibiting 
the components of autophagosome formation directly.[25] Consequently, inhibition of mTOR by 
rapamycin induces autophagy. This canonical pathway is sensitive to nutrient levels and can 
therefore be activated by withdrawal of amino acids or glucose. In the second pathway, elevated 
levels of cyclic AMP (cAMP) and Ca2+ inhibit autophagy by activating PLCε.[26] Additional 
regulators of autophagy are B cell lymphoma 2 (Bcl-2), which blocks autophagy by sequestering 
Beclin-1 from the Beclin-1/PI3K complex,[27] and transcription factor EB (TFEB), which induces 
autophagy upon dephosphorylation.[28]  
 Although several signaling pathways that regulate autophagy and their key players have 
been identified, these remain unclear. Numerous missing links within each pathway and lacking 
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information about the cross-talk between these urge the discovery of novel proteins involved in the 
regulation of this catabolic process. This knowledge can ultimately provide important information 
about the role of autophagy in disease and its potential in therapy. 
 
Figure 3. Representation of the two major pathways regulating autophagosome formation. Right: PLCε-
dependent pathway; left = mTOR-dependent pathway. ER = endoplasmatic reticulum; GPCR = G-protein 
coupled receptor; RTK = receptor tyrosine kinase; AC = adenylate cyclase; EPAC = exchange protein 
directly activated by cAMP; PIP2 = phosphatidylinositol 4,5-bisphosphate; IP3 = inositol 1,4,5-
trisphosphate; TSC = tuberous sclerosis; RHEB = Ras homolog enriched in brain; AMPK = 5’-AMP-
activated protein kinase. Adaptation from Rubinsztein et al.[15] 
 
2.1.3. Role of Autophagy in Disease  
Because of its important role in numerous cellular functions, altered levels of autophagy and genetic 
defects in the autophagic machinery have been linked to the development and onset of diseases, 
such as neurodegenerative disorders, cancer, and diabetes.[15, 29] For instance, physical exercise has 
been proven to induce autophagy and protect mice from diabetes.[30]  
Most late-onset neurodegenerative diseases can arise from toxic protein aggregates failing 
to be cleared in neurons. For example, aggregates of β-amyloid and mutant forms of huntingtin and 
α-synuclein are responsible for Alzheimer’s, Huntington’s, and Parkinson’s disease, respectively. 
Recent studies show that the clearance of these aggregates is enhanced when autophagy is induced. 
Furthermore, their accumulation is observed at low levels of autophagy.[31-33] Consistent with these 
findings, an impairment of autophagosome formation and degradation has been reported in 
Alzheimer’s disease.[15, 34]  
Evidence suggests a dual role of autophagy in cancer, depending on the stage of 
tumorigenesis.[35] The increased clearance of toxic cellular waste acts as a preventive mechanism 
against cancer. E.g., tumor suppressor genes such as tuberous sclerosis (TSC) 1 and 2 stimulate 
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autophagy. Moreover, the mitophagy-mediated clearance of damaged mitochondria prevents ROS 
generation, which has a known tumorigenic potential. On the other hand, autophagy can promote 
tumor cell survival by providing these with energy despite the nutrient-limiting conditions of tumor 
microenvironments.[15, 35] Consequently, whereas autophagy upregulation might serve as a 
preventive strategy against cancer, autophagy inhibition is a potential approach in cancer therapy.  
 
2.1.4. Small-Molecule Autophagy Modulators 
Of the numerous autophagy modulators identified to date, several have entered clinical trials (Table 
1). The mTOR-inhibitor rapamycin is widely used for specific induction of autophagy and has been 
shown to reduce amyloid-β levels.[36] Further examples of autophagy activators are lithium and 
metformin, which are currently in phase II clinical trials for Alzheimer’s disease.[29] Inhibitors of 
autophagy include bafilomycin A1 and the unselective PI3K inhibitor Wortmannin.[15] Due to their 
off-target effects and high cytotoxicity, these compounds are only utilized in research. Only 
recently, selective inhibitors of the mTOR upstream kinases AMPK, ULK1, and VPS34 were 
developed, which, as expected, inhibit autophagy. Other important tools for the modulation of 
autophagy are the autophagy flux inhibitor chloroquine and its derivative hydroxychloroquine. 
These quinoline-derived modulators act by inhibiting autophagosome–lysosome fusion, thereby 
leading to an accumulation of autophagosomes. Surprisingly, chloroquine and hydroxychloroquine 
are the only autophagy inhibitors in advanced clinical trials, which highlights the need for new 
modulators of this process. 
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Table 1. Examples of autophagy modulators in research and clinics.[29, 37-38] 
 Modulator Structure Mode of Action Clinics/Model 
A
ct
iv
at
or
s 
Rapamycin 
 
inhibits of 
mTOR 
Alzheimer’s 
disease, animal 
models 
Lithium Li+ reduces IP3 levels  
Alzheimer’s 
disease, phase II 
Metformin 
 
upregulates 
AMPK 
Alzheimer’s 
disease, phase II 
Carbamazepine 
 
reduces IP3 
levels 
α1-antitrypsin 
deficiency liver 
cirrhosis, phase 
II 
Trehalose 
 
unknown 
Huntington’s 
disease, animal 
models 
In
hi
bi
to
rs
 
(Hydroxy)chloroquinea 
 
inhibits 
autophagosome–
lysosome fusion 
various cancers 
Bafilomycin A1 
 
inhibits 
vATPase and 
autophagosome–
lysosome fusion 
experimental 
agent 
Dorsomorphin 
 
inhibits AMPK in preclinical evaluation 
SAR405 
 
inhibits class III 
PI3K 
in preclinical 
evaluation 
SBI-0206965 
 
Inhibits ULK1 in preclinical evaluation 
Spautin 
 
lowers beclin-1 
levels 
experimental 
agent 
 Wortmannin 
 
inhibits PI3K experimental agent 
a) R = H: chloroquine; R = OH: hydroxychloroquine. 
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 As many questions remain open regarding the function of autophagy in disease, there is a 
strong need for a deeper understanding of the mechanisms underlying this cellular process. 
Therefore, the development of novel autophagy small-molecule activators and inhibitors is of great 
importance in areas beyond therapeutic research. For example, the specific modulation of 
autophagy at the various stages of the process enables the detailed study of its function in different 
cellular environments. Furthermore, identification of the cellular targets of modulators in an 
approach called forward chemical genetics enables the discovery of new autophagy regulators and 
can ultimately reveal new targets for drug discovery. 
 
2.2. Chemical Genetics  
Classical and chemical genetics are biological tools used in the study of the function of a signaling 
pathway, protein, or gene. In classical genetics, genes that play a role in a specific pathway can be 
identified and their function determined by screening mutant libraries of an organism and evaluating 
their phenotype. Its chemical-biological equivalent uses libraries of small molecules to perturb the 
function of a protein.[39] Unlike in the study of genetic effects, modulation by small molecules 
allows a temporal and much more rapid readout, as compounds can trigger a phenotypic response 
within seconds. In addition, the extent of the phenotypic response can be fine-tuned by varying the 
concentration of the compound utilized, which is not feasible when conducting a genetic 
experiment.[40-41] Further advantages of the chemical approach include the ability of small 
molecules to disrupt protein-protein interactions and perturb a single function of a multifunctional 
protein.[42] The major limitation of chemical genetics is that small molecules are often not specific 
for one single protein. Moreover, whereas every gene can be manipulated, selective modulators are 
available only for a fraction of all proteins.[39] 
 Similarly to classical genetics, the chemical approach distinguishes between forward and 
reverse chemical genetics. The goal in forward chemical genetics (FCG) is to identify proteins that 
regulate a given cellular process. In reverse chemical genetics (RCG), the function of a protein is 
determined by identifying a selective small-molecule modulator of a protein and subsequently using 
this compound to analyze the triggered phenotypic response and hence understand the function of 
the protein (Figure 4).[41, 43]  
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Figure 4. Difference between forward and reverse classical and chemical genetics. Adaptation from Lehar 
et al. [41] 
 
2.2.1. Target Identification by Forward Chemical Genetics 
The discovery of proteins involved in a signaling pathway can give great insight into important 
cellular processes and provide the basis for new drug discovery programs. To this end, the targets 
of small molecules with a desired phenotypic effect can be identified using FCG.  
 A typical FCG experiment starts with the screening of a compound library for the desired 
phenotypic response in cells or organisms. The use of libraries consisting of bioactive compounds 
with known targets, such as the library of pharmaceutically active compounds (LOPAC®), can 
significantly accelerate the identification of new regulators of a pathway. On the other hand, 
screening of unbiased libraries may lead to novel targets for which no specific modulators are 
known or that are poorly characterized.  
 Once a compound is identified that triggers the desired response, the hit is tested in 
orthogonal assays to discard the possibility of a false-positive. The validated hit compound is then 
optimized to obtain more potent modulators with enhanced properties. For this step, it is necessary 
to generate a compound collection of structurally derived analogs of the parent hit. The structural 
analogs are then tested in the initial phenotypic screen to obtain information about the structure–
activity relationship (SAR) of the compound class. The target of the small-molecule modulator can 
be identified by performing e.g. proteomics experiments or computational target prediction and 
subsequently validated in target engagement assays (Figure 5).  
Phenotype	of	interest
Random	
mutagenesis
Small	molecule	with	
unknown	target
Protein	of	interest
Specific	
mutant
Targeted	small	
molecule
Forward
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Figure 5. Workflow of forward chemical genetics for the target identification of a small-molecule that 
modulates a cellular process.  
 
i. Phenotypic Screening  
Common methods employed in phenotypic assays include cell viability, genetic engineering, and 
fluorescence-based techniques.[40, 44]  
 Viability screens with cancer vs. healthy cells allow the identification of compounds that 
are selectively toxic towards cancer cells. Most approaches assessing cell viability use reagents that 
are metabolized only in viable cells with an intact metabolism or protease activity to produce a 
fluorescent or colorimetric product.[45] 
 To investigate pathways that involve the activation of specific transcription factors, the 
sequence of an intracellular reporter that produces a measurable signal is fused to the promoter 
region of the gene of interest.[46] One example is the broadly applied luciferase-based phenotypic 
screen to study the Wnt/β-catenin signaling pathway. When this pathway is active, a cascade 
triggers the translocation of β-catenin into the nucleus, which then binds to T-cell factor/lymphoid 
enhancer factor (TCF/LEF) transcription factors, leading to the transcription of the target genes. To 
detect the activation of the pathway, a vector containing the TCF/LEF-binding promoter sequence 
fused to the firefly luciferase gene can be transfected into cells. Hence, activation of the Wnt 
signaling cascade leads to the transcription of luciferase, which catalyzes the reaction of luciferin 
to the fluorescent oxyluciferin.[47] Additional reporter proteins utilized are β-galactosidase and 
green fluorescent protein (GFP). The latter has been optimized to produce higher intensity emission 
upon excitation with blue light. This enhanced GFP (eGFP) allows, besides its use as a reporter 
protein, the localization of eGFP-tagged proteins in vivo and is hence a powerful tool in phenotypic 
screening.[48-49]  
 In addition to fluorescently tagged proteins, specific organelles or biomolecules can be 
visualized using selective cellular dyes. The readout of multiple parameters, e.g. cell morphology 
or multiple fluorescence signals can be performed by high-content screening (HCS). This technique 
has gained great importance over the past two decades and is nowadays a standard procedure for 
drug discovery, as it incorporates cellular imaging into a high-throughput strategies.[50] 
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ii. Proteomic Hit Identification Strategies 
The most challenging and time-consuming steps of an FCG project are the target identification and 
validation of a small-molecule. The human genome encodes around 20,000 proteins,[51] 600 
lipids,[52] and 10,000–20,000 carbohydrate epitopes for glycan-binding proteins,[53] all of which, 
including nucleic acids, could be the target of a small molecule.[40] Given this vast diversity and the 
distinct chemical properties of each small molecule present in a chemical library, no general method 
can be applied to the target identification of a compound hit. For instance, the identification of 
integral membrane proteins requires different techniques than the one of cytosolic proteins. 
Moreover, the chemical nature of a small molecule or natural product may not allow the 
modifications required for various proteomics experiments. Despite these limitations, the most 
widely applied target identification methodology is affinity-based chromatography, which has 
provided the cellular targets for numerous compounds over the past decades.[40]  
 
a) Affinity-Based Proteomics 
In a so-called “pull-down” experiment, the modulator is immobilized to a solid support and 
subsequently exposed to a cell lysate, thereby allowing binding to its target. Stringent washing 
removes non-specific binding, and the remaining bound proteins are analyzed by mass spectrometry 
(MS) (Figure 6)  
 
Figure 6. Principle of an affinity-based proteomics experiment (“pull-down”). R = resin; SMM = small-
molecule modulator. 
 
 For the immobilization to a solid support, a linker needs to be attached to the compound. 
To identify a site that allows modifications without compromising the activity of the parent 
compound, the information derived from the SAR study is necessary. Depending on its chemical 
nature, the compound can be attached to the linker directly, i.e. through a functional group already 
present in the molecule, or via a spacer bearing a reactive group, such as an amine, a carboxylic 
 18 
acid, or an alcohol. In addition to the active chemical probe, a negative control probe is required, 
which is derived from an inactive analog.  
 The use of a linker is essential, as it prevents steric hindrance between the target and the 
solid support. Furthermore, it can allow the compound to enter a potentially unexposed binding site 
of a protein. Depending on its composition, hydrophilic linkers can enhance the solubility of the 
small molecule and prevent non-specific binding to the target. Commonly used linkers are two- and 
three-unit polyethylene glycol (PEG)-based, as they meet all the above-mentioned criteria. Other 
linkers with enhanced properties include polyproline and tartaric acid linkers.[54-55] The pull-down 
probe can be immobilized to the beads either covalently or by affinity. For a covalent attachment, 
beads bearing activated groups, e.g. N-hydroxysuccinimide (NHS), are employed, which readily 
react with alcohols and amines. Affinity binding can be performed with the well-established 
biotin/streptavidin or a similar system.[40]  
 When bound to the matrix, the proteins can be eluted using an excess of unmodified 
compound. Alternatively, release of the bound proteins can be accomplished by denaturation with 
detergents (e.g. sodium dodecyl sulfate [SDS]). This method is utilized for gel-based proteomics, 
in which the proteins in the elution sample are separated by SDS-polyacrylamide gel electrophoresis 
(PAGE) and the bands cut, tryptically digested, and analyzed by MS. For a quantitative analysis, 
the proteins are directly digested while still immobilized to the beads and the released tryptic 
peptides analyzed by high resolution MS. In liquid chromatography (LC)-MS/MS (tandem MS), 
the peptides are separated by reversed-phase LC prior to MS analysis. A tandem mass spectrometer 
detects peptide ions and their fragmentation products, resulting in an ultra-high-resolution 
spectrum. The results are then compared to a protein database, e.g. UniProt, to identify the proteins 
isolated. Proteins enriched by the active probe when compared to the negative control are 
considered as potential targets.[56]  
 Carr and coworkers developed a quantitative approach for affinity-based proteomics that 
combines stable isotope labeling with amino acids in cell culture (SILAC)[57] with affinity 
enrichment.[58] This technique has, next to the recent advances in mass spectrometry, greatly 
enhanced the capabilities of affinity-based proteomics.[40, 56] As the name implies, cells are cultured 
with medium containing heavy isotope-labeled amino acids, e.g. 13C6,15N2-L-lysine and 13C6,15N4-
L-arginine, leading to the incorporation of these into their proteins. The “heavy” lysate is then 
incubated with the active probe, and a normal lysate, i.e. with isotopically unlabeled proteins, is 
incubated with the control. Subsequently, both samples are combined and analyzed by tandem MS. 
The labelling results in a characteristic mass shift, i.e. 8 Da for lysine- and 10 Da for arginine-
labeled peptides.[58] A protein enriched by the active probe exhibits “heavy” mass peaks with a 
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higher intensity than the “light” peaks and is thus identified as potential target of the small molecule 
(Figure 7). 
 
Figure 7. Principle of quantitative affinity-based proteomics by SILAC. Adaptation of Ziegler et al.[40] 
 
b) Label-Free Methods 
Target identification technologies that require labeling of the bioactive molecule have certain 
drawbacks. For instance, modifications on the hit compound may not be tolerated, leading to 
inactive pull-down probes.[59] In addition, the incorporation of a linker can result in off-target 
binding or lower solubility. These limitations can be overcome by employing linker-free 
techniques. Some of these methods rely on the fact that proteins are stabilized when bound to a 
compound. One example is the drug affinity responsive target stability (DARTS), which takes 
advantage of the lower susceptibility of a ligand-bound protein towards proteases than when in the 
unbound state.  
 Thermal proteome profiling (TPP) is an alternative label-free approach, which combines 
the cellular thermal shift assay (CETSA) with quantitative proteomics.[60] The main principle behind 
this strategy is based on the changes in thermostability of a protein when bound to a ligand. With 
increasing temperature, the interactions within a protein that stabilize its tertiary structure break, 
and the protein unfolds or “melts”. Binding to a compound can result in a measureable shift of a 
protein’s melting temperature. In a TPP, cell lysate is incubated with either compound or a control 
and each sample is divided into ten aliquots. The aliquots are incubated at different temperatures, 
and the soluble fraction of each is analyzed by tandem MS. Since a protein precipitates upon 
unfolding, the intensity of a protein peak will decrease with increasing temperature, resulting in a 
melting curve. Proteins displaying a shift in the curve upon incubation with the compound are 
identified as potential targets. By using different neutron-encoded isobaric mass tagging reagents 
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(TMT10) for each aliquot, the ten samples of each set can be combined and analyzed 
simultaneously, thereby reducing the measurement time significantly (Figure 8).[60-61] 
 
Figure 8. Principle of TPP. Compound- and DMSO-treated lysates are aliquoted into ten samples, and each 
set is incubated in a temperature gradient. The soluble fractions are TMT-labeled and analyzed by MS/MS. 
Adaptation from Savitski et al.[60] 
 
Despite the remarkable advances in proteomics, the need for a cell lysate restricts the 
diversity of the pool containing potential targets to soluble and highly abundant proteins. For 
example, multispan-membrane proteins, such as membrane receptors and channels, represent a 
major obstacle in proteomics, as mild detergents are not capable of solubilizing these, and strong 
detergents can disrupt their structure.[56] Therefore, strategies for which protein solubilization is not 
necessary serve as attractive alternatives, in particular when a membrane protein is suspected as the 
target of a compound. Along these lines, a method that has been applied for the identification of 
membrane proteins involves in situ labeling with a chemical probe that can bind to their targets 
covalently in vivo, either through their intrinsic chemical reactivity or photocrosslinking. For in-gel 
fluorescence purposes, a second requirement is a probe that has a fluorescent tag in addition to the 
covalent or photo-tag. After incubation with the trifunctional probe and irradiation, the cells can be 
lysed with a strong detergent, such as SDS, and the samples analyzed by gel electrophoresis and 
fluorescence scanning.[56] 
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iii. Genetic Hit Identification 
Yeast is a model system for the study of cellular mechanisms in humans, as at least one third of the 
encoded proteins are homologous in both organisms.[40] An effective method for target 
identification of small molecules is drug-induced haploinsufficiency profiling (HIP).[62] This 
genetic approach uses a set of bar-coded heterozygous yeast deletion strains, each of which has one 
specific monoallelic deletion and hence a lower concentration of the respective encoded protein. 
Consequently, each strain is highly sensitive to the interference of the function of the deleted gene. 
Thus, a small molecule targeting the locus of a gene leads to growth inhibition of the corresponding 
mutant strain, and the target can be identified by quantification thereof. A complementary strategy 
is the multicopy suppression profiling, which is based on the opposite principle to HIP. Here, a 
strain with the overexpressed target becomes more tolerant to the modulating small molecule.[40]  
 In most cases, a genetic profiling identifies not only the sought-after target, but also proteins 
involved in the same pathway. Thus, it can provide additional information, e.g. about the upstream 
regulation of the target. However, further experiments are necessary in this case to isolate the 
target.[40]  
 
iv. Computational Hit Identification Strategies 
Targets can be predicted using computational tools that compare the structural similarity of the 
query small molecule with a database of compounds whose cellular targets are known. One example 
is the Similarity Ensemble Approach (SEA), an algorithm that calculates the two-dimensional 
similarity developed by Shoichet and coworkers.[63] Using this powerful tool, the authors were able 
to confirm reported targets and identify new targets for numerous pharmaceutical compounds and 
U.S. Food and Drug Administration (FDA)-approved drugs, thereby demonstrating the value and 
reliability of computational methods.[64] Other algorithms, such as SwissTargetPrediction use the 
three-dimensional similarity to compare the shape of a pair of ligands,[65] which performs better 
when these display a low structural similarity.[66]  
 The downside of computational strategies lies in the dependence of similarity-based 
algorithms on existing protein-targeting ligands. Hence, a target for which either no or only 
structurally unrelated small-molecule modulators have been developed will not be identified.[66]  
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v. Validation of Identified Targets 
The last step in forward chemical genetics consists in the confirmation of the identified protein as 
target of the small-molecule modulator in binding, functional, and genetic assays. This is the most 
important part of a target identification project, as it rules out off-target binding and proves an 
existing role of the target in the studied cellular process. Given that most target identification 
experiments deliver lists of numerous potential targets, validation studies need to prioritize 
according to whether their function can be relevant in the studied process.  
Depending on whether a chemical probe is available or not, different methodologies can be 
applied. For example, binding of the molecular target can be confirmed by performing a competitive 
pull-down experiment with the linker-free compound, followed by immune-blotting.[40] When the 
lysate is incubated with the active probe together with the unmodified compound at high 
concentrations, the latter can outcompete binding of the active probe to the target, and thus less 
protein is isolated. However, proof of binding alone does not suffice to validate the potential target, 
since the protein may not be involved in the regulation of the studied pathway. To address this 
question, potent, selective modulators of the identified target, if available, can be tested in the initial 
phenotypic screen and should elicit the same response as the hit compound.  
Binding affinity can be determined in biophysical assays. Commonly used techniques that 
do not require the modification of the compound or the protein include isothermal titration 
calorimetry (ITC) and differential scanning fluorimetry (DSF). The former measures the heat 
generated or required upon protein-compound binding and allows the determination of the 
dissociation constant (KD). DSF uses the principle of the thermal shift assay (TSA) and thus 
determines the changes in protein thermostability. If a chemical probe of the compound is 
accessible, additional methods can be employed such as fluorescence polarization (FP) of surface 
plasmon resonance (SPR).[40] Binding studies, as well as co-crystallization of the protein-compound 
target, can give solid evidence of target engagement. However, all these approaches can be 
hampered by the poor accessibility of the target protein.  
 As binding of the compound may not affect the function of the target, orthogonal assays 
are mandatory for target confirmation. In this respect, functional assays can be conducted to 
investigate whether the compound modulates the activity of the putative target, provided that this 
is a protein whose function can be measured directly, such as an enzyme or a receptor. However, 
non-cellular biochemical assays may deliver conflicting information due to cell permeability, 
compound solubility, and cross-talk between different pathways.[40] 
 23 
Small interfering RNA (siRNA) and complementary DNA (cDNA) are more accessible 
than the corresponding purified protein and allow the cellular knock-down and overexpression of 
the target, respectively. A genetic knock-down should display the same phenotype as an inhibitor 
of the studied pathway and an increased sensitivity towards treatment with the small molecule, 
leading to a shift in the IC50. Inversely, cells with the overexpressed target should be more tolerant 
towards the treatment with the compound and display the same phenotype as an activator.  
If no link between the identified target and the studied pathway has been established or the 
cellular function of the protein is unknown, the protein needs to be extensively characterized in 
order to understand its regulating role. The study of an uncharacterized protein is highly challenging 
but ultimately delivers novel regulators of a pathway and consequently valuable information for 
untangling the puzzle of cell biology.  
 
2.3. Forward Chemical Genetics in Autophagy  
As described in Chapter 2.1, the molecular mechanisms of autophagy regulation are poorly 
understood, despite the extensive research performed to counteract this lack of information. 
Nevertheless, the application of methods in both classical and chemical genetics have given rise to 
a significant number of modulators[15] and allowed the identification of multiple autophagy 
regulators.[67] 
 Cell-based screening is a useful starting point in the discovery of pathway regulators. Most 
screens monitor autophagy by determining the levels or localization of specific markers, e.g. LC3, 
a cytosolic protein essential in the formation and maturation of autophagosomes (Chapter 2.1.1). 
The development of GFP-LC3 transgenic mice to analyze autophagy in vivo by Mizushima et al.[68] 
revolutionized the field and provided a basis for the identification of autophagy modulators. This 
technique is based on the observation that, upon autophagy activation, LC3-I is conjugated to PE 
and consequently recruited to the isolation membrane. Therefore, whereas at basal conditions the 
GFP-LC3-I fluorescence is distributed throughout the cytoplasm, GFP-LC3-II accumulates to the 
autophagosomes when the autophagic response is active, and green fluorescent puncta can be 
detected (Figure 9). 
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Figure 9. Schematic representation of the principle of the GFP-LC3-based phenotypic assay. Cells with basal 
levels of autophagy have a diffuse GFP signal. The GFP-tagged autophagy marker LC3-I is lipidated with 
PE upon induction of autophagy to form LC3-II and consequently recruited to the membrane of growing 
autophagophores. Autophagosomes can be detected as green puncta using fluorescence microscopy and 
quantified. Autophagy can be artificially induced by amino acid starvation or by inhibition of mTOR using 
rapamycin. Inhibition of the fusion to lysosomes by chloroquine causes an accumulation of puncta and thus 
an enhanced signal-to-noise ratio. Autophagy inhibitors reverse this phenotype, leading to a diffuse 
fluorescence signal. 
 
Subsequently, Balgi et al. established the first automated phenotypic screen using the GFP-
LC3 system in human cells, through which they identified numerous inducers of autophagy.[69] This 
method has been adapted for high-throughput screening and led to the discovery of numerous FDA-
approved and GPCR-targeting compounds that modulate autophagy.[70-72] Moreover, the screening 
of unbiased chemical libraries has enabled the identification of compounds with novel chemotypes 
and targets that are yet to be discovered, including oxautins and autophagonizer.[73-75] Recently, 
Park and coworkers presented an alternative high-throughput screening approach to identify 
autophagy modulators that monitors lipid droplets. This methodology allows the direct 
measurement of a late-stage phenotypic effect of autophagy, and hence autophagic flux, by 
quantifying lipid droplets.[76]  
 Following a pilot phenotypic screen, hit validation is performed in a series of secondary 
screens and assays. Common techniques to confirm modulation of autophagy include the repetition 
of the phenotypic assay in different cell lines or in a tandem monomeric red fluorescent protein 
(mRFP)-GFP-LC3-based assay and immunoblotting for LC3-II or other autophagy markers.[67, 71] 
Further proof for autophagy modulation can be obtained by determining the levels or localization 
of downstream targets of autophagy regulators, e.g. the mTOR targets S6K1 and eukaryotic 
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initiation factor 4E-binding protein 1 (4EPB1) and the phosphatidylinositol 3-phosphate (PI3P) 
sensors FYVE and WIPI2.[70-71, 73]  
 For the numerous autophagy modulators discovered in unbiased phenotypic screens, only 
few targets have been identified, most likely because of the recentness of the various assays required 
for this purpose. Using affinity-based proteomics, Sasazawa et al. identified valosin-containing 
protein (VCS) as the target of xanthohumol.[77] The label-free approach DARTS was applied in the 
identification of Cathepsin D and (TXNL1) as potential targets of dichloroacetate.[78] Most recently, 
Waldmann et al. discovered the potent autophagy inhibitor Autophinib and identified VPS34 as its 
target using target deconvolution.[79] The latter example represents one of the few target 
identifications of a synthetic modulator of autophagy and thereby highlights the importance of using 
target-agnostic phenotypic screens for the discovery of modulators with novel chemotypes. An 
unbiased strategy is therefore an effective way to identify novel regulators of autophagy. 
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3. AIM OF THE THESIS 
Autophagy is an emerging therapeutic target for neurodegenerative disorders and cancer. Therefore, 
unraveling the mechanisms underlying autophagy is crucial to understand cell catabolism and its 
role in disease.  
 For this purpose, an autophagy inhibitor, identified in an in-house medium-throughput 
screen, was selected for further studies because of its potency and chemotype. The goal of this thesis 
was to validate the hit as an autophagy inhibitor in secondary assays and to identify its target(s) by 
means of forward chemical genetics. For this purpose, a compound collection of structural analogs 
should be generated and biologically evaluated to derive the SAR of the compound class. Based on 
the knowledge gained from the SAR analysis, a chemical probe for affinity-based proteomics 
should be prepared. Moreover, alternative target identification strategies, e.g. thermal proteome 
profiling and computational methods, should be exploited. The putative targets identified should be 
confirmed in biochemical and biophysical assays and evaluated for their role in autophagy. The 
identification of modulators is a useful way to study cellular pathways and can provide the basis for 
the discovery of autophagy regulators and ultimately novel targets for therapy.  
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4. RESULTS AND DISCUSSION 
4.1. Identification of an Indoline-Based Autophagy Inhibitor 
Specific modulation is a widely-used tool to study the effect of abnormal levels of autophagy on 
homeostasis and other vital processes in cells. The discovery of potent, specific autophagy 
modulators allows not only the study of this process, but also provides the foundation for its specific 
therapeutic targeting. Furthermore, by identifying the targets of specific autophagy modulators, 
further insight into the mechanisms regulating this vital signaling pathway can be gained.  
 
4.1.1. Phenotypic Screen for the Identification of Autophagy Inhibitors 
To discover new autophagy modulators, a medium-throughput screen for autophagy inhibition was 
established at the Compound Management and Screening Center (COMAS) of the Max Planck 
Institute of Molecular Physiology. Compounds that were able to inhibit artificially induced 
autophagy were identified as hits. 
To monitor autophagy levels, the procedure developed by Balgi et al.[69] was employed in 
human MCF7 breast carcinoma cells stably expressing eGFP-LC3 (Chapter 2.3). In the assay, 
autophagy is induced in cells either by replacing full growing medium by Earle’s balanced salt 
solution (EBSS), which triggers acute amino acid starvation, or by using the mTOR inhibitor 
rapamycin. In fed conditions, the fluorescence is distributed throughout the cytoplasm, and when 
the autophagic response is active, eGFP-LC3 accumulates to the autophagosomes and green 
fluorescent puncta can be detected (Figure 10). Inhibitors of autophagosome formation can reverse 
this phenotype. By using chloroquine (CQ), an inhibitor of the autophagosome-lysosome fusion, 
the degradation of autophagosomes can be blocked and the fluorescent signal enhanced. 
Initially, 150,000 compounds were screened at a single concentration against starvation-
induced autophagy. Compounds displaying an inhibition ≥ 70% (5,500 compounds) were 
rescreened in starvation-mode and for inhibition of autophagy induced by targeting mTOR using 
rapamycin. The dose-dependent inhibitory effect was determined for compounds exhibiting an 
average inhibition of ≥ 70%. Autophagy inhibitors with an IC50 ≤ 5 µM were divided into two 
categories: active in starvation-induced autophagy (profile “S”, 128 compounds) and active in 
starvation- and rapamycin-induced autophagy (profile “SR”, 118 compounds). Given that S-
inhibitors are not able to elicit an inhibitory response if autophagy is induced by inhibiting mTOR, 
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they are expected to act upstream of mTORC1 or via an orthogonal pathway. In contrast, SR-
inhibitors are expected to act either downstream of mTOR or through an mTOR-independent 
pathway. This strategy facilitates an early classification of autophagy inhibitors according to their 
modes of action. 
Indoline 1a was identified as a potent inhibitor of autophagic flux of the S-class (Figure 10, 
middle row), as it does not inhibit rapamycin-induced autophagosome formation at 10 µM (Figure 
10, bottom row). Moreover, it was shown that 1a inhibits autophagy dose-dependently with an IC50 
= 520 ± 550 nM (Figure 11). 
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Figure 10. Phenotypic assay employed to identify autophagy inhibitors using eGFP-LC3. MCF7 cells stably 
expressing eGFP-LC3 were either treated with rapamycin or starved of amino acids with EBSS, 
simultaneously treated with compound, and incubated for 3 h. The cells were fixed with formaldehyde and 
the nuclei stained blue with the DNA-binding reagent Hoechst. The green-fluorescent puncta are quantified 
and normalized to the MEM and EBSS or rapamycin controls. MEM = minimal essential medium; Rapa = 
rapamycin. Representative images shown (n = 4, each in N = 3). 
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Figure 11. Indoline 1a (right) inhibits starvation-induced autophagy in a dose-dependent manner in the 
phenotypic assay described in Figure 10 (left). Autophagy is quantified by the number of puncta per nucleus 
and normalized to the MEM and EBSS controls. Data shown are mean values ± SEM (n = 4). Representative 
graph shown. 
  
GFP is prone to proteolytic degradation is the lysosomes, which can decrease its fluorescence when 
autophagosomes fuse to lysosomes. Moreover, its fluorescence is sensitive to the acidic lysosomal 
milieu.[80] Therefore, an apparent inhibitory effect observed in the GFP-based phenotypic screen 
can arise from enhancement of autophagosome–lysosome fusion leading to false positives.[81-82] In 
contrast, the mCherry signal is not affected by acidic pH. Consequently, the use of mCherry-GFP-
tagged LC3 enables the visualization of autophagosomes and autolysosomes. In this tandem assay, 
whereas colocalization of the signals represents intact autophagosomes, an mCherry signal 
indicates the presence of autolysosomes. A true inhibitor of autophagosome formation should be 
able to decrease the number of both autophagosomes and autolysosomes.  
 As a first approach in the validation as an autophagy inhibitor, 1a was tested in the above-
described tandem mCherry-eGFP assay. The confocal images reveal that 1a strongly inhibits 
autophagosome and hence autolysosome formation dose-dependently (Figure 12, Figure 13), 
thereby supporting the findings of the primary phenotypic assay. 
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Figure 12. Indoline 1a inhibits the formation of autophagosomes. Effect of 1a on autophagosomes (yellow) 
and autolysosomes (red) on starved MCF7 cells stably expressing mCherry-eGFP-LC3. Cells were incubated 
with 1a either in MEM or EBSS, incubated for 3 h, and imaged. Representative images shown (N = 5). 
 
  
Figure 13. Indoline 1a inhibits autophagosome formation in a dose-dependent manner. Left: quantification 
of GFP puncta showed a decrease in autophagosomes in fed and starved conditions. Right: quantification of 
mCherry puncta showed a decrease in autolysosomes in starved and fed conditions. 
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4.1.2. Effect of Autophagy Inhibitors on Known Regulators of Autophagy 
Prior to performing target identification with resource- and time-intensive methods, such as affinity-
based proteomics, it is crucial to determine whether the identified inhibitors act on known regulators 
of autophagy that are easily accessible for functional or binding assays. Therefore, the most potent 
inhibitors (IC50 £ 5 µM) were selected for testing against a number of targets. Given that 
phosphorylation processes play a major role in autophagy, three kinases and a small panel of 
phosphatases were evaluated. 
Phosphorylation events by the kinases VPS34, ULK1, and AMPK activate autophagy 
(Figure 3). Being, directly involved in the formation of autophagosomes, VPS34 is the most 
downstream kinase in the regulation pathway of autophagy. It produces PI3P in a localized 
manner,[83] which triggers the recruitment of WIPI-1 (the mammalian orthologue of Atg18) and 
other effector proteins to the growing autophagosomal membrane.[84-86] Activation of VPS34 
complexes is caused by the phosphorylation of Beclin-1 by ULK1,[87] which is itself phosphorylated 
by AMPK and mTOR.[25] AMPK can additionally inhibit the repressive function of mTOR on 
autophagy by phosphorylating TSC2,[88] a negative regulator of mTOR, and the mTORC 
component raptor.[89]  
According to their mode of action, 42 S-type and 45 SR-type inhibitors were assayed 
against the mTOR upstream kinase AMPK or the mTOR downstream kinases ULK1 and Vps34, 
respectively. In addition, the four most potent S-type inhibitors were evaluated against a panel of 
23 phosphatases. Most of the compounds, including 1a, showed no or little effect on the activity of 
the tested targets (Figure 14) and thus remain promising tools for finding novel regulators of 
autophagy.  
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Figure 14. Indoline 1a has no effect on the activity of most of the phosphatases tested and AMPK at 10 µM. 
Phosphatase activities were determined in a colorimetric assay using purified phosphatase targets and p-
nitrophenylphosphate or BIOMOL® Green reagent. AMPK activities were determined in a radiometric assay 
using purified AMPK and 33P-ATP. Performed by SignalChem. Data shown are mean ± SEM (N = 2). 
 
4.1.3. Validation of Indoline 1a as an Inhibitor of Starvation-Induced Autophagy  
To confirm the findings of the phenotypic screen and evaluate its toxicity, 1a was tested in three 
independent assays.  
 GFP-based phenotypic screens can have certain limitations. As described in the previous 
chapter, GFP is sensitive to lysosomal environment. Furthermore, as a non-native protein, GFP is 
a target for proteasomal degradation and can affect the function of LC3 because of its size.[90] 
Therefore, an independent analysis of LC3 levels is necessary in parallel to the phenotypic screens. 
One strategy is to monitor the levels of LC3-II by immunoblotting, which increase upon activation 
of autophagy due to the lipidation of LC3-I. Another widely used marker is the ubiquitin-binding 
protein p62 (also known as sequestosome-1), which is degraded when the autophagic response is 
active. Using similar conditions as for the phenotypic screen, it was demonstrated that 1a inhibits 
the accumulation of lipidated LC3 and the degradation of p62 in amino acid-starved cells in a dose-
dependent manner (Figure 15).  
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Figure 15. Indoline 1a inhibits the autophagy-induced accumulation of LC3-II and degradation of p62 in 
MCF7-eGFP-LC3 cells. MCF7 cells stably expressing eGFP-LC3 were incubated with either MEM, EBSS, 
or EBSS and compound for 3 h and lysed with Laemmli buffer. Denatured proteins were resolved on SDS-
PAGE, transferred to a polyvinylidene fluoride (PVDF) membrane and probed for LC3-B (Cell Signaling, 
cat# 2775), p62 (MBL international, cat# PM045), and β-actin (Abcam, cat# ab8227) (n = 4). 
 
In order to study any cellular pathway using chemical genetics, it is essential to determine 
the toxicity of the biologically active compounds on the cell lines employed, as cytotoxic 
compounds can generate false-positive results. Moreover, as starved cells are not able to produce 
energy when autophagy is blocked, non-toxic autophagy inhibitors should be selectively toxic 
towards nutrient-deprived cells.  
A common method to assess cell viability monitors the cleavage of water soluble 
tetrazolium salt 1 (WST-1) by mitochondrial dehydrogenases, which generates the dye formazan. 
The overall activity of these enzymes and hence the formation of formazan directly correlates with 
cell growth and can be monitored over time. By performing a WST-1 assay, it could be 
demonstrated that 1a inhibits growth selectively in amino acid-starved MCF7 cells with an IC50 = 
3.0 ± 0.4 µM (Figure 16). 
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Figure 16. Indoline 1a is selectively toxic towards starved MCF7 cells. MCF7 cells in either full medium 
(MEM, blue) or under starvation conditions (EBSS, black) were treated with 1a, and the viability was 
determined after 48 h by monitoring the absorbance for 1 h after addition of WST-1 reagent. Data shown are 
mean ± SEM (n = 3). 
 
To determine the mechanism of cell death, the apoptosis rate of MCF7 cells in the presence 
of 1a was evaluated using an IncuCyte® analysis system. This automated platform combines 
contrast/fluorescence microscopy with cell incubation for time-dependent live-cell imaging of 
multiple samples and hence allows cell monitoring in the presence of compound under various 
conditions. The method employed here makes use of a DNA-intercalating agent, which is 
fluorescent when cleaved by active caspase 3/7 upon induction of apoptosis. Analysis of the cell 
confluence and fluorescence over 72 h revealed that 1a has no effect on fed cells but induces 
apoptosis in amino acid-starved cells dose-dependently (EC50 = 4.4 ± 0.3 µM, Figure 17), indicating 
that nutrient-deprived cells undergo cell death by means of apoptosis when autophagy is inhibited 
by 1a.  
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Figure 17. Indoline 1a selectively induces apoptosis 
in starved MCF7 cells. MCF7 cells in either a) full 
medium (DMEM) or b) under starvation conditions 
(EBSS) were treated with 1a and the apoptotic cells 
were monitored over 48 h using the green 
fluorescent dye IncuCyte™ Kinetic Caspase-3/7 
Apoptosis Assay Reagent in the Incucyte Zoom. The 
ratio of apoptotic cells was defined as green 
fluorescence confluence as a percentage of phase 
contrast confluence and is normalized to the DMSO 
control. Only relevant concentrations shown for 
clarity. c) The graph shows the dose-response 
influence of 1a after 48 h of treatment. Data shown 
are mean values ± SEM (n = 3, N = 3). 
c) 
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4.1.4. Conclusion 
Using a GFP-based and a tandem mCherry-GFP-based assay, it was demonstrated that 1a is a potent 
inhibitor of starvation-induced autophagy. Furthermore, its inability to inhibit rapamycin-induced 
autophagy indicates that 1a acts presumably upstream of mTOR. The inhibitor was validated by 
immunoblotting and cell viability assays, which show that its cytotoxicity is selective for starved 
cells. Since it did not target any of the known regulators tested, different approaches to identify its 
target were applied, which will be discussed in the next chapters. 
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4.2. Synthesis of an Indoline-Based Compound Collection 
Given its strong potency and inhibitory profile, 1a was selected for further studies. As only few 
structural analogs of 1a were present in the COMAS library or commercially available, a compound 
collection derived from 1a was synthesized in order to delineate the SAR. In this chapter, the 
synthetic routes employed in the preparation of the compounds will be described in detail. The 
derivation of the SAR based on the biological evaluation of the analogs will be illustrated in Chapter 
4.3. 
 
4.2.1. Retrosynthetic Analysis of Indoline 1a 
Indoline 1a can be disconnected at the sulfonamide moiety to an amine and a suitable sulfonyl 
indoline, such as a sulfonyl chloride. The groups at C5 and C6 in 2 can be derived from acyl indoline 
3 by bromination and chlorosulfonylation, using the directing properties of the acyl group 3, which 
in turn can be traced back to commercially available indoline (4) (Scheme 1). 
  
Scheme 1. Retrosynthetic analysis for autophagy inhibitor 1a from commercially available indoline (4). 
 
When studying the SAR of a compound class, it is important to compare single 
modifications of each site, while keeping the rest of the molecule intact. To generate compound 
collections bearing only one modification at the same site in an efficient way, two divergent 
synthetic routes were employed, which allowed the introduction of either the acyl or the 
sulfonamide functionalities at the last step. 
 
4.2.2. Synthesis of Indoline 1a Analogs with Varying Sulfonamide Aryl Groups 
In the first route towards analogs of 1a, early installation the cyclopropanecarbonyl group allowed 
the generation of an aryl sulfonamide series 1a–x in four steps from 4 (Scheme 2).  
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Scheme 2. Synthesis of aryl sulfonamide series 1a-x from commercially available indoline (4) via acylation, 
bromination, chlorosulfonylation, and aminolysis. DMAP = 4-dimethylamino pyridine; NBS = N-
bromosuccinimide. 
 
Acylation of 4 was accomplished by treatment with cyclopropanecarbonyl chloride (5) 
using Et3N as a base and a catalytic amount of DMAP in excellent yield. Subsequent bromination 
with NBS gave the C5-bromide 6, which is in agreement with the selectivity reported for aromatic 
amines, including acyl indolines.[91-95] Acyl bromoindoline 6 was sulfonylated using chlorosulfonic 
acid and the resulting crude product reacted with various anilines in pyridine, leading to target 
compounds 1a–x. The yields of this reaction strongly correlated with the electronic properties of 
the substituents, i.e., the more electron donating the substituents, the higher the yield. Furthermore, 
aminolysis with anilines bearing substituents ortho to the amine resulted in lower yields, most likely 
due to steric effects. However, this was not studied in detail in the context of this thesis. 
Though not fully understood, the regioselective chlorosulfonylation of 6 at C6 of acyl 
bromoindolines, which is contradictory to the ortho/para-directing effect of amides, has been 
previously reported.[96] This regioselectivity can be rationalized by the ortho-directing effect of the 
C5-bromide or steric hindrance caused by the N-acyl group. Another explanation is a possible 
complexation between chlorosulfonic acid and the amide functionality, which would render the 
nitrogen more electron-deficient and hence meta-directing.[96] Likewise, consistent with the 
reported reactivity of non-brominated indolines, chlorosulfonylation of N-acyl indoline 3 occurred 
exclusively at C6, affording 7 in good yield (Scheme 3). 
 
Scheme 3. C6-selective chlorosulfonylation of acyl indoline 3 and subsequent aminolysis with m-
trifluoromethyl aniline. 
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4.2.3. Synthesis of Indoline 1a Analogs with Varying Carboxamide Groups 
A slightly different route from the one described in the previous chapter allowed late-stage 
functionalization of the indoline-N with varying carboxy substituents (Scheme 4). Starting from 
commercially available N-acetylindoline (8), sulfonamide 9 was prepared the same way as 1, 
employing p-chloro-m-trifluoromethyl aniline (10) for the aminolysis step, in good overall yield 
(81%). Saponification of 9 lead to free indoline 11. Additionally, the preparation of m-
trifluoromethyl analog 12 was conducted following the procedure employed for 11 and used as a 
precursor of a second carboxamide series.  
 
Scheme 4. Route employed in the synthesis of the precursor 11 of an indoline carboxamide series, starting 
from commercially available N-acetylindoline (8). Deacetylation and reacylation with different carboxy 
reagents allowed late stage functionalization. 
 
Acylation of NH-indoline 12 should give the target amides 13. However, when 12 was reacted with 
acyl chlorides using the same conditions as for the synthesis of 3, only the double acylation product 
14 was observed (Table 2, entry 1). Lowering the equivalents of the acyl chloride, as well as slow 
addition of the reagent and higher dilution had the same outcome (entry 2). Therefore, introduction 
of the carboxy moiety was attempted using the carboxylic acid analogs and standard amide coupling 
conditions with 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC)/DMAP, dicyclohexyl-
carbodiimide (DCC)/DMAP, and (1-cyano-2-ethoxy-2-oxoethyliden-aminooxy)dimethylamino-
morpholino-carbenium hexafluorophosphate (COMU)/oxyma as coupling reagents, which resulted 
in no conversion of starting material 12. Only the use of benzotriazol-1-yl-
oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP) with N-methyl-morpholine (NMM) 
as base gave traces of the desired product 13 (entry 6).  
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Table 2. Optimization of reaction conditions for the N-acylation of bromosulfonamide indolines. 
 
Entry X R Equivalents Acyl Source 
Coupling 
Reagent(s) Base Solvent Products 
1 Cl[a] 
 
2.3 DMAP Et3N CH2Cl2 13, 14 (1:1)[c] 
2 Cl[a] 
 
1.1 DMAP Et3N CH2Cl2 13, 14 (1:1)[c] 
3 OH[b] 
 
2.0–4.0 EDC, DMAP DIPEA CH2Cl2 no conversion[d] 
4 OH[b] 
 
2.0 DCC, DMAP DIPEA CH2Cl2 no conversion[d] 
5 OH[b] 
 
4.0 COMU, oxyma – DMF no conversion[d] 
6 OH[b] 
 
4.0 PyBOP NMM DMF traces of 13[d] 
7 OH[b] 
 
4.0 PyBOP, DMAP DIPEA DMF 13 (57%) 
8 OH[b] 
 
1.5 T3P DIPEA EtOAc 13 (58%) 
[a] To a mixture of 12 in the indicated solvent, the coupling reagent, the base and the acyl chloride were 
added successively. [b] To a mixture of the acid (chloride) and the coupling reagent(s) in the indicated solvent 
under an argon atmosphere, 12 and the base were added successively. [c] Product/side product ratio 
determined by 1H NMR. [d] Monitored by ultra-high-performance column chromatography (U-HPLC). 
DIPEA = N,N-diisopropylethylamine; T3P = propylphosphonic anhydride. 
  
 Reaction with the reagents PyBOP/DMAP or T3P gave the desired products 13 in moderate 
yields (entries 7 and 8). Therefore, these conditions were employed in the generation of series 13 
and 15 (Scheme 5). 
 
Scheme 5. Optimized conditions employed in the synthesis of carboxamide series 13 and 15. 
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The optimal conditions found for the regioselective acylation of free indolines were not 
applicable to the reaction with pivalic acid (Table 3, entry 1). No conversion of 11 was observed 
when using pivalic acid anhydride or pivalic acid chloride in CH2Cl2 under basic conditions (entries 
2 and 3). Increasing the effect of the base by performing the reaction in pyridine as solvent led to 
the desired pivalic acid analog 15h in moderate yield (entry 4). 
 
Table 3. Optimization of reaction conditions for the preparation of pivalic analog 15h.[a] 
 
Entry X Coupling reagent(s) Base (eq.) Solvent Yield 
1 OH T3P DIPEA (8.0) EtOAc –[b] 
2 piv. anh DMAP Et3N (2.0) CH2Cl2 –[b] 
3 Cl DMAP Et3N (3.0) CH2Cl2 –[b] 
4 Cl – – pyridine 65% 
[a] To a mixture of 11 in the indicated solvent under an argon atmosphere, the coupling reagents, the base, 
and the pivalic acid (chloride/anhydride) were added successively. [b] Monitored by U-HPLC. Piv. anh. = 
pivalic anhydride. 
 
4.2.4. Synthesis of Indole Derivatives of Indoline 1a 
Indole scaffolds are ubiquitous structures found in numerous natural products, including the amino 
acid tryptophan, a major constituent of proteins. Its presence in a variety of alkaloids and the 
neurotransmitter serotonin has driven pharmaceutical companies to synthesize indole-containing 
libraries for targeting GPCRs, enzymes, and ion channels.[97-98] Due to its structural similarity to 
indoline, the indole analogs 16a and 16b were considered as an interesting addition to the compound 
collection, which should be prepared via oxidation of 1a and 1b, respectively.  
 First attempts to oxidize 1b with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) in 
different solvents at a range of temperatures resulted in little or no conversion (Table 4, entries 1–
3). Increasing the number of equivalents of the oxidant had no effect on the outcome (entries 4–6). 
Therefore, different oxidizing agents were tested. Whereas no conversion was observed when using 
NS
O O
N
H
O
CF3
Br
H
NS
O O
N
H
CF3
Br
X
O
Cl Cl
coupling reagent
base
solvent, rt, 16 h
11 15a
 43 
Mn(OAc)3 (entry 7), better results were obtained with MnO2 as an oxidant (entry 8). Using the 
latter, an increase of the reaction temperature gave the desired indole 16b in excellent yield (entry 
9). The synthesis of indole 16a was performed analogously in comparable yield (92%). NH-
indolines, such as 11, were considerably more reactive and were readily oxidized with MnO2 to 17 
at lower temperatures (CH2Cl2, reflux). 
 
Table 4. Optimization of reaction conditions for the oxidation of 1b.[a] 
 
 
Entry Oxidant (eq.) Solvent Temperature 
Heat 
Source Time Yield 
1 DDQ (1.1) MeCN rt – 3 h no conversion[b] 
2 DDQ (1.1) toluene rt, reflux c 24 h traces[b] 
3 DDQ (1.1) toluene/CH2Cl2 rt, reflux c 16 h 9% 
4 DDQ (2.0) DMF rt, 80 °C, reflux c 16 h no conversion[b] 
5 DDQ (2.0) toluene 150 °C mw 1 h 18% 
6 DDQ (5.0) dioxane 150 °C mw 3 h 19% 
7 Mn(OAc)3 (1.2) toluene reflux c 4 h no conversion
[b] 
8 MnO2 (10.0) CH2Cl2 reflux c 4 h 31% 
9 MnO2 (10.0) toluene reflux c 4 h 94% 
[a] A mixture of 1b and the oxidant in the indicated solvent were heated to the indicated temperature. 
[b] Determined by 1H nuclear magnetic resonance (NMR). c = conventional heating; mw = microwave 
irradiation. 
 
4.2.5. Synthesis of Additional Analogs of Indoline 1a 
To study the effect of the bromide group on the activity of aryl sulfonamide indoline analogs, 1a 
and b were submitted to Pd/C-catalyzed hydrogenolysis in the presence of Et3N, giving compounds 
18a and b in excellent yields (Scheme 6).  
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Scheme 6. Synthesis of dehalogenated derivatives 18a and b, via hydrogenolysis of 1a and b. 
 
  The last analog described in this section consists in oxetane 19. Oxetanes are considered 
carbonyl bioisosteres, but have enhanced physicochemical and pharmacological properties 
compared to carbonyl moieties, which makes them attractive functional groups in medicinal 
chemistry.[99] To determine the influence of a carbonyl-to-oxetane replacement on the activity 
profile of the indoline compound class, oxetane 19 was synthesized following a reported procedure 
from 11 and 3-oxetanone via reductive amination (Scheme 7).[100] Interestingly, the ethyl substituted 
analog 20 was formed as a side product. However, the mechanism of this reaction was not 
investigated in the context of this thesis.  
 
Scheme 7. Preparation of oxetane 18 from 11 via reductive amination, using 3-oxetanone, following a 
reported procedure.[100] 
 
4.2.6. Conclusion 
A compound collection of structural analogs of 1a was successfully generated. The first steps 
leading to the common precursors 6, 10, and 11 were conducted in multi-gram scale, and obstacles 
in the later steps of the routes were overcome by successful optimization of reaction conditions. 
Using divergent synthetic routes, two series of compounds were produced, which consisted in 
analogs with varying sulfonamide aryl groups or carboxamide moieties. The preparation of further 
analogs was accomplished via oxidation or hydrogenation of 1a and 1b, or via reductive amination 
of 11. The biological evaluation of the compound collection will be discussed in the next chapter.  
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4.3. Structure–Activity Studies of an Indoline 1a-Derived Compound 
Collection 
Hit optimization using the SAR of a compound class can give rise to equally or more potent 
inhibitors with enhanced physicochemical and biological properties. Furthermore, SAR can provide 
information on functional group and site tolerability for the design of a chemical probe for affinity-
based chromatography experiments. For this purpose, the activity of the compound collection 
described in Chapter 4.2 was evaluated in the phenotypic assay described in Chapter 4.1.1. To 
identify the impact of each functional group of 1a and corresponding modifications thereof, the 
activities of compounds with single-site modifications were compared among each other (Scheme 
8).  
 
Scheme 8. Functional groups modified to study the SAR of the compound collection derived from 1a. 
 
4.3.1. Biological Relevance of the Aryl Sulfonamide Functionality 
A preliminary SAR study with ten analogs of 1a already present in the COMAS library revealed 
that an aromatic moiety directly attached to the sulfonamide is essential for activity. For example, 
an isopropyl sulfonamide indoline showed no inhibition (Table 5, entry 1). Analogs with larger 
groups, such as a piperidine or a piperazine linked through a C2H4 spacer, display a weak potency 
as well (entries 2 and 3). Analogs with aromatic groups attached to the sulfonamide through an 
alkane spacer, such as thiophene, o-chlorophenyl, or N-ethylaniline, did not inhibit autophagy or 
only weakly.  
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Table 5. Analogs of 1a in the COMAS library lacking an aryl sulfonamide moiety and their corresponding 
inhibition potencies towards starvation-induced autophagy at 10 µM. 
Entry Molecule Inhibition (%) 
1 
 
11 
2 
 
54 
3 
 
-11 
4 
 
6 
5  64 
6  18 
Inhibition potencies of starvation-induced autophagy are shown. Inhibition was measured in the phenotypic 
screen described in chapter 4.1.1. 
 
 Given the initial SAR with aliphatic sulfonamides described above, only the substitution 
on the aryl ring was analyzed for R1 (Scheme 8) in detail. According to Erlenmeyer’s definition of 
bioisosters, which is based on the similarity in the number of peripheral electrons, bromo- and 
chloro-substituents can be considered as bioisosteres.[101] In line with this rule, replacement of the 
p-chloro-substituent by its bioisosteric bromide had no significant effect on the activity of the 
compound class (Table 6, entry 1 vs. 3). This bioisosteric analogy does not apply to the replacement 
by methyl, another bioisostere of the chloro-substituent with a similar size and lipophilicity but a 
weaker inductive effect,[101] as 1d is slightly less active than 1a (entry 1 vs. 4). Trifluoromethyl aryl 
1b has a nearly identical activity as 1a and 1c, suggesting that a small-sized substituent in para-
position to the sulfonamide is crucial for activity (entries 1–3). This finding is supported by the loss 
in potency upon replacement of the trifluoromethyl group by the considerably bigger methoxy-
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group (entry 4 vs. 8). Replacement of hydrogen by the fluoro-substituent causes a 2.5-fold loss in 
activity, despite their similarity in size and lipophilicity and could therefore arise from the 
substantial difference in electronics (entry 2 vs. 9). These results indicate that only a moderate to 
low inductive effect of the group in p-position to the sulfonamide is tolerated. 
 The importance of the trifluoromethyl group is showcased by the dramatic loss in activity 
upon its replacement to bioisosterically related groups. For example, replacement by the 
electronically similar nitrile (entry 2 vs. 20), carboxylic acid (entry 2 vs. 21), and chlorine (entry 8 
vs. 13) groups[102-103] or by the much smaller hydrogen (entry 9 vs. 17) and fluorine groups (entries 
2 vs. 16) renders the compounds considerably less active or even inactive. Judging by the similarity 
in electronics of many of these analogs, it is possible that the indispensability of the trifluoromethyl 
substituent is caused not only by its strong electronegativity, but also additional factors, including 
size, lipophilicity and direct interactions of the fluorine atoms.  
 Unlike the overall electronegativity of the aryl ring, the substitution pattern has a major 
impact on the activity of the compound class. Thus, the m- and o-chloro analogs 1e and 1g are 1.6 
and 2.1-times less active than the p-chloro 1a (entries 5 and 7 vs. 1). The position of the 
trifluoromethyl group affects the activity strongly: the meta-to-para- (entry 2 vs. 11) or meta-to-
ortho-modification (entry 1 vs. 10) causes a 4.1 or 5.5-fold loss in activity, respectively. Generally, 
a negative effect on activity upon ortho-substitution was observed (entries 7, 10, and 22). Finally, 
the replacement of the aryl ring by heteroaromatic groups (entries 14, 23, and 24) did not increase 
the activity of 1a.  
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Table 6. Structures and activities for analogs of 1a with varying aryl substitution (Scheme 8, R1). 
Entry R1  IC50 (µM)  Entry R1  IC50 (µM) 
1 
  
(1a) 0.52 ± 0.55  13 
 
(1m) 4.30 ± 2.30 
2  (1b) 0.56 ± 0.38  14 
 
(1n) 5.90 ± 1.80 
3  (1c) 0.56 ± 0.15  15 
 
(1o) 9.20 ± 0.90 
4 
 
(1d) 0.81 ± 0.49  16 
 
(1p) inactive 
5 
 
(1e) 0.84 ± 0.16  17  (1q) inactive 
6 
 
(1f) 1.00 ± 0.40  18 
 
(1r) inactive 
7 
 
(1g) 1.10 ± 0.50  19 
 
(1s) inactive 
8 
 
(1h) 1.30 ± 0.30  20 
 
(1t) inactive 
9 
 
(1i) 1.40 ± 0.40  21 
 
(1u) inactive 
10 
 
(1j) 2.40 ± 0.20  22 
 
(1v) inactive 
11 
 
(1k) 3.10 ± 1.00  23 
 
(1w) inactive 
12 
 
(1l) 4.30 ± 0.80  24 
 
(1x) inactive 
Inhibition potencies of starvation-induced autophagy are shown. Inhibition was measured in the phenotypic 
screen described in chapter 4.1.1. Data shown are mean values ± SEM (N ≥ 3).  
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4.3.2. Biological Relevance of the Carboxamide Functionality 
Given that 1a and 1b were the most active compounds of the series described in the previous 
chapter, the aryl moieties of these compounds were maintained constant in the SAR analysis of the 
carboxamide functionality (Scheme 8, R2). 
 The cyclopropyl ring on the carbonyl (Table 7, entry 1) was replaced by a variety of 
structurally related alkyl analogs, such as isopropyl (entry 3), cyclobutyl (entry 4), cyclopentyl 
(entry 6), pivalyl (entry 8), methanecyclopropyl (entry 9), and ethyl (entry 13). The smaller 
substituents acetyl (entry 12) and ethyl (entry 14), as well as aromatic moieties (entries 2, 5, 7, and 
10) and an oxetane analog 19 (entry 11) were also evaluated. In all cases, modifications of this 
substituent had a strong negative effect on the inhibition potency of the indoline compound class, 
making this site unsuitable for the attachment of a functional tag.  
 
Table 7. Structures and activities for 1a analogs with varying N-indoline substitution. 
Entry R2 IC50 (µM) Entry R2 IC50 (µM) 
1 
  
(1a, 13a) 0.52 ± 0.55
[a] 
0.56 ± 0.38[b] 8   
(15h) 4.10 ± 0.90[a] 
2 
 
(15b) 2.40 ± 0.30[a] 9 
 
(13i, 15i) 4.50 ± 0.50
[a] 
inactive[b] 
3 
 
(13c; 15c) 3.00 ± 0.70
[a] 
8.70 ± 0.80[b] 10 
 
(15j) 5.00 ± 1.40[a] 
4 
 
(13d; 15d) 3.30 ± 0.60
[a] 
7.90 ± 0.00[b] 11  (19) 6.30 ± 1.60
[a] 
5 
 
(15e) 3.50 ± 0.30[a] 12 
 
(13k, 9) 6.90 ± 2.20
[a] 
inactive[b] 
6 
 
(13f; 15f) 3.80 ± 0.60
[a] 
7.00 ± 1.50[b] 13  
(13l) 7.00 ± 2.20[b] 
7 
 
(15g) 4.10 ± 0.90[a] 14  (20) inactive
[a] 
Inhibition potencies of starvation-induced autophagy are shown. Inhibition was measured in the phenotypic 
screen described in Chapter 4.1.1. [a] R1 = Cl (15); [b]: R1 = H (13). Data shown are mean values ± SEM 
(N ≥ 3). 
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 The cyclopropyl moiety is a frequent scaffold found in clinically approved drugs.[104] 
Compared to its alkyl isosteres methyl and isopropyl, it has proven to have enhanced metabolic 
stability in numerous cases caused by its C–H bond properties. On the other hand, its ring strain 
can lead to metabolic activation, which is in contradiction to the first statement.[105] These unique 
properties could be the origin of the steep SAR observed for R2, which suggests that replacement 
of the cyclopropyl ring is not tolerated.  
 
4.3.3. Biological Relevance of Additional Modifications  
The biological activity of further analogs with single modifications was evaluated in the eGFP-LC3 
phenotypic screen. Compounds with an N-alkylated sulfonamide (Table 8, entries 1 and 2) were 
inactive. C2-methylation of indoline resulted in a slightly more active inhibitor (32) than its 
demethylated analog 13k (Table 8, entry 3 vs. Table 7, entry 12). Modification of the substitution 
pattern on the indoline ring to give C5-sulfonamide 7 resulted in an inactive compound (entry 5). 
The activity of C5-sulfonamide 33 is contradictory to the findings derived from the aryl 
sulfonamide series (Chapter 4.3.1), which suggested that the trifluoromethyl group is essential for 
activity. Hence, one would predict a higher activity for 7 than for 33, which was not the case (entries 
4 vs. 5). However, this unexpected behavior could be caused by an off-target effect. The C5-
debrominated 18a and 18b and their alk(en)yl hydroxy analogs 34 and 35 showed a significant drop 
in activity (entries 6–9). Indoles 16a, 16b, and 17 were also less active (entries 10–12). Given its 
chemical accessibility, the indole-C3 position was explored on 16a. Considering the importance of 
the cyclopropyl ring and the indoline moiety described in the previous chapters, the activities of 
indoles 37 and 38 (entries13 and 14) were, although still low, rather unexpected and render this 
position a potential site for linker attachment in the synthesis of a chemical probe.  
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Table 8. SAR of further analogs of 1a. 
Entry Structure  IC50 (µM) Entry Structure  
IC50 
(µM) 
1  (30) inactive 8  (18a) 6.6 ± 1.2 
2  (31) inactive 9  (18b) inactive 
3  (32) 3.9 ± 0.5 10  (16a) 2.2 ± 0.1 
4  (33) 5.7 ± 0.5 11  (16b) 4.6 ± 0.1 
5  (7) inactive 12  (17) 5.4 ± 1.5 
6  (34) 9.2 ± 0.9 13  (37) 7.6 ± 2.3 
7 
 
(35) 9.9 ± 0.4 14 
 
(38) 7.3 ± 2.6 
Inhibition potencies of starvation-induced autophagy are shown. Inhibition was measured in the phenotypic 
screen described in Chapter 4.1.1. Data shown are mean values ± SEM (N ≥ 3). 
 
4.3.4. Conclusion 
From the SAR derived for analogs of 1a, it was evident that all the functional groups in 1a are 
indispensable for strong activity. Consequently, any site modification for the attachment of a tag 
could potentially affect the activity of the identified inhibitor and result in an inactive probe. 
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According to the activity of 38, C3 was the most promising site for modification. Another possible 
modification site is C5, despite the 18-fold lower potency of 34, when compared to the initial hit 
1a, as the loss in activity could arise from the properties of the hydroxyl group. Furthermore, unlike 
a C2-derived probe, both sites are chemically accessible either from 1a or a precursor thereof, which 
would require late-stage ring closure to build the indoline moiety. 
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4.4. Target Identification by Affinity Chromatography 
One of the methods utilized towards the determination of the target of 1a consists in the most widely 
utilized technique in this field: affinity-based proteomics, or “pull-down” (Chapter 2.2.1). In this 
chapter, the design, synthesis, and biological evaluation of a pull-down probe based on the 
information obtained from the SAR will be discussed. Moreover, the results obtained in a pull-
down experiment and the validation of the isolated proteins will be explained.  
 
4.4.1. Design and Synthesis of Pull-Down Probes 
As described in Chapter 2.2.1, a pull-down experiment requires the immobilization of the active 
compound on a matrix using a functional tag. Herein, an amine-tag was chosen for covalent 
attachment to NHS-activated magnetic sepharose beads. A spacer between the amine and the active 
compound should minimize steric hindrance between the target proteins and solid support. For this 
purpose, the hydrophilic 3-unit PEG linker was employed. PEG-based linkers are commonly used 
in affinity-based proteomics, as they improve the solubility of the probe and reduce non-specific 
binding due to their hydrophilicity (Chapter 2.2.1).[40]  
 Based on the derived SAR and because of their synthetic accessibility, two probes were 
designed which involved either C5-functionalization of indoline 1a or C3-functionalization of 
indole 16a. In order to evaluate their suitability for pull-down experiments, the probes were tested 
for their inhibitory activity in the GFP-based phenotypic screen for autophagy inhibition. Probes 
derived from an inactive analog of the compound collection served as negative controls. To increase 
the probability of binding to the sought-after target, pull-down probes should ideally retain the 
specific activity of the parent compound and be stable in aqueous media. 
 
a) Synthesis of 1st Generation Pull-Down Probes 
Prior to the attachment of a linker at C5, the bromide needed to be replaced by a bifunctional group 
which could be then reacted with a linker. Boronic acid pinacol ester 50 was a suitable candidate, 
as it can be inserted via palladium-catalyzed cross-coupling and then deprotected to give an alcohol 
nucleophile. Indoline 1a was coupled to 50 using standard Suzuki conditions to give protected 51 
in moderate yield. Tetrabutylammonium fluoride (TBAF)-mediated t-butyldimethylsilyl (TBDMS) 
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removal gave 34. Subsequent SN2 reaction with linker 52 using a reported procedure[106] afforded 
Boc-protected probe 53 (Scheme 9).  
 
Scheme 9. Route employed in the preparation of a pull-down probe for 1a with a linker attached at C5; pin 
= pinacol ester. 
 
 Trifluoroacetic acid (TFA)-mediated deprotection of 53 in CH2Cl2 resulted in 
uncharacterized side products, which were observed even upon reduction of the TFA concentration 
(Table 9, entry 1). Use of TFA in toluene or a CH2Cl2/toluene mixture as solvent afforded only 
traces of the desired product 54 (entries 2 and 3). Therefore, a mixture of HCl in dioxane was 
employed, yielding probe 54 in an overall yield of 18% after purification by preparative high-
performance liquid chromatography (HPLC) in the absence of TFA (entry 4).  
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Table 9. Optimization of reaction conditions for the deprotection of 53.[a] 
 
Entry Acid Solvent Yield 
1 TFA (7–50% v/v) CH2Cl2 many side products[b] 
2 TFA (20% v/v) toluene traces[b] 
3 TFA (20% v/v) toluene/CH2Cl2 traces[b] 
4 HCl (20% v/v) dioxane 59% 
[a] To a solution of 53 in the indicated solvent under an argon atmosphere, the acid was added dropwise. 
[b] Monitored by U-HPLC. 
 
 For the synthesis of a control probe, the inactive analog 1p was selected as a starting point. 
However, when the Suzuki conditions used for the conversion of 1a were applied to 1p, only the 
formation of sultam 55 was observed (Scheme 10). Generation of the 5-membered ring could occur 
via palladium-mediated activation of the alkene moiety in 56 and subsequent attack by the 
sulfonamide-N, followed by elimination of the TBDMSO group and final rearrangement to 55. 
Given that this side product was not detected upon reaction with 1a, this altered reactivity could be 
explained by an increased nucleophilicity of the sulfonamide-N, arising from the lower 
electronegativity on the aryl ring in 1p. No consumption of starting material 1p was observed upon 
reduction of the reaction temperature, whereas prolonged reaction time lead to formation of a 
second side product (uncharacterized) in addition to 55. As an alternative starting material, an 
inactive analog with an additional fluoro-substituent at the sulfonamide aryl ring and hence 
increased electronegativity was chosen. As predicted, control probe 57 was prepared in a 
satisfactory overall yield of 8% from 3,5-difluoro analog 1r. 
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Scheme 10. Suzuki-cross coupling conditions employed successfully in the synthesis of positive probe 54 lead 
to the formation of side product 56 when applied to the preparation of 55. After prolonged time at lower 
temperatures, only the formation of a second product was observed. 
 
b) Synthesis of 2nd Generation Pull-Down Probes 
Based on the SAR, which showed that C3 was a promising site for linker attachment (Chapter 
4.3.3), a pull-down probe was designed consisting of indoline 1a with a linker at C3. Probe 70 can 
be traced back to an indoline bearing a functional group R suitable for linker attachment (71). The 
C3-functionalized indoline can be obtained by reduction of the corresponding indole 72. Given that 
C3 is the most nucleophilic position on indoles, 16a can be reacted with a suitable electrophile to 
afford 72 (Scheme 11).  
 
NS
O O
N
H
F
O
Br
Pd(PPh3)4 (8 mol%)
Na2CO3 (3 eq.)
DMF/H2O 10:1, 105 °C, 20 h
TBDMSO B(pin)
NS
O O
N
O
F
55
40%
56
1p
50 (2 eq.)
NS
O O
N
H
O
F
O
TBDMS
Pd
NS
O O
N
O
F
 57 
 
Scheme 11. Retrosynthetic analysis used in the design of a second pull-down probe for affinity 
chromatography.  
 
i. C3-Functionalization of Indoles 
In a first functionalization attempt, indole 16a was planned to be converted to 73 by electrophilic 
aromatic substitution with oxalyl chloride and subsequent condensation with EtOH. Alternatively, 
direct reaction with ethyl chlorooxoacetate was pursued. However, reaction with oxalyl chloride 
and EtOH resulted in no conversion of the starting material (Table 10, entry 1). The same outcome 
was observed upon change of solvent and temperature increase (entries 2, 3). Using AlCl3 as a 
catalyst in a Friedel-Crafts acylation reaction at room temperature or reflux, no conversion was 
detected (entries 4, 5). Furthermore, employment of ethyl chlorooxoacetate gave the same result as 
the previous conditions (entries 6–8).  
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Table 10. Reaction conditions tested for the oxalylation of indole 16a. 
 
Entry X Eq. Oxalyl Reagent Reagents Solvent T Time Product
[c] 
1[a] Cl 2.0 2. EtOH Et2O rt 3.5 h no conversion 
2[a] Cl 2.0 2. EtOH Et2O/CH2Cl2 1:1 rt 4 h no conversion 
3[a] Cl 2.0 2. EtOH toluene reflux 16 h no conversion 
4[a] Cl 10.0 1. AlCl3, 2. EtOH CH2Cl2 rt 4 h no conversion 
5[a] Cl 10.0 1. AlCl3, 2. EtOH CH2Cl2 reflux 4 h no conversion 
6[b] Et 10.0 AlCl3 CH2Cl2 rt 14 h no conversion 
7[b] Et 10.0 AlCl3 CH2Cl2 reflux 14 h no conversion 
8[a] Et 10.0 1. AlCl3, 2. EtOH CH2Cl2 rt 14 h no conversion 
[a] To a solution of 16a in the indicated solvent, the oxalyl chloride source (and AlCl3, if indicated) was 
added, and the mixture was stirred at the indicated temperature for 3 h. The mixture was concentrated under 
reduced pressure, EtOH was added, and the mixture was stirred for a further 2–14 h. [b] To a solution of 
16a in the indicated solvent, the ethyl oxalyl chloride and AlCl3, were successively added, and the mixture 
was stirred at the indicated temperature for 14 h. [c] Conversion determined by 1H NMR. 
 
 In a second attempt to functionalize 16a, reported conditions for the Heck cross-coupling 
of indoles with t-butyl acrylate[107] were applied with no success (Scheme 12).  
 
Scheme 12. Attempted C3-functionalization of indole 16a via Heck-coupling, following a reported 
procedure.[108] 
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 The lack of reactivity observed could originate in the low nucleophilicity of the indole-C3 
due to the electron-withdrawing properties of the N-acyl moiety. Therefore, free indole 17 was 
submitted to the reaction conditions tested in the 16a functionalization attempts, affording 74 and 
75 in moderate and good yield, respectively (Scheme 13), thereby confirming our hypothesis. 
 
Scheme 13. C3-functionalization of indole 17 via Heck-coupling (74) and Friedel-Crafts acylation (75). 
 
ii. Reduction of C3-Functionalized Indoles 
After successful C3-functionalization of 16a, the next step towards a C3-functionalized derivative 
of 1a consisted in reduction to its indoline analog, followed by N-acylation. For the reductive step, 
conditions were necessary that would not compromise the C5-bromide functionality, thereby 
excluding Pd-catalyzed hydrogenations. A widely-used method for the reduction of indoles is the 
acid-mediated hydrogenation, which proceeds, similarly to most electrophilic aromatic 
substitutions on indoles, via C3-protonation and subsequent hydride attack at C2 (Scheme 14).[109] 
 
Scheme 14. Mechanism of the acid-mediated hydrogenation of indoles. 
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 Treatment of 74 with NaBH3CN and acetic acid as a hydride source/acid pair resulted in 
no conversion of the starting material (Table 11, entry 1). Given that the first step in this reaction 
involves dearomatization of the indole, it is plausible that this is the rate-determining step and a 
stronger acid than AcOH is needed. Therefore, the broadly-used Et3SiH/TFA pair[110-111] was 
employed in a test reaction to reduce C3-unsubstituted indole 17 and lead to full conversion to the 
corresponding indoline 10 (monitored by analytical HPLC and 1H-NMR, data not shown). When 
applied to 74, these conditions lead exclusively to reduction of the alkene while leaving the indole 
moiety intact (entry 2). No difference was observed when using CH2Cl2 as solvent or increasing the 
number of equivalents of the hydride/acid pair (entries 2–3).  
 
Table 11. Optimization conditions tested for the reduction of 74. 
 
Entry Hydride Source Acid Solvent Product[c] 
1[a] NaBH3CN (5 eq.) AcOH – starting material 
2[a] Et3SiH (6 eq.) TFA (37 eq.) – B (R = H) 
3[b] Et3SiH (6 eq.) TFA (6 eq.) CH2Cl2 B (R = H) 
4[a] Et3SiH (151 eq.) TFA (316 eq.) – B (R = H) 
[a] To a solution of 74 in the indicated acid, the hydride source was added. [b] To a solution of 74 in the 
indicated solvent, the acid and the hydride source were added. [c] The reaction was monitored by U-HPLC 
after 2–48 h. 
 
 Likewise, reduction of 75 using Et3SiH and TFA yielded only the deoxygenation of the 
oxalyl moiety (Scheme 15). Given that a) reduction of indoles with similar functional groups at C3 
as 75 has been reported before[112] and b) reduction of indole 17 was successful, the lack of reactivity 
could come from the cumulative effect of all the electron-withdrawing groups on the indole ring, 
which would render the C3 insufficiently nucleophilic. Therefore, a new strategy was attempted, in 
which the C3 group should be installed prior to C5- and C6-functionalization. 
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Scheme 15. Indole-reduction attempt of 75 by acid-mediated hydrogenation. 
 
iii. Early Installation of C3-Functionality Strategy 
An alternative strategy for the preparation of a probe with a linker at C3 consisted in the early 
installation of a C3 group. After reduction of the indole, the remaining functionalities of 1a should 
be installed prior to linker attachment. Starting from 5-bromoindole (76) the same conditions used 
for C3-functionalization of 17 were employed to give Heck-product 77 and ethyl oxoacetate 78 in 
satisfactory yields (Scheme 16) 
 
Scheme 16. C3-Functionalization of 5-bromoindole (76) via Heck-cross coupling (77)[107] and Friedel Crafts 
acylation (78). 
 
 In order to reduce the indole moiety, 77 was subjected to several conditions (Table 12). In 
neat NaBH3CN/AcOH, only the alkene group was reduced (entry 1). Traces of the desired product 
were observed when NaBH3CN was used in excess (entry 2). No conversion of the starting material 
was detected when using MeOH or DMF as solvents (entries 3–4) or the stronger acid TFA (entry 
5). Reaction with triethylsilane and TFA resulted in a number of uncharacterized side products 
(entry 6). Using the same hydride/acid system, traces of the indoline were detected when performing 
the reaction in CH2Cl2 (entry 7). However, increase of temperature or prolonged reaction time 
resulted again in several side products (not shown). Sodium borohydride in combination with TFA 
or acetic acid or in THF as a solvent resulted in either side products or starting material (entries 9–
11). 
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Table 12. Reaction conditions tested for the reduction of 77. 
 
Entry Reducing Agent (eq.) Acid Solvent Products[c] 
1[a] NaBH3CN (2) AcOH – starting material, B1 
2[a] NaBH3CN (5–20) AcOH – B1, traces of A1, side products 
3[b] NaBH3CN (4) AcOH MeOH starting material 
4[b] NaBH3CN (4) AcOH DMF starting material 
5[a] NaBH3CN (6) TFA – starting material 
6[a] Et3SiH (6–12) TFA – many side products 
7[b] Et3SiH (6–12) TFA CH2Cl2 B2, traces of A2 
8[a] BH3-THF (5) TFA – many side products 
9[a] NaBH4 (5) TFA – many side products 
10[a] NaBH4 (4) AcOH – starting material, B1 
11[a] NaBH4 (4) THF – starting material 
[a] To a solution of 77 in the indicated acid, the hydride source was added. [b] To a solution of 77 in the 
indicated solvent, the acid and the hydride source were added. [c] The reaction was monitored by U-HPLC 
after 2–48 h. 
 
 Alternatively, the reduction of 78 was performed with triethylsilane/TFA, yielding indoline 
79 in excellent yield (Scheme 17). Acylated indoline 80 was obtained in good yield following the 
procedure employed in the synthesis of 1a. 
 
Scheme 17 Reduction and subsequent acylation of oxalyl indole 78 leading to C3-functionalized acyl indoline 
80. 
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 Chlorosulfonylation of 80 was attempted using the general procedure employed in the 
generation of compound series 1. However, whereas no conversion was observed at room 
temperature in neat conditions or using a solvent (Table 13, entries 1–3), numerous side products 
were obtained at higher temperatures (entries 4–6).  
 
Table 13. Reaction conditions tested for the chlorosulfonylation of 80. 
 
Entry Temperature Time Solvent Product[c] 
1[a] rt 3 h – no conversion 
2[b] rt 3 h CH2Cl2 no conversion 
3[b] rt 3 h CH2Cl2/EtOH no conversion 
4[a] 40–70 °C 1–3 h – side products 
5[b] 40–70 °C 1–3 h CH2Cl2 side products 
6[b] 40–70 °C 1–3 h CH2Cl2/EtOH side products 
[a] To chlorosulfonic acid (≥ 12 eq.) at rt under an argon atmosphere, 80 was added and the mixture was 
stirred at the indicated temperature. [b] To a mixture of 80 in the indicated solvent at rt under an argon 
atmosphere, chlorosulfonic acid (1–12 eq.) was added dropwise, and the mixture was stirred at the indicated 
temperature. [c] Monitored by U-HPLC. 
 
 A possible cause for the aberrant reactivity of 80 in contrast to bromoindoline 3 is the ester 
functionality, which can hydrolyze in acidic milieu and consequently interfere with the electrophilic 
aromatic substitution with chlorosulfonic acid. Therefore, a protecting group was chosen, which 
was more tolerant towards acidic conditions than an ester. For this purpose, the ester functionality 
in 80 was reduced selectively using lithium borohydride. The resulting alcohol 81 was reacted with 
a) TBDMSCl or b) acetic anhydride to give the corresponding TBDMS- and acetate-protected 
alcohols 82 and 83, respectively. However, chlorosulfonylation leading to the desired products 84 
and 85 was not successful (Scheme 18). 
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Scheme 18. Selective reduction of the ester acetate functionality at C3, protection of the generated alcohol, 
and subsequent chlorosulfonylation attempts for the synthesis of a C3-functionalized indoline derivative of 
1a. 
 
 Due to the poor reactivity of multifunctionalized indoles towards mild reduction agents and 
the low tolerance of acid-labile groups towards chlorosulfonylation, it was not possible to obtain a 
C3-functionalized indoline analog of 1a from the precursors available. Late-stage ring closing of 
the indoline moiety might represent a better strategy to circumvent the above-mentioned issues. 
However, because of time limitations, a different synthetic strategy was not attempted in the course 
of this thesis. Nevertheless, a pull-down probe with an indole core provided a good alternative to 
the initially designed probe, as indole analogs of 1a inhibited autophagy with low micromolar 
potencies (Chapter 4.3.3).  
 
iv. Probe Synthesis 
The second generation of pull-down probes was prepared starting from indole 17 (Scheme 19). 
Friedel-Crafts acylation followed by deoxygenation of the resulting oxoacetate moiety afforded 90 
in good overall yield. Given that reaction with cyclopropane carboxylic acid gave a 1:1 mixture of 
the mono- and double-acylated products and hydrolysis of the ester was not chemoselective, i.e. 
also cleaved the previously installed acyl groups (not shown), the acyl group needed to be installed 
at a later stage. Thus, ester 90 was hydrolyzed and subsequently reacted with mono-Boc PEG linker 
91 using standard amide coupling conditions to give 92. Acylation and final Boc-deprotection 
afforded pull-down probe 93, which was separated from the double-acylated product by preparative 
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HPLC. The 1r-derived negative control 94 was synthesized analogously from indole 95 in 30% 
overall yield. 
 
Scheme 19. Route employed in the preparation of a pull-down probe for 1a with a linker attached at C3. 
 
4.4.2. Biological Activity and Stability of Pull-Down Probes 
To avoid off-target binding during a pull-down experiment, a chemical probe should ideally retain 
the activity of the parent compound and be stable in assay conditions. To address these questions, 
the pull-down probes were tested by COMAS in the phenotypic screen for autophagy inhibition. 
Whereas pull-down probe 53 displayed no activity, 93 inhibited autophagy, although nearly 15-
times less potently than 1a, still in the low micromolar range (Scheme 20). Additionally, stability 
analysis by NMR and analytical HPLC revealed that probe 54 decomposed over time. 
Consequently, only probe 93 was evaluated further  
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Scheme 20. Inhibition potencies of starvation-induced autophagy are shown for the pull-down probes 53 and 
93. Inhibition was measured in the phenotypic screen described in Chapter 4.1.1. Data shown are mean 
values ± SEM (N ≥ 3). 
 
 To determine whether the probe was stable under the conditions employed in a pull-down 
experiment, 93 was incubated in aqueous buffers and monitored by analytical HPLC. In coupling 
buffer (used for the immobilization of chemical probes to a solid support) at pH 8.4 and 4 °C, one 
main peak was visible in the chromatogram after incubation for 13 h (Figure 18). Analysis of this 
peak by MS revealed an m/z = 713.2, which was assigned to hydrolysis product 96, and only traces 
of 93 were obtained. Partial conversion to 93 also occurred after a shorter incubation time, 
indicating that these conditions were not optimal for coupling. Therefore, the stability of 93 was 
monitored at lower pH. Whereas no hydrolysis of the probe was observed in water after 13 h, a 1:1 
ratio of 93/96 was detected in coupling buffer at physiological pH. Nevertheless, the latter 
conditions were selected for the experiment, as slightly basic conditions are required for efficient 
coupling. 
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Figure 18. Pull-down probe 93 hydrolyzes in aqueous solutions at pH > 7. Reaction was monitored by 
preparative MS-coupled HPLC. Coupling buffer: 0.15 M triethanolamine, 0.5 M NaCl. 
 
4.4.3. Affinity Chromatography and Subsequent SILAC-Based Quantitative Proteomics 
To identify the target of 1a, a label-free pull-down experiment was conducted using active probe 
93 and control probe 94. For this purpose, lysates were prepared from MCF7-eGFP-LC3, i.e. the 
cell line used in the phenotypic assay. Immobilization of the probes to NHS-magnetic sepharose 
beads was performed at pH 7.4 and 4 °C for 13 h due to the unstable character of the probes at 
higher pH (see previous chapter). According to the analysis of the samples by tandem MS/MS, none 
of the proteins quantified (ca. 800 in each sample) were enriched in the active probe sample 
compared to the control, hence no potential targets were determined. Therefore, SILAC (Chapter 
2.2.1) was employed, which allows for quantitative analysis of the probes as a result of its higher 
sensitivity. For this experiment, two lysates were prepared from MCF7-eGFP-LC3 cells. The first 
contained proteins with natural amino acids (“light”, L). For the second lysate, cells were utilized 
that had incorporated isotopically labeled arginine and lysine into their proteins (“heavy”, H). This 
results in a characteristic mass shift for every protein. Each lysate was incubated with active probe 
93 and control 94 separately, thereby generating the samples Hactive, Hcontrol, Lactive, and Lcontrol. The 
lysates were then combined as follows: Lactive with Hcontrol and Lcontrol with Hactive, and the tryptic 
peptides of the mixtures analyzed by tandem MS/MS. Proteins enriched by only by active probe 93 
displayed peak pairs with an opposite H:L ratio for each sample (Figure 19) and were thus identified 
as potential targets of 1a. 
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Figure 19. Mass shift and peak intensities observed by MS/MS for proteins enriched by the active pull-down 
probe in a SILAC-based proteomics experiment. 
 
 A total of three proteins were identified as target candidates for 1a: glutamate 
dehydrogenase (GDH or GLUD), calpain-1, and histidine triad nucleotide binding protein 1 
(HINT-1) (Table 14). Because of their cellular functions, GDH and calpain-1 were selected as high 
priority target candidates for 1a, and the effect of 1a on these enzymes was evaluated in biochemical 
and biophysical assays. 
 
Table 14. Proteins identified by SILAC-based quantitative pull-down as potential targets of 1a, using 2nd 
generation pull-down probe 93.  
Protein (Gene Name) Hact : Lctrl Lact : Hctrl 
 GDH 2.19 ± 0.18 3.23 ± 0.02 
 CAPN1 1.64 ± 0.27 1.75 ± 0.02 
HINT-1 1.71 ± 0.18 2.63 ± 0.02 
The active probe and the control (10 µM) were immobilized to NHS magnetic sepharose beads and incubated 
with “heavy” and “light” MCF7-eGFP-LC3 lysates separately for 2 h at 4 °C. Values shown are MS-intensity 
ratios for the enriched proteins in the pull-downs. H = heavy lysate; L = light lysate; act = active probe; ctrl 
= control probe. 
 
4.4.4. Target Validation 
The last step in a target identification approach consists in the validation of the identified hits in 
proteomics experiments as targets of the modulator in question. Confirmation of the pull-down 
results can be accomplished by means of a competitive pull-down. For this purpose, cell lysate is 
Lactive 
Hcontrol 
Hactive 
Lcontrol 
m/z m/z 
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incubated with the probe together with the linker-free compound. The higher the concentration of 
the linker-free compound, the less amount of target protein will bind to the probe, as a result of a 
higher degree of saturation of the target by the free compound (Figure 20). Proteins bound to the 
solid support are then analyzed by western blotting. 
 
Figure 20. Schematic representation of the principle of a competitive pull-down experiment, employed to 
validate the results of a quantitative pull-down. 
 
 Other techniques to assess target engagement include DSF, ITC, FP, and microscale 
thermophoresis (Chapter 2.2.1). For the validation of targets for 1a, biophysical assays that did not 
require labeling were prioritized because of the unstable nature and relatively low activity of the 
probe. 
 Potential enzymatic targets can be validated by determining the effect of the compound on 
their specific enzymatic activity. An additional tool is to study the effect of a genetic knockdown 
or overexpression of the target on the studied pathway. Once validated, the regulatory function of 
the target can be determined.  
 
a) Evaluation of Glutamate Dehydrogenase as a Target of Indoline 1a 
Glutaminolysis is the process responsible for the metabolism of the amino acid glutamine by 
converting it to α-ketoglutarate (α-KG). This metabolic pathway is activated by leucine and 
glutamine and thus involved in amino acid sensing. Furthermore, it has been proven to stimulate 
mTORC1 via the activation of prolyl hydroxylases (PHDs),[113] thereby regulating autophagy.[114] 
One of the key players of glutaminolysis is the enzyme GDH, which catalyzes the conversion of 
glutamate to α-KG upon activation by L-Leu, L-Ile, L-Val, or ADP. Recent studies by Blenis and 
coworkers showed that mTORC1 activates GDH via transcriptional repression of sirtuin 
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(SIRT4),[115] thereby establishing a possible connection to autophagy. Not much later, Lorin et al. 
reported the regulation of autophagy by GDH.[116] The authors describe an increase in LC3 puncta 
and LC3-II levels upon knock-down of GDH, which is consistent with autophagy activation. In 
addition, their results indicate that GDH is required for leucine-sensing in autophagy, as a GDH 
knock-down prevents the stimulation of mTOR by L-Leu and ultimately the inhibition of 
autophagy. These findings provide evidence for a negative regulation of autophagy by GDH via the 
activation of mTORC1, which, together with the findings of Blenis and coworkers, would suggest 
a feedback loop (Figure 21). Following the observations of Lorin et al., an inhibitor of autophagy 
targeting GDH would be expected to act as an activator thereof. To test whether 1a inhibits 
autophagy via modulation or binding of GDH, three independent assays were performed.  
 
Figure 21. GDH negatively regulates autophagy via the activation of mTORC1.[113-114, 116]  
 
i. Competitive Pull-Down 
Whereas GLUD2 is enriched in Sertoli cells (testis) and astrocytes (brain), GLUD1 is expressed in 
all human tissues.[117] Moreover, both isozymes have a remarkably high sequence identity (96%). 
Therefore, validation studies focused on GLUD1. A competitive pull-down experiment confirmed 
that probes 93 and 94 bind to GDH in MCF7-eGFP-LC3 lysate (Figure 22). A slightly higher level 
of the protein was detected for the active probe by western blotting, which is consistent with the 
proteomics experiment. However, 1a was not able to outcompete binding of the active probe 93, 
suggesting that GDH is not a target of 1a.  
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Figure 22. Pull-down probes 93 and 94 bind to GDH in cell lysate, but free 1a is not able to outcompete the 
positive probe. Competitive pull-down was performed with active pull-down probe 93 (10 µM) in presence of 
increasing concentrations of 1a using MCF7-eGFP-LC3 cell lysate and NHS magnetic sepharose beads (GE 
Healthcare®, cat# 28951380) followed by SDS-PAGE and immunoblotting for detection of GDH using Anti-
Glud1 (Merck Millipore, cat# ABN443). Control probe 94 was used as a control (n = 3).  
 
ii. Differential Scanning Fluorimetry 
TSAs make use of the fact that protein thermostability can be enhanced by binding of a small 
molecule.[61] Hence, a shift in the melting temperature of a protein can be observed upon incubation 
with a small-molecule inhibitor. As a protein unfolds due to a gradual temperature increase, it 
exposes hydrophobic regions. By utilizing a dye whose fluorescence is enhanced when bound to 
these hydrophobic regions, protein denaturation can be monitored (Figure 23).[118] In a DSF assay, 
the fluorescence produced by Sypro Orange upon binding to a protein can be measured in a thermal 
cycler. One of the advantages of DSF is that no modification on the compound is required. 
However, as for most target engagement assays, large amounts of purified protein are needed. 
 
Figure 23. Principle of a TSA using DFS. A fluorescence increase of the dye Sypro Orange upon binding of 
a protein can be monitored in a real-time quantitative polymerase chain reaction (qPCR) cycler. A protein 
binder increases the melting point Tm. 
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 Bovine GDH (bGDH) was used in the DSF assay because of its commercial availability, 
as it shares a high sequence homology with GDH1 (98%) and GDH2 (94%). Incubation of bGDH 
with its allosteric regulator L-leucine[119] resulted in a strong increase of the melting temperature 
only at concentrations > 1 mM (Figure 24 and Table 15, entries 4–6), suggesting that high 
concentrations are required for a measurable effect.  
 
Figure 24. Indoline 1a has no effect on the thermostability of GDH. Melting curves of compound-treated 
bovine GDH (0.1 mg/mL) in phosphate buffer (pH = 8) determined by differential scanning fluorimetry using 
Sypro Orange). Lower concentrations omitted for clarity. Representative graph shown (n = 2–3, each in N = 
3). RFU = Relative fluorescence units. 
 
 Other compounds were tested only at lower maximal concentrations than L-Leu because of 
their low solubility in aqueous solutions. Only negligible melting temperature shifts (dTm < 0.5 °C) 
were obtained for 1a (Table 15, entries 1–3) and pull-down probes 93 (entries 8–10) and 94 (entries 
11–13) at any of the concentrations assayed. Tested as additional controls, the known inhibitor 
epigallocatechin gallate (EGCG),[120] and the known activator 2-aminobicyclo[2.2.1]heptane-2-
carboxylic acid (BCH)[119] displayed no effect on the thermostability of GDH (entries 7 and 14). 
The target engagement results for 1a in this assay were therefore inconclusive, as no effect was 
observed for any of the controls tested at the concentrations accessible for 1a. 
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Table 15. Melting temperature differences for bovine GDH upon incubation with different compounds 
compared to DMSO control, measured using differential scanning fluorimetry. Data shown are mean values 
± SD (n = 2–3, each in N=3).  
Entry Compound c dTm (°C) Entry Compound c dTm (°C) 
1 
1a 
10 µM 0.33 ± 0.24 8 
93 
10 µM 0.25 ± 0.35 
2 50 µM 0.28 ± 0.19 9 50 µM - 0.17 ± 0.24 
3 200 µM 0.17 ± 0.29 10 200 µM - 0.58 ± 0.35 
4 
L-Leu 
200 µM 0.50 ± 0.24 11 
94 
10 µM 0.25 ± 0.12 
5 1 mM 1.58 ± 0.35 12 50 µM 0.42 ± 0.35 
6 10 mM 7.00 ± 0.33 13 200 µM 0.42 ± 0.12 
7 BCH 200 µM 0.39 ± 0.19 14 EGCG 50 µM 0.56 ± 0.25 
 
 
iii. Glutamate Dehydrogenase Activity 
To determine whether 1a affected the activity of GDH, a colorimetric assay was employed, which 
allowed the quantification of the generated NADH during the enzymatic reaction (Figure 25). The 
amount of NADH produced over a specific time range correlates with the enzymatic activity of 
GDH.  
 
Figure 25. Principle of the enzymatic activity assay employed to test the modulating effect of 1a on GDH. 
GDH catalyzes the conversion of L-Glu to α-KG. The generated NADH is reacted with a developer to produce 
a colorimetric product. An NADH dilution series is employed to generate a standard curve, which is used to 
determine the specific activity of the enzyme. 
 
 As for the DSF assay, bGDH was employed, with L-Leu and EGCG as controls. It could 
be demonstrated that EGCG inhibits GDH activity at 10 µM and L-Leucine only slightly activates 
GDH at 20 mM (109% activity), which is consistent with the literature.[120] Furthermore, a similar 
abrogative effect of L-Leu at on the inhibition of EGCG was observed (109%). No activation of 
GDH was measured when treated with 1a alone (10 or 100 µM, 96 and 94%, respectively), as well 
-O2C CO2-
NH3+
-O2C CO2-
O
GDH
H2O
NAD+
NH4+
NADHL-glutamate α-ketoglutarate
colorimetric 
product
developer
(kit)
 74 
as in the presence of EGCG (93%). Compared to EGCG, the inhibitory effect of 1a was considered 
negligible (Figure 26). 
 
Figure 26. Indoline 1a has no effect on the enzymatic activity of GDH. GDH activity was determined in 
presence of 1a, the endogenous allosteric activator L-Leu, and the inhibitor EGCG. The amount of glutamate 
consumed by GDH is measured by monitoring the amount of NADH generated per min in a colorimetric 
assay using bGDH at 2 µg/mL. Each data point represents a duplicate measurement of the activity normalized 
to the DMSO control. Further concentrations were omitted for clarity. 
 
 To address the question whether a negative modulator of GDH activity had any effect on 
autophagy, the inhibitor EGCG was tested in the phenotypic assay for autophagy inhibition and was 
found to be inactive. Selective activators have unfortunately not yet been discovered, hence a 
positive control for GDH activation could not be tested for autophagy inhibition. In conclusion, 
whereas the thermostability studies were inconclusive, both the competitive pull-down and activity 
assay strongly suggest that GDH is not the target of 1a. Therefore, further target validation studies 
were not pursued. 
 
b) Evaluation of Calpain-1 as a Target of Indoline 1a 
The second protein isolated by pull-down, CAPN1, is a subunit of calpain-1. The calpain family 
comprises over a dozen isoforms of calcium dependent cysteine proteases. The best-characterized 
calpains are the ubiquitously expressed calpain-1 and calpain-2. Both enzymes consist of a catalytic 
subunit (CAPN1 and CAPN2, respectively) and a common regulatory subunit (CAPNS1).[121] It has 
been reported that autophagy is impaired in calpain-deficient cells.[122] Moreover, studies prove that 
calpains are involved in the downregulation of the ATG5–ATG12 conjugate, which is required for 
0
50
100
L-Leu
1a
10
 µ
M
10
 m
M
20
 m
M
10
0 
µM
10
0 
µM
+ EGCG 10 µM
D
M
SO
G
D
H
 a
ct
iv
ity
 (%
 o
f D
M
SO
)
 75 
autophagosome formation, by cleaving ATG5.[123] Therefore, as calpains are negative regulators of 
autophagy, an activator of these proteases would inhibit autophagy. To test this hypothesis 
regarding 1a and validate the pull-down results, a competitive pull-down and activity assays were 
performed.  
 
i. Competitive Pull-Down 
A competitive pull-down was conducted under the same conditions as for the devalidation of GDH. 
Unlike for the first hit, no binding of the pull-down probe 93 or its control 94 was observed (Figure 
27), thereby contradicting the initial finding. The low intensity observed in the input control 
indicates low levels of calpain-1 in the lysate, which could explain why enrichment by the active 
probe was only detected by the highly sensitive SILAC method. Therefore, an orthogonal assay 
was performed to address target engagement.  
 
Figure 27. Indoline-based probes do not bind to calpain-1 in cell lysate. Competitive pull-down of active 
pull-down probe 93 (10 µM) with increasing concentrations of 1a, using MCF7-eGFP-LC3 cell lysate and 
NHS magnetic sepharose bead followed by SDS-PAGE and immunoblotting for detection of calpain-1 using 
Anti-CAPN1. Probe 94 was used as a negative control (n = 3). 
 
ii. Calpain-1 Activity 
Calpain-1 activity was measured in a fluorescence-based assay, which utilizes Ac-LLY-7-amino-
4-trifluoromethylcoumarin (AFC), a substrate for the protease (Figure 28). Generation of the 
fluorescent AFC upon cleavage by calpain-1 can be monitored over time. The calpain activator 
dibucaine[124] and the inhibitor MDL-28170[121, 125] were used as controls.  
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Figure 28. Calpain-1 activity can be determined by monitoring the calpain-1-mediated cleavage of Ac-LLY-
AFC, which generates fluorescent AFC.  
 
 In agreement with the literature, MDL-28170 strongly inhibited calpain-1 at 500 nM (Table 
16, entries 1–3), whereas only a slight activation was observed for the activator dibucaine (entries 
4, 5). In contrast, 1a had no effect on the activity of calpain (entries 6–8). Neither dibucaine nor 1a 
were able to abrogate the inhibition of MDL-28170. Additionally, dibucaine and MDL-28170 were 
tested in the LC3-puncta assay and showed no inhibition of autophagy at 10 µM (Figure 29). 
 
Table 16. Effect of 1a on the activity of calpain-1. 
Entry Compound(s) c Inhibition (%) Entry Compound(s) c Inhibition (%) 
1 
MDL-28170 
50 nM 23.3 ± 2.3 6 
1a 
10 µM - 7.3 ± 3.7 
2 100 nM 68.7 ± 5.5 7 5 µM 7.2 ± 6.5 
3 500 nM 94.3 ± 4.7 8 3 µM 9.4 ± 7.2 
4 
dibucaine 
2.5 µM - 6.2 ± 8.5 9 dibucaine,  MDL-28170 
10 µM,  
100 nM 78.0 ± 4.2 
5 10 µM - 7.5 ± 1.6 10 1a,  MDL-28170 
10 µM,  
100 nM 80.0 ± 6.2 
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Figure 29. Indoline 1a does not inhibit the enzymatic activity of calpain-1. Calpain-1 activity was determined 
in a fluorescence-based assay using human calpain-1 inhibition screening kit, by monitoring the cleavage of 
Ac-LLY-AFC by the enzyme (i.e. the generation of the fluorescent AFC) after incubation with 1a, the known 
activator dibucaine, or the known inhibitor MDL 28170 at 37 °C for 5 min. Each data point represents a 
duplicate measurement of the inhibition related to the DMSO control. Additional concentrations omitted for 
clarity (n = 2, each in N = 2). 
 
4.4.5. Conclusion 
Two pull-down experiments were performed to identify the target of 1a. To this end, two different 
pull-down probes were designed based on the SAR delineated for the autophagy inhibitor. Whereas 
no major difficulties were encountered when synthesizing a probe with a linker at the C5 of 1a (53), 
all attempts to access a C3-functionalized derivative of indoline 1a were unsuccessful. Given that 
the activities of indole analog 16a and a C3-functionalized analog (38) were in the micromolar 
range, a pull-down probe was synthesized with an indole core instead (93). Stability tests revealed 
that Boc-protected 53 was highly unstable. The 2nd generation probe 93 on the other hand, was 
stable only under neutral or acidic conditions, and hydrolyzed under standard pull-down coupling 
conditions. Therefore, the conditions for the pull-down experiments were optimized to minimize 
hydrolysis. 
 GDH, calpain-1, and HINT-1 were isolated in a quantitative pull-down. However, the 
validation studies indicate that neither GDH nor calpain-1 are targets of 1a. HINT-1 was not 
pursued as a putative target due to the low ratios detected by MS/MS. The results taken together 
provide evidence that the probes designed, which suffered from stability and biological activity 
issues, were not suitable for a pull-down assay. Furthermore, the surprisingly low number of hits 
obtained in both pull-down experiments could arise from the structural similarity of the probes, as 
these only differ in the sulfonamide aryl ring. The short list in the SILAC-based pull-down 
experiment may also suggest that the target of 1a is either of low abundance, a membrane protein, 
-25
0
25
50
75
100
ca
lp
ai
n-
1 
in
hi
bi
tio
n 
(%
 o
f D
M
SO
)
10
 µ
M
10
 µ
M
2.
5 
µM
3 
µM
10
 µ
M
10
 µ
M
+ MDL 28170
(100 nM)
D
M
SO
dib. 1a
 78 
or both. Despite the high sensitivity of SILAC-based proteomics, low abundant proteins remain a 
significant hurdle. The identification of membrane proteins by affinity chromatography is another 
major challenge, as they are prone to aggregation in solution, and most detergents present in lysis 
buffers disrupt their secondary structure,[56] making them inaccessible for small molecule binders 
(Chapter 2.2.1). Considering all the obstacles faced by the target identification of 1a using affinity 
chromatography, a different approach was necessary. 
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4.5. Target identification by Thermal Proteome Profiling 
As described in the previous chapters, pull-down techniques are often hampered by modifications 
of the parent compound for the introduction of a linker, as it can interfere with binding to the target 
protein. TPP represents an attractive linker-free alternative to affinity-based proteomics. This 
method is based on the thermal stability of proteins, which can change upon binding of a small 
molecule (Chapter 2.2.1). Full cell lysates are incubated with either the studied compound in DMSO 
or DMSO alone in a thermal gradient and the soluble fractions analyzed by MS/MS. The peak 
intensities for each protein are then plotted against the temperature, thereby generating melting 
curves. A protein displaying a shift in its melting curve for the compound-treated sample in 
comparison to the DMSO-treated lysate represent potential targets of the compound.  
  
4.5.1. Thermal Proteome Profiling with Indoline 1a 
A TPP for 1a was performed with MCF7-eGFP-LC3 cell lysate. A lysis buffer containing NP-40 
alternative was used to enhance the solubility of membrane proteins and therefore increase their 
concentration in the lysate. To search for potential targets of 1a, the results were filtered by the 
following criteria: 1) the protein is either stabilized or destabilized in all three replicates and 2) a 
strong (de)stabilization is observed with an average shift in melting temperature (dTm) > 1.5 °C or 
an average final intensity difference (dInt) > 10%. A total of 96 proteins were identified as hits 
following the constraints set (Table 17).  
 
 80 
Table 17. Selected potential targets of 1a identified in TPP experiment based on their melting temperature 
shift compared to DMSO (n = 3). 
Entry Gene Names Protein names dTm (°C) dIntT9 dIntT10 
1 P2RX4 P2X purinoreceptor 4 3.27 0.14 0.08 
2 SLC39A14 Zinc transporter ZIP14 2.71 0.08 0.08 
3 RAB27A Ras-related protein Rab-27A 2.64 0.19 0.18 
4 CCS Copper chaperone for superoxide dismutase 2.43 0.09 0.07 
5 LAMTOR5 Ragulator complex protein LAMTOR5 2.39 0.12 0.05 
6 ATRX Transcriptional regulator ATRX -4.04 0.10 0.10 
7 FAM114A1 Protein NOXP20 -2.95 0.02 0.04 
8 TSPYL5 Testis-specific Y-encoded-like protein 5 -2.58 0.08 0.09 
9 RAB11FIP1 Rab11 family-interacting protein 1 -2.51 0.14 0.15 
10 TBC1D5 TBC1 domain family member 5 -2.37 0.06 0.09 
11 LTN1 E3 ubiquitin-protein ligase listerin -2.30 0.08 0.04 
12 CAMSAP3 Calmodulin-regulated spectrin-associated protein 3 -2.22 0.04 0.03 
13 ARMC1 Armadillo repeat-containing protein 1 -2.18 0.08 0.07 
14 TFG Protein TFG -2.14 0.06 0.02 
15 EPB41 Protein 4.1 -2.12 0.09 0.06 
16 POLR2I DNA-directed RNA polymerase II subunit RPB9 -2.12 0.09 0.18 
17 SUOX Sulfite oxidase, mitochondrial -2.09 0.02 0.03 
18 VCPIP1 Deubiquitinating protein VCIP135 -2.07 0.12 0.09 
19 RBM12B RNA-binding protein 12B -2.02 0.05 0.05 
20 MRPS27 28S ribosomal protein S27, mitochondrial -1.30 0.17 0.18 
21 FOXK1 Forkhead box protein K1 0.30 0.13 0.15 
22 FHOD1 FH1/FH2 domain-containing protein 1 -0.27 0.15 0.14 
23 PPP1R13B Apoptosis-stimulating of p53 protein 1 -0.27 0.16 0.13 
24 ATXN2 Ataxin-2 1.07 0.13 0.13 
25 SLC7A6OS Probable RNA polymerase II nuclear localization protein SLC7A6OS -1.90 0.13 0.13 
26 PPP1R2 PPP1R2P3 Protein phosphatase inhibitor 2 0.37 0.10 0.11 
MCF7-eGFP-LC3 cell lysates were incubated with 1a (2.5 µM) or DMSO (1 v/v%) for 30 min and aliquoted 
into ten samples, each of which was incubated at increasing temperatures. The soluble fraction of each 
sample was processed for MS-analysis. Proteins listed are stabilized or destabilized by 1a with an average 
melting temperature shift of ≥ 2 °C or intensity shift of ≥ 10% at the highest temperature. dTm = difference in 
melting temperature between DMSO- and compound-treated samples; dInt = difference in signal intensity 
between DMSO- and compound-treated samples at 65 °C (T9) and 67 °C (T10) normalized to 1. 
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4.5.2. Target Validation 
As in every proteomics experiment, the hits identified by TPP needed to be confirmed as targets of 
1a. P2X4 and LAMTOR5 were selected as high priority candidates for further validation due to the 
strong stabilization displayed by these hits upon uncubation with 1a. Depending on the protein class 
and function, different methods were employed for these putative targets.  
 
a) Evaluation of P2X4 as a Target of Indoline 1a 
The best hit in the TPP, P2X4, was stabilized in the presence of 1a in all three biologically 
independent replicates. The melting point in the presence of 1a was in average 3.3 °C higher than 
for the DMSO control, whereby a 14% stabilization was observed at 65 °C (Figure 30).  
 
Figure 30. Melting curves of P2X4 upon incubation with 1a (compound, blue) or DMSO (vehicle, red) for 
each replicate.  
 
 The ionotropic purinergic receptor P2X4 is an ATP-gated cation channel of the purinergic 
receptor family, with a strong affinity for Ca2+. Though little is known about its function, it appears 
to regulate vascular tone and the development of neuropathic and inflammatory pain.[126] To date, 
only ATP and closely related analogs, such as 2-meSATP and α,β-meATP, have been identified as 
potent agonists. The macrolactone ivermectin, a glutamate-gated chloride channel (GluCl) and 
GABAA binder, can potentiate the currents evoked by ATP binding of P2X4.[126-127] The only 
antagonist known, benzodiazepine 5-BDBD, was developed over a decade ago.[128] This lack of 
potent, selective modulators is a major drawback in the study of this receptor and other subtypes of 
the P2X family.  
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 Only recently it was shown that ivermectin induces autophagy in breast cancer cells.[129] 
However, a direct link between P2X channels and autophagy has not been demonstrated yet. 
Nevertheless, numerous calcium permeable channels have been reported to regulate autophagy,[130] 
which is consistent with the fact that Ca2+ plays a crucial role in the mTOR-independent inhibition 
of this pathway.[15] To confirm that 1a acts via P2X4 to inhibit autophagy, different experiments 
were performed.  
 
i. Cellular Thermal Shift Assay  
 CETSA is a complementary approach to TPP, which allows the visualization of protein 
melting by western blot. The samples utilized in both techniques may originate from the same 
experiment and are split after ultracentrifugation. For CETSA, the soluble fraction is processed for 
protein separation and immunostaining.  
 The findings of the TPP were confirmed for P2X4 by CETSA, as a substantial difference 
was observed between the compound- and DMSO-treated samples by immunoblotting (dTm = 
1.2 °C, Figure 31). 
 
Figure 31. The thermostability of P2X4 is enhanced by 1a. Top: Visualization by immunoblotting; bottom: 
quantification of western bands strength using ImageStudio software. MCF7-eGFP-LC3 cell lysates were 
incubated with 1a (2.5 µM) or DMSO (1 v/v%) for 30 min and aliquoted into 10 samples, each of which was 
incubated at a different temperature. Proteins in the soluble fraction were separated by SDS-PAGE and 
probed for P2X4 using anti-P2X4 (Alomone Labs, cat# APR-002) (n = 3). 
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ii. Functional and Binding Assays  
The role of Ca2+ in autophagy is not fully clear and still a matter of debate. It has been demonstrated 
that the divalent cation is involved in numerous pathways leading to both the induction and 
inhibition of autophagy.[131] For example, Ca2+-release from the ER triggers autophagy through 
binding of calmodulin, which ultimately leads to the inhibition of mTOR.[132] Other studies suggest 
that extracellular influx of calcium activates calpain, which cleaves ATG5 thereby inhibiting the 
autophagosome formation.[123] Given the importance of calcium in the regulation of autophagy, 
modulation of the P2X4 receptor by an autophagy inhibitor could represent a possible relationship 
between the two.  
 As an initial study, the influence of 1a on intracellular calcium levels was tested in MCF7 
cells. Whereas the control ionomycin elicited a strong influx of calcium, no change was observed 
upon incubation with 1a (Figure 32). Testing 1a in antagonist mode was not possible in this setup, 
i.e. with cells expressing endogenous levels of P2X4, due to the lack of a selective agonist.  
 
Figure 32. Indoline 1a does not increase intracellular calcium levels. Intracellular calcium levels in MCF7 
cells were measured using the calcium-sensitive fluorescent dye Fluo-8NW and ionomycin as a positive 
control (n = 2, each in N = 3). 
 
 The evaluation of ion receptor function in cell-based assays is generally not straightforward 
due to several issues: Although a high expression level of the studied receptor is necessary to detect 
a response in Ca2+-based assays, overexpression of certain ion receptors can lead to cytotoxicity.[133-
134] Unlike in the study of GPCRs, specific high-affinity receptor agonists are rare for certain 
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channels or may not allow the detection of weak antagonists.[134-135] These are most likely the 
reasons why gating of P2X4 receptor is commonly studied using electrophysiological methods.[136-
138] Electrophysiology is widely applied to the study of the functional characteristics of ion channels, 
as it provides high-quality functional information on channel–compound interaction.[133] Therefore, 
the effect of 1a on P2X4 is currently being evaluated in a patch clamp assay. 
 A procedure to study binding of ion channels, consists in measuring the displacement of a 
labeled receptor binder by the studied compound, using membranes from a tissue with 
endogenously high levels of the studied receptor. Preliminary results showed only 5% [3H]α,β-
meATP displacement inhibition by 1a for the P2X family, hence a negligible binding affinity. 
However, these results only prove that 1a does not bind at the same site as ATP. It remains to be 
seen whether 1a acts at a different allosteric site to ATP. 
 
b) Evaluation of LAMTOR5 as a Target of Indoline 1a 
The protein LAMTOR5 was identified as a putative target of 1a because of its strong stabilization 
observed upon treatment with the compound. An average 2.4 °C melting point shift and a 12% 
intensity increase at 65 °C were detected with 1a in contrast to the DMSO control (Figure 33). 
 
Figure 33. Melting curves of LAMTOR5 upon incubation with 1a (compound, blue) or DMSO (vehicle, red) 
for each replicate.  
 
 LAMTOR5 constitutes part of the pentameric Ragulator complex and was only identified 
five years ago.[139] The Ragulator complex itself was found to exhibit binding affinity and a guanine 
nucleotide exchange factor (GEF) activity towards RagA and RagB upon activation by v-ATPase. 
The Rag heterodimer consists of a RagA/B and a RagC/D unit, both small GTPases. Upon 
activation, the dimer switches from RagA/B(GDP)-RagC/D(GTP) to RagA/B(GTP)-
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RagC/D(GDP), which then recruits and activates mTORC1, leading to inhibition of autophagy.[139] 
No activity of individual Ragulator subunits has been reported to date. Thus, to examine whether 
1a inhibits autophagy by specific modulation of the complex, the activity of the downstream 
effector mTOR could be tested. In a more direct assay, the GEF activity of Ragulator towards 
RagA/B in the presence of 1a could be evaluated by analyzing the displacement of GDP-γS from 
RagA/B-RagCD181N, as described by Sabatini and coworkers.[139] To address binding affinity of 
LAMTOR5 towards 1a, biophysical studies with the purified proteins could be performed.  
 As for the CETSA by immunoblotting, no change in the melting behavior of LAMTOR5 
upon treatment with 1a was observed (Figure 34). However, this result does not devalidate the 
findings in the TPP, as subtle differences in the amounts of soluble protein may necessarily be 
detected by immunoblotting, especially from poorly resolved bands, as was the case for the low-
molecular-weight protein LAMTOR5. Therefore, the Ragulator subunit remains a valid candidate 
in the search for the target of 1a. Evaluation of LAMTOR5 as a target of 1a is currently under 
investigation in the group of Dr. Yaowen Wu. 
 
Figure 34. The thermostability of LAMTOR5 is not enhanced by 1a in immunoblotting. MCF7-eGFP-LC3 
cell lysates were incubated with 1a (2.5 µM) or DMSO (1 v/v%) for 30 min and aliquoted into 10 samples, 
each of which was incubated at a different temperature. Proteins in the soluble fraction were separated by 
SDS-PAGE and probed for LAMTOR5 using anti-LAMTOR5 (Cell Signaling, cat# 14633) (n = 3). 
 
4.5.3. Conclusion 
In a TPP with MCF7-eGFP-LC3 cells, 96 proteins were (de)stabilized by 1a and thus identified as 
potential targets of the autophagy inhibitor. The ion receptor P2X4 and the Ragulator member 
LAMTOR5 were selected as most promising candidates due to the strong stabilization observed 
upon incubation with 1a. Preliminary results show no binding of 1a to the P2X family. Because 
additional evidence is needed for a conclusive result, P2X4 is currently being tested in a patch 
clamp assay. As an upstream regulator of mTOR, LAMTOR5 plays an important role in autophagy 
and represents therefore an attractive candidate for the target of 1a. Evaluation of this putative target 
will be performed by the group of Dr. Yaowen Wu. 
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4.6. Computational Target Prediction  
Virtual target prediction is an alternative approach to proteomics in the identification of targets for 
small molecules (Chapter 2.2.1). Various computational tools, including SwissTargetPrediction,[65] 
SEA,[63] and a structure similarity/substructure search in SciFinder[140] were employed in order to 
predict a target for 1a (Table 18). SwissTargetPrediction predicts targets by comparing shape and 
fingerprints with small molecules present in the ChEMBL that have an activity < 10 µM for a protein 
or protein complex.[65] SEA compares the query molecule to several databases based on fingerprints 
using the Tanimoto coefficient. As for the SciFinder similarity search, which searches through the 
Chemical Abstracts Service (CAS) database based on the Tanimoto similarity, references 
containing biological activities for similar molecules were selected and analyzed individually. 
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Table 18. Selected examples of predicted targets using SEA and SwissTargetPrediction. 
Entry Target Gene Code 
# 
Ligands Probability Most similar structure 
A1 Urotensin II receptor UR2R 71 0.42 
 
A2 
Serine/threoni
ne-protein 
kinase RAF 
RAF1; 
BRAF 739 0.35 
 
A3 
Tyrosine-
protein kinase 
ABL 
ABL1 7 0.34 
 
A4/ 
B1 
Pyruvate 
kinase 
isozymes 
M1/M2 
PKM 52 0.49 
 
B2 
5-
hydroxytrypta
mine receptor 
6 
HTR6 58 0.29 
 
B3 
Tyrosyl-DNA 
phosphodieste
rase 1 
TDP1 20 0.25 
 
B4 
RAF1; BRAF 
and ARAF 
kinases 
RAF1; 
BRAF; 
ARAF 
83 0.19 
 
Entries A1–4 and B1–B4 correspond to search results of SEA and SwissTargetPrediction, respectively. 
Probability for A1–3 is the Tanimoto coefficient calculated for the most similar compound. 
 
 Within the numerous predictions obtained, pyruvate kinase (PK, entry A4/B4) and the 
serotonin GPCR family (5-HTR, entry B2) appeared as hits in both target prediction tools and the 
SciFinder similarity/substructure search results and represented therefore the most promising 
targets to pursue. Furthermore, the rapidly accelerated fibrosarcoma (RAF) kinase family was 
predicted as a target of 1a by SEA (entry A3) and SwissTargetPrediction (entry B4).  
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4.6.1. Evaluation of Pyruvate Kinase as Target of Indoline 1a 
Pyruvate kinase is a key glycolytic enzyme responsible for net energy production by catalyzing the 
conversion of phosphoenolpyruvate (PEP) and ADP to pyruvate and ATP.[141] This metabolic 
enzyme forms homotetramers and is ubiquitous in all organisms. Whereas the isozyme M1 is 
expressed in all tissues, PK-M2 is often found overexpressed in tumors.[142] Despite its importance 
in cancer, only one micromolar PK inhibitor has been identified to date.[143] Therefore, the discovery 
of selective small molecule regulators would largely contribute to the study of this enzyme and 
possibly provide a new druggable target. A possible relationship between the regulation of PK and 
autophagy was described by Chiavarina et al., who demonstrate that PK-M2 overexpression leads 
to the activation of autophagy in stromal cells.[144] Given the important role of PK in glycolysis, it 
is possible the ATP production by the enzyme triggers the activation of autophagy via the glucose-
sensing regulating proteins involved in this pathway. 
 To test the effect of 1a on the activity of its predicted target PK, a fluorescence-based assay 
was employed. The method utilizes pyruvate oxidase to convert the produced pyruvate to acetyl 
phosphate, generating one molecule of H2O2, which can be quantified upon reaction with OxiRedTM 
Probe (Scheme 21). 
 
Scheme 21. Principle of the assay employed to determine the activity of PK. 
 
 No activity change was observed upon treatment of PK with 1a at either of the 
concentrations tested (Figure 35). Due to the lack of a potent PK inhibitor, staurosporine was 
employed as an inhibition control, which inhibited PK by ca. 25%. Given these results, a different 
predicted target was pursued. 
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Figure 35. Indoline 1a has no effect on the enzymatic activity of PK. PK activity was determined in a 
fluorescence-based assay using Pyruvate Kinase Activity Colorimetric/Fluorometric Assay Kit, by 
monitoring the pyruvate kinase-catalyzed generation of pyruvate. Pyruvate is then oxidized by pyruvate 
oxidase, producing fluorescence. Each data point represents a duplicate measurement of the relative activity 
to the DMSO control. Data shown are mean values ± SEM (N = 2). 
 
4.6.2. Evaluation of RAF and ABL1 Kinases as Targets of Indoline 1a 
RAF kinases are serine/threonine kinases involved in the mitogen activated protein kinase (MAPK) 
cascade. The signal transduction starts with an extracellular stimulus that binds to a receptor, 
leading to the activation of rat sarcoma (RAS). Activated RAS activates RAF kinases, which in turn 
activate mitogen-activated protein kinase kinase (MKK) by phosphorylation. MKK phosphorylates 
and activates mitogen-activated protein kinase (MAPK, also ERK), which can activate the cellular 
tumor antigen p53.[145] The MAPK pathway has been linked to autophagy through MAPK and p53. 
Moreover, modulation of RAF kinases has been associated with regulation of autophagy in 
numerous examples.[146-148]  
 The third kinase predicted, abelson murine leukemia viral oncogene homolog 1 (ABL1) is 
a proto-oncogenic tyrosine kinase implicated in numerous cancers, which is constitutively activated 
when fused to BCR. This chimera is caused by the Philadelphia translocation, an abnormal 
chromosomal defect, in which segments of chromosomes 9 and 22 are swapped, thereby 
juxtaposing the gene locus of BCR onto ABL.[149-150] Both ABL and BCR-ABL have been 
demonstrated to regulate autophagy at a downstream level.[151-152]  
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 Given that RAF and ABL1 kinases represent attractive targets of 1a, the compound was 
tested against RAF1, BRAF, and ABL1 in a functional assay. However, as the autophagy modulator 
did not affect the activity of any of the three kinases (-7, -15, and 18% inhibition, respectively), 
these were not pursued as targets of 1a.  
 
4.6.3. Evaluation of Serotonin Receptors as Targets of Indoline 1a 
5-Hydroxytryptamine (5-HT, serotonin) GPCRs comprise 13 receptor subtypes and are thus the 
largest family of neurotransmitter receptors. Together with adrenergic, dopamine and histamine 
receptors, they are members of the Rhodopsin-like superfamily of GPCRs (type A).[153] Serotonin 
receptors are found both in the central and peripheral nervous systems and mediate a variety of 
physiological responses, including behavior, sensory perception, memory, and contraction of 
smooth muscle. Consequently, small molecules modulating their activity are used in clinics for 
various neurological disorders, such as anxiety, depression, Schizophrenia, and, more recently, 
Alzheimer’s disease.[153-155]  
 The serotonin receptor subtypes 1, 2, 4–7 are not coupled to the same G protein and elicit 
thus different cellular responses. For instance, receptors of the subtype 2 are coupled to Gi/o, whose 
α-subunit, upon activation of the receptor, dissociates from the G protein and binds to PLCβ. 
Cleavage of PIP2 to inositol 1,4,5-trisphosphate (IP3) and diacyl glycerol (DAG) by PLCβ triggers 
the activation of protein kinase C (PKC) and the release of Ca2+ from the ER. The receptors 4, 6, 
and 7 are Gs-coupled and, as opposed to the Gi/o-coupled receptors 1 and 5, activate adenylyl 
cyclase. Active adenylyl cyclase catalyzes the formation of the secondary messenger cAMP, which 
in involved in numerous signaling pathways by activating ion channels, protein kinase A (PKA), 
cAMP response element-binding protein (CREB), and EPAC.[153] Despite the fact that most of the 
downstream effectors of serotonin receptors are involved in autophagy, no direct link between the 
two has been established yet. 
 To ascertain whether 1a had a regulatory effect on serotonin receptors, the compound was 
tested in two cell-based assays using stable cell lines, each expressing one 5-HTR subtype. 
Depending on whether the receptor was Gq/11- or Gs/Gi/o-coupled, its activity was measured in a 
different readout, i.e. levels of IP1 (a downstream metabolite of IP3)[156] or impedance, respectively. 
Impedance-based biosensors rely on the observation that alterations in cAMP levels arising from 
Gs/Gi/o-coupled receptor modulation induce morphological changes, which result in varying 
extracellular and transcellular currents.[157-158]  
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  In the first assay, 1a was tested in agonist mode against nine receptor subtypes but had no 
effect on any of these. In the second assay, an antagonistic effect was determined by measuring the 
inhibition of the response triggered by an agonist. It could be shown that the autophagy inhibitor 
1a had a strong antagonistic effect on serotonin receptor 5-HT6, and a moderate effect on receptors 
5-HT1B, 5-HT2B, 4e, and 7 (Figure 36).  
 
Figure 36. Left: Indoline 1a has no considerable agonistic effect on nine tested subtypes of the serotonin 
family of GPCRs. Agonistic effect of 1a was measured at 10 µM using 7-(dipropylamino)-5,6,7,8-
tetrahydronaphthalen-1-ol (8-OH-DPAT) for 5-HT1A and serotonin for the remaining receptors as agonist 
controls; right: indoline 1a has a strong antagonistic effect on the serotonin GPCR subtypes 6 and a moderate 
effect on the subtypes 1B, 2B, 4e, and 7. Antagonist effect of 1a was measured at 10 µM using 8-OH-DPAT 
(for 5-HT1A) and serotonin (for the remaining receptors) to stimulate the receptor. Data shown are mean 
values ± SEM (N = 2). 
 
 Moreover, dose-response analysis revealed a strong antagonistic effect for 1a on 5-HT6 
with an IC50 = 1.0 µM (Figure 37). Consequently, serotonin receptor 5-HT6 was identified as a target 
of 1a and was evaluated for its role in the inhibition of autophagy.  
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Figure 37. Indoline 1a is an antagonist of the serotonin GPCR 5-HT6. Increase of intracellular cAMP levels 
upon treatment with 1a was monitored in human CHO cells stably expressing 5-HT6. by HTRF. Data shown 
are mean values ± SEM (N = 2). 
 
 To test the hypothesis whether 1a inhibits autophagy by antagonizing 5-HT6, potent and 
selective antagonists of 5-HT6 were tested for autophagy inhibition. Additionally, antagonists of 
the moderately inhibited receptors shown in Figure 36 were evaluated in the phenotypic screen. 
However, none of the antagonists inhibited autophagy (Table 19), indicating that serotonin 
receptors are most likely not responsible for the inhibitory effect of 1a on autophagy. 
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Table 19. Selected examples of potent serotonin receptor antagonists against subtypes 1B, 2B, 4, 6, and 7 
tested for autophagy inhibition in the LC3-phenotypic screen. 
Entry Antagonist Selectivity Structure Autophagy Inhibition (%) 
1 SB 216641 5-HT1B 
 
-10 
2 SB 224289 5-HT1B 
 
27 
3 SB 215505 5-HT2B 
 
9 
4 SB 204741 5-HT2B 
 
-3 
5 SB 204070 5-HT4 
 
10 
6 SB 203186 5-HT4 
 
-5 
7 GR 113808 5-HT4 
 
10 
8 SDZ-205,557 5-HT4 
 
9 
9 Ro 04-6790 5-HT6 
 
-14 
10 SB 269970 5-HT7 
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4.6.4. Evaluation of Different GPCR families as Targets of Indoline 1a 
Given the low IC50 obtained for 5-HT6, it was hypothesized that 1a could inhibit autophagy by 
targeting a different GPCR of the same family as serotonin receptors, as these share a high sequence 
homology. Moreover, numerous GPCRs play an important role in autophagy via different 
mechanisms, making them likely targets of autophagy modulators.[159] However, as the 
identification of integral membrane proteins by proteomics has major obstacles, alternative 
strategies are necessary. Therefore, 1a was tested against a small, unselective panel of consisting 
of a subset of GPCR families from rat (Figure 6). The binding assay uses whole membranes with 
endogenously high levels of the corresponding receptor and measures the compound-induced 
displacement of a specific radiolabeled ligand, which is selective for each receptor family. Indoline 
1a inhibited binding of the purinergic GPCR family (P2Y) to a radiolabeled analog of its native 
ligand ([35S]-ATP-αS) by 42% (Figure 38). 
 
Figure 38. Indoline 1a moderately inhibits bombesin and purinergic GPCR families in a non-selective 
radioligand binding assay. Radioligand displacement by 1a (10 µM) was measured using rat brain tissue and 
potent radioligands specific for each receptor family. Data shown are mean values ± SEM (N = 2). 
 
 Considering the unselective nature of the assay, it is possible that the moderate inhibition 
measured arises from the strong inhibition of a single receptor subtype. Hence, 1a was tested against 
five P2Y subtypes (1, 2, 4, 6, and 11) but neither an agonistic nor an antagonistic effect on any of 
these receptors could be detected (Figure 39). Interestingly, the P2Y12 antagonist PSB-0739, 
developed by Müller and coworkers,[160] strongly inhibits starvation-induced autophagy (IC50 = 64 
± 17 nM). Moreover, P2Y13 has been demonstrated to positively regulate autophagy.[161] Since 1a 
was not tested against P2Y12 or P2Y13 initially, due to the inaccessibility of the receptors, P2Y 
receptors remain a potential target, and the remaining subtypes need to be evaluated in further detail.  
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Figure 39. Indoline 1a has no considerable agonistic (left) or antagonistic effect (right) on five tested subtypes 
of the purinergic family of GPCRs. The effect of 1a was measured at 10 µM using human recombinant 1321N1 
cells and 2-MeSATP (for P2Y1), UTP (for P2Y2 and P2Y4), UDP (for P2Y6), and ATP (for P2Y11) as a 
positive control or stimulus. Data shown are mean values ± SEM (N = 2). 
 
4.6.5. Conclusion 
Computational target prediction is a powerful tool in the identification of the biological targets of a 
small molecule. By utilizing various tools and performing database searches, pyruvate kinase, 
serotonin receptors, ABL, and RAF1 and related kinases were predicted. Of all hits, only 5-HT6 
was validated as a target of 1a. However, no evidence was found for a regulatory role of serotonin 
receptors on autophagy. Nevertheless, the strong potency obtained for 5-HT6 is a possible clue to 
the identification of a different GPCR as the target of 1a, as these membrane receptors share a high 
structural similarity. Therefore, 1a was tested against a small panel of GPCRs, which revealed that 
1a binds moderately to the purinergic family P2Y. Despite the preliminary results, P2Y remains a 
putative target of 1a and will be evaluated through a collaboration with the group of Prof. Dr. 
Christa Müller.  
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5. SUMMARY 
Autophagy is a highly conserved cellular process found in eukaryotes that mediates the degradation 
of cytosolic components. This dynamic process is regulated by upstream signaling and can 
compensate shortly for the lack of nutrients. Furthermore, autophagy is involved in the clearance 
of long-lived proteins and dysfunctional organelles,[15] and, at basal levels, it is necessary for 
maintaining cellular homeostasis.[16] Autophagy is therefore an essential catabolic process in the 
development, differentiation, and survival of cells.[15, 17-19]  
 Recent studies have revealed a crucial role of autophagy in the degradation of the protein 
aggregates responsible for Alzheimer’s, Huntington’s, and Parkinson’s disease.[15, 34] These 
aggregate-prone proteins accumulate when autophagy is inhibited at various stages, and their 
clearance is enhanced by autophagy stimulators.[31-33] Moreover, evidence reveals that autophagy is 
involved in both the prevention of cancer initiation, by degrading toxic cellular waste, and the 
promotion of tumor cell survival.[15] Consequently, whereas autophagy upregulation might serve as 
a preventive strategy against cancer, autophagy inhibition is a potential approach for cancer therapy.  
 As many questions remain open regarding the function of autophagy in disease, there is a 
strong need for a deeper understanding of the mechanisms underlying this cellular process. By 
discovering novel autophagy small molecule activators and inhibitors, new tools for the modulation 
of this pathway can be developed. On the other hand, by determining the specific targets of 
autophagy modulators, new key players in the regulation of autophagy can be identified, which will 
allow a deeper understanding of autophagy and provide new targets for drug discovery. The goal 
of this thesis was to identify an autophagy inhibitor and the target thereof by means of forward 
chemical genetics. 
 In a fluorescence-based medium throughput screen that monitors the localization of the 
autophagy marker LC3, indoline 1a was identified as a potent inhibitor of starvation-induced 
autophagy (IC50 = 520 nM, Figure 40). Furthermore, its inability to inhibit rapamycin-induced 
autophagy indicates that 1a presumably acts upstream of mTOR. The inhibitor was validated in a 
tandem mCherry-GFP-LC3 assay and by immunoblotting. Additionally, cell viability assays show 
that its cytotoxicity is selective for starved cells, which is consistent with inhibition of autophagy.  
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Figure 40. Left: Phenotypic assay employed to identify autophagy inhibitors. MCF7 cells stably expressing 
eGFP-LC3 were starved of amino acids with EBSS, simultaneously treated with compound, and incubated 
for 3 h. Blue = Hoechst (nuclei), green = eGFP-LC3 (n = 4, representative images shown). All data shown 
are mean values ± SEM. MEM = minimal essential medium; EBSS = Earle’s balanced salt solution; CQ = 
chloroquine. Right: structure of indoline 1a. 
 
 A compound collection of structural analogs of 1a was successfully synthesized using 
divergent synthetic routes (Scheme 22). To this end, indoline (4) was reacted with an acyl chloride 
to give the corresponding acyl indoline 100. After C5-bromination, the sulfonamide moiety was 
introduced at C6 by treatment with chlorosulfonic acid and subsequent aminolysis. Alkyl groups 
(R1) other than cyclopropyl were introduced by saponification of the acetyl group in 101 and 
subsequent acylation using amide coupling conditions. Further derivatives were obtained by 
oxidation of the indoline ring in 102 or dehalogenation via palladium-catalyzed hydrogenolysis. 
 
Scheme 22. Synthetic route for the preparation of aryl sulfonamide indolines and indoles. i) R1COCl, Et3N, 
DMAP, CH2Cl2, rt, 2 h; ii) NBS, CH2Cl2, rt, 2 h; iii) ClSO3H (neat), 70 °C, 5 h; iv) Ar-NH2, pyridine, 70 °C, 
16 h; v) (from 101) aq. NaOH (40% w/v)/MeOH 1:1, reflux, 8 h; vi) R1-COOH, T3P, EtOAc, rt, 16 h; vii) H2, 
Pd/C, rt, 16 h; viii) MnO2, toluene, reflux, 5 h. 
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 The compound collection was evaluated in the initial phenotypic screen and a structure–
activity relationship (SAR) could be delineated (Scheme 23). Replacement of the trifluoromethyl- 
and chloro-substituents on the aryl ring (R1) had a negative impact on the potency, whereby only 
few bioisosteres were tolerated. The substitution pattern of these substituents was also crucial, as 
compounds with an ortho-substituent to the sulfonamide were less active. Replacement of the 
cyclopropane carbonyl (R2) by similarly sized groups decreased the activity of the inhibitor 
strongly. Further replacements such as N-alkylation of the sulfonamide moiety or C5- and C6-
modifications resulted in less potent inhibitors as well. For the design of a chemical probe, C3 was 
explored as a potential site for modification. For this purpose, the H-indole analog of 1a was 
derivatized at its most nucleophilic position C3. The resulting indole-based analogs displayed 
weaker activities but nevertheless in the low-micromolar range. Therefore, C3 was identified as a 
suitable site for the attachment of a linker for pull-down experiments. 
 
Scheme 23. SAR for an indoline 1a-derived compound collection, based on the activities measured in the 
eGFP-LC3 puncta phenotypic screen. 
 
 Based on the delineated SAR, two pull-down probes were designed for affinity-based 
proteomics. The first probe consisted of 1a with a linker attached at either C5 and was prepared 
from 1a in 18% overall yield. In contrast, the synthesis of an indoline-based probe with a linker at 
C3 was unsuccessful despite numerous efforts. Therefore, a pull-down probe with an indole core 
instead was obtained from the NH-indole analog in 12% overall yield (Scheme 24).  
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Scheme 24. Synthesis of a chemical probe for affinity proteomics. i) ethyl chlorooxoacetate, AlCl3, CH2Cl2, 
0 °C 	 rt, 16 h, 90%; ii) Et3SiH, TFA, rt, 60 h, 58%; iii) LiOH, THF/MeOH/H2O 2:1:1, rt, 1 h, quant.; iv) 
BocNH-PEG3-NH2, EDC·HCl, HOBt·H2O, DMF, rt, 4 h; v) cyclopropane carboxylic acid chloride, DMAP, 
Et3N, CH2Cl2, 0 °C " rt; vi) CH2Cl2/TFA 4:1, rt, 1 h. 
 
 Numerous tests revealed both probes had stability issues. Whereas the C5-derived probe 
readily decomposed under various conditions, the indole-based probe only hydrolyzed under basic 
conditions. Because of the higher potency of the C3-derived probe (7.7 ± 2.3 µM), the conditions 
for the pull-down experiments were optimized for this probe to minimize hydrolysis. Using the 
active probe and a negative control probe derived from an inactive analog, a quantitative pull-down 
was conducted, which led to the identification of glutamate dehydrogenase (GDH), calpain-1, and 
histidine triad nucleotide binding protein 1 (HINT-1) as putative targets of 1a. 
 GDH is involved in glutaminolysis and amino acid sensing as it catalyzes L-Glu to α-
ketoglutarate (α-KG) upon activation by L-Leu, L-Ile, L-Val, or ADP. This metabolic enzyme has 
been proven to negatively regulate autophagy via the activation of the mammalian target of 
rapamycin complex (mTORC).[116] To test whether 1a inhibits autophagy via modulation or binding 
of GDH, three independent assays were performed. A competitive pull-down experiment showed 
that 1a was not able to outcompete binding of the active probe. Furthermore, 1a had no effect on 
the thermostability or enzymatic activity of GDH. Therefore, we concluded that GDH is not the 
target of 1a.  
 The second protein isolated by pull-down, CAPN1, is the catalytic subunit of calpain-1—
a cysteine protease required for autophagy[122] involved in the cleavage of autophagy-related protein 
ATG5.[123] In a competitive pull-down, no binding of the active probe was detected and thus no 
competition could be observed, thereby devalidating the initial finding. Similarly as for GDH, 1a 
had no effect on the activity of calpain-1, and the enzyme was discarded as putative target. 
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 HINT-1 was not pursued as a putative target because of the low ratios detected by tandem 
mass spectrometry. The results taken together suggest that the probes designed, which suffered 
from stability and biological activity issues, were not suitable for a pull-down assay. Pull-down 
techniques are often hampered by modifications of the parent compound for the introduction of a 
linker, which can interfere with binding to the target protein. Furthermore, the target of 1a may be 
either of low abundance, a membrane protein, or both and therefore difficult to identify by means 
of proteomics. Considering all the obstacles faced by the target identification of 1a using affinity 
chromatography, a different approach was applied. 
 Thermal proteome profiling (TPP) represents an attractive linker-free alternative to 
affinity-based proteomics. Using 1a and DMSO as control, a TPP was conducted with MCF7-
eGFP-LC3 cell lysate. A total of 96 proteins were found to be thermally (de)stabilized by the 
inhibitor and thus identified as potential targets thereof. The ATP-gated ionotropic receptor P2X4 
and the Ragulator member LAMTOR5 were selected as most promising candidates because of their 
strong thermostabilization upon incubation with 1a. Preliminary results showed no binding of 1a 
to the P2X family. As additional evidence is needed for a conclusive result, P2X4 is currently being 
tested in a patch clamp assay. LAMTOR5 is a member of the Ragulator complex and represents 
therefore an attractive putative target of 1a. Evaluation of LAMTOR5 as target of 1a will be 
performed by the group of Dr. Yaowen Wu. 
 In a different approach, various computational tools, including SwissTargetPrediction,[65] 
SEA,[63] and a structure similarity search in SciFinder[140] were employed in order to predict a target 
for 1a. Within the numerous potential targets found, pyruvate kinase (PK), abelson murine leukemia 
viral oncogene homolog 1 (ABL1), rapidly accelerated fibrosarcoma (RAF) kinases, and the G-
protein-coupled serotonin receptor family (5-HTR) were the most promising targets to pursue and 
hence selected for further investigation. Whereas no change in PK, ABL, or RAF activity was 
observed upon treatment with 1a, the autophagy inhibitor had a strong antagonistic effect on 
serotonin receptors 5-HT1B, 5-HT2B, and 5-HT6, with an IC50 = 1.0 µM for the latter (Figure 41). 
However, none of the tested selective antagonists for the corresponding receptors inhibited 
autophagy, indicating that serotonin receptors may not be responsible for the inhibitory effect of 1a 
on autophagy.  
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Figure 41. a) Indoline 1a has a strong antagonistic effect on the serotonin GPCR subtypes 1B, 2B, and  6 
and a moderate effect on the subtypes 4e and 7. Antagonist effect of 1a was measured at 10 µm using 8-OH-
DPAT (for 5-HT1A) and serotonin (for the remaining receptors) to stimulate the receptor. Data shown are 
mean values ± SEM, N = 2); b) Indoline 1a has a dose-dependent antagonistic effect on serotonin GPCR 5-
HT6. Increase of intracellular cAMP levels upon treatment with 1a were monitored in human CHO cells 
stably expressing 5-HT6. by HTRF. Data shown are mean values ± SEM (N = 2). 5-HT = 5-
hydroxytryptamine. 
  
 The low IC50 obtained for 5-HT6 indicates that 1a could target a different G-protein-coupled 
receptor (GPCR) of the same family as 5-HTRs. Therefore, 1a was tested against a small, 
unselective panel of GPCRs and was found to inhibit binding of the purinergic GPCR family (P2Y) 
to a radiolabeled analog of its native ligand ([35S]-ATP-αS) by 42%. In a follow-up study, 1a was 
assayed against five P2Y subtypes (1, 2, 4, 6, and 11) but neither an agonistic nor an antagonistic 
effect was observed for any of these receptors. Interestingly, the P2Y12 antagonist PSB-0739, 
developed by Müller and coworkers,[160] strongly inhibits starvation-induced autophagy (IC50 = 64 
± 17 nM). Since 1a was not tested against P2Y12 initially, due to the inaccessibility of the receptor, 
P2Y receptors remain a potential target, and the remaining subtypes will be evaluated in further 
detail through a collaboration. Additionally, more powerful computational tools, as well as 
alternative genetic target identification strategies, such as haploinsufficiency profiling (HIP), could 
be employed to predict the cellular target of this potent autophagy inhibitor.[40] 
 Despite its hurdles and challenges, forward chemical genetics represents a powerful tool in 
the study of cellular pathways and processes. Of the numerous proteins identified as potential 
targets of 1a, only receptor 5-HT6 could be confirmed so far, although only as an off-target. The 
results combined highlight the need for the further evaluation of GPCRs and other receptors as 
targets of 1a. The successful target identification of this potent inhibitor could help untangle the 
complex mechanisms of autophagy. 
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6. EXPERIMENTAL PART  
6.1. Materials used in Biological Experiments 
6.1.1. Buffers and Solutions 
• PBS 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2.0 mM 
 KH2PO4, pH 7.4 
• TBS  10 mM Tris/HCl, 150 mM NaCl, pH 7.4 
• TBS-T  10 mM Tris/HCl, 150 mM NaCl, 0.1% v/v Triton X-100, 
 pH 7.4 
• Lysis buffer  50 mM PIPES, 50 mM NaCl, 5 mM MgCl2, 5 mM EGTA, 
 0.1% v/v NP40, 0.1% v/v Triton X-100, 0.1% v/v Tween 
 20, Protease Inhibitor Cocktail, pH 7.4 
• Fixation buffer  3.7% Formaldehyde in PBS 
• Blocking buffer 10 mM Tris, 150 mM NaCl, 0.05% v/v Tween-20, pH 7.5 
 (supplemented with blocking substances) 
• Blocking substances 1-5% w/v Dry milk powder or BSA in TBS-T 
• Coomassie destaining solution  30% v/v MeOH, 10% v/v acetic acid 
• Coomassie staining solution  0.25% w/v Coomassie brilliant blue G-250, 45% v/v 
 MeOH, 10% v/v acetic acid 
• Laemmli buffer (2x) 20% v/v Glycerol, 120 mM Tris (pH 6.8), 4% w/v SDS 
• SDS loading buffer (5x) 50% v/v Glycerol, 250 mM Tris (pH 6.8), 10% w/v SDS,  
 500 mM DTE, 360 µM bromophenol blue 
• SDS sample buffer 10% v/v Glycerol, 50 mM Tris (pH 6.8), 2% w/v SDS,  
 500 mM DTE, 360 µM bromophenol blue 
• SDS running buffer (10x) 2.5 M Glycine, 250 mM Tris, 35 mM SDS 
• SDS gels  According to Harlow and Lane, 1988[162] 
• Transfer buffer  14.41 g/L glycine, 3.03 g/L Tris, 20% v/v MeOH 
• Coupling buffer  0.15 M triethanolamine, 0.5 M NaCl, pH 7.0 
• Block A solution  0.5 M ethanolamine, 0.5 M NaCl, pH 8.3 
• Block B solution 0.1 M sodium acetate, 0.5 M NaCl, pH 4.0 
• Reducing/denaturing buffer  8 M urea in 50 mM Tris, pH 7.9 
• OBD alkylation buffer  50 mM chloroacetamide in reducing/denaturing buffer 
• Lys-C digestion solution 0.25 µg/µL Lys-C in H2O 
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• Trypsin digestion solution  0.01 µg/mL trypsin (proteomic grade) in 25 mM 
 NH4HCO3 
• STAGE elution buffer  0.1% v/v formic acid, 80% v/v acetonitrile in H2O 
• STAGE equilibration buffer  0.1% v/v formic acid in H2O 
• IGD washing solution 1  25 mM NH4HCO3/acetonitrile (3:1) 
• IGD washing solution 2  25 mM NH4HCO3/acetonitrile (1:1) 
• IGD reducing solution  50 mM DTT in 25 mM NH4HCO3 
• IGD alkylation solution 55 mM iodoacetamide in 25 mM NH4HCO3 
• CETSA reducing buffer 200 mM TCEP, 0.2 mM triethylammonium bicarbonate 
 (TEAB) 
• CETSA alkylation solution 375 mM iodoacetamide in CETSA reducing buffer 
• CETSA digestion solution 0.4 µg/mL trypsin in 10 mM HCl 
 
6.1.2. Antibodies for Western blotting 
Target Host Cat# Manufacturer Dilution Incubation Conditions 
Anti-rabbit-HRP goat 31460 Pierce 1:10,000 5% w/v milk in TBS-T 
β-actin rabbit ab8227 Abcam 1:1,000 5% w/v milk in TBS-T 
CAPN2 (M-type) rabbit 2539 Cell Signaling 1:1,000 2% w/v milk in TBS-T 
Glud1 (GDH) rabbit ABN443 Merck Millipore 1:1,000 5% w/v milk in TBS-T 
LAMTOR5 rabbit 14633 Cell Signaling 1:1,000 5% w/v BSA in TBS-T 
LC3-B rabbit 2775 Cell Signaling 1:1,000 5% w/v milk in TBS-T 
P2X4 rabbit APR-002 Alomone Labs 1:1,000 5% w/v milk in TBS-T 
 
6.1.3. Software 
• EnsoChemLab Version 5.0.8 Enso Software GmbH, Erbach, Germany 
• Image Studio™ Version 5.2 LI-COR Biosciences GmbH, Bad Homburg vor der Höhe, 
Germany 
• IncuCyte® ZOOM Version 2016A, Essen BioScience, Ann Arbor, USA 
• Maestro Version 10.5, Schrödinger LLC, New York, USA  
• MaxQuant Version 1.4.1.2 MaxQuant; Cox & Mann, 2008[163] 
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• MestReNova Version 6.0.3-5604, Mestrelab Research, Santiago de Compostela, Spain 
• MetaMorph Offline Version 7.7.0.0 Molecular Devices, Biberach, Germany 
• MetaXpress Version 5.0.0.26 Molecular Devices, Biberach, Germany 
• Tecan i-control Version 3.4.2.0 Tecan AG, Männedorf, CH 
 
6.1.4. Laboratory Equipment 
• AxioVert 200M fluorescence microscope, Carl Zeiss Microscopy GmbH, Oberkochen, 
Germany 
• Centrifuge 5415R, Eppendorf, Hamburg, Germany 
• Centrifuge, Minispin, Eppendorf, Hamburg, Germany 
• CFX96 Touch™ Real-Time PCR Detection System, BioRad, Munich, Germany 
• Concentrator Plus SpeedVac, Eppendorf, Hamburg, Germany 
• ImageXpress Micro XLS Widefield High Content, Molecular Devices, California, USA  
• Incubator Nuaire DHD Autoflow NU 5510 E, IBS Tecnomara, Fernwald, Germany 
• IncuCyte® S3, Essen BioScience, Ann Arbor, USA 
• Infinite M200 Plate Reader, Tecan, Männedorf, CH 
• Invitrogen™ Countess™ II Automated Cell Counter, Life TechnologiesTM, Darmstadt, 
Germany  
• MagRack 6, GE Healtcare Life Sciences, Chicago, USA 
• Mastercycler ep gradient S, Eppendorf, Hamburg, Germany 
• Mini-PROTEAN® Tetracell Electrophoresis System, Bio-Rad, Munich, Germany 
• NanoDrop 2000c UV-Vis Spectrophotometer, Thermo Fisher Scientific, Waltham, USA 
• Odyssey® Fc imaging System, LI-COR Biosciences, Bad Homburg, Germany  
• pH-Meter, Mettler Toledo, Giessen, Germany 
• Q ExactiveTM Plus Hybrid Quadrupole-Orbitrap Mass Spectrometer, Thermo Fisher 
Scientific, Waltham, USA 
• Sterile Bench Microflow, NuncNalge, Rochester, USA  
• Sterile Bench Nuaire, IBS tecnomara, Fernwald, Germany 
• UltiMateTM 3000 RSLCnano system, Thermo Fisher Scientific, Waltham, USA 
• Ultracentrifuge Optima™ MAX-XP, Beckman Coulter, Brea, USA 
• Vortex Genie 2, Roth, Karlsruhe, Germany 
• Waterbath (Memmert), Hettich AG, Bäch, Germany 
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6.2. Methods used for Biological Experiments 
6.2.1. Methods in Mammalian Cell Culture 
a) General Methods in Mammalian Cell Culture 
All the work involving living mammalian cells was performed with sterile equipment, media, and 
solutions in cell culture-approved benches. The generated waste was collected and sterilized by 
autoclaving at 134 °C for 15 min. 
Human breast cancer MCF7 cells (Sigma-Aldrich, cat# 800021) stably transfected with 
eGFP-LC3 (MCF7-eGFP-LC3) were cultured at 37 °C with 5% CO2 using Eagle’s DMEM (PAN 
Biotech, cat# P04-03550) or MEM (PAN Biotech, cat# P04-08500) containing 10% FBS 
(Invitrogen, cat# 10500-084), 1% sodium pyruvate (PAN Biotech, cat# P04-43100), 1% non-
essential amino acids (PAN Biotech, cat# P08-32100), 0.01 mg/mL bovine insulin (Sigma Aldrich, 
cat# I9278), and 200 µg/mL G418 as the medium. Untransfected MCF7 cells were incubated in 
Eagle’s MEM with the same additives as used for transfected cells but without G418.  
 
i. Thawing and Freezing of Cryo-Conserved Cells 
Aliquots of mammalian cells stored in liquid nitrogen were thawed by transferring the vial 
containing the cells into a 37 °C water bath. The cell suspension was diluted in 10 mL of the 
respective medium and the resulting suspension transferred into a 75 cm2 tissue culture flask. The 
cells were incubated overnight. The DMSO-containing medium was replaced by fresh DMSO-free 
medium.  
For cryo-conservation, mammalian cells were grown until reaching 80–95% confluence 
and then detached by trypsinization. The detached cells were suspended in the corresponding cell 
medium to inactivate the trypsin, and the cell number was determined. The suspension was 
centrifuged (rt, 150 x g, 5 min) and the medium replaced by an appropriate volume of DMSO-
containing medium (5% v/v) to reach a final concentration of ca. 1 x 106 per cryo-vial. The vials 
were frozen in a cell freezing container (CoolCell® LX) at -80 °C overnight, to ensure a temperature 
decrease of 1 °C/min, and then stored in liquid nitrogen for long-term storage.  
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ii. Passaging Mammalian Cells 
MCF7 cells were grown until reaching a confluence of 80–90%. The medium was removed, the 
cells were washed with PBS (5 mL for 75 cm2, 10 mL for 175 cm2 tissue culture flasks) and then 
detached from the flasks by trypsinization (Trypsin/EDTA, 1 mL for 75 cm2, 3 mL for 175 cm2 
tissue culture flasks, 1–5 min incubation at 37 °C and 5% CO2). After full detachment, fresh 
medium was added to inactivate trypsin. 1/6 of the cell suspension was transferred into a new flask, 
containing 10 mL of pre-warmed (37 °C) fresh medium.  
 
iii. Determination of Cell Number 
The cell number was determined using a Neubauer Counting Slide. The cell suspension was diluted 
with Trypan blue in a 1:1 ratio to distinguish between living and dead cells. The glass cover was 
moistened and placed on the Neubauer chamber’s central area and 10 µL of the cell suspension 
prepared as described above were inserted into the chamber carefully. Cells in 4–5 quadrants were 
counted using a microscope, averaged and multiplied with the respective chamber factor (here 
1 x 104) and dilution factor (here 2). 
Alternatively, the Invitrogen™ Countess™ II Automated Cell Counter (Thermo Fisher 
Scientific, cat# AMQAX1000) together with Countess® Cell Counting Chamber Slides (Thermo 
Fisher Scientific, cat# C10228) was used according to the manufacturer’s instructions. The sample 
was prepared as for the Neubauer chamber.  
 
iv. Routine Check for Mycoplasma Contaminations in Cell Culture 
Cultured cells were routinely checked for mycoplasma contamination using the MycoAlertTM 
Mycoplasma Detection Kit (Lonza) according to manufacturer’s instructions.  
 
v. Cell Treatment with Compounds 
Compounds were dissolved in DMSO (Bioreagent, Sigma Aldrich, cat# D8418). Cells were plated 
into vessels in a cell number that allows 75–90% confluence at the end of the experiment. After 14–
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24 h incubation, the cells were treated with compounds pre-diluted in the given medium. The final 
DMSO concentration did not exceed 0.5% v/v.  
 
6.2.2. Autophagy-Related Assays 
a) High-Content Screening for Autophagy Inhibitors 
The phenotypic autophagy screen utilizes MCF7-eGFP-LC3 cells. A total of 10,000 cells per well 
were seeded in 100 µL medium in 96-well Corning® CellBIND® plates (cat# 3340) and incubated 
overnight. Additional preincubation of cells (optional) was carried out by adding 20 µL of 
compound solution in MEM at multiple concentrations (10 µM to 4.6 nM in 1:3 steps) to cells 
followed by incubation for one hour. Cells were washed with 50 µL PBS followed by a final 
aspiration of the washing buffer. Autophagy was induced by addition of 100 µL compound solution 
at multiple concentrations (10 µM to 4.6 nM in 1:3 dilution steps) in chloroquine-containing EBSS 
medium (50 µM). Alternatively, EBSS (100 µL) was added to the cells prior to compound addition 
(20 µL, diluted in EBSS). After incubation for 3 h cells were fixed by addition of 25 µL 4% 
formaldehyde in PBS + 1:500 Hoechst (stock: 1 mg/mL, Sigma Aldrich, cat# B2261-25mg) and 
incubation for 20 min at room temperature. Cells were then washed twice with and stored in 100 µL 
PBS. Four images per well were taken with an automated AxioVert 200M fluorescence microscope 
(Zeiss) at 20x. Automated image analysis was performed using a modified configuration of the 
granularity assay (approx. granule min. and max. width: 0.4 and 5 µm resp.; approx. nuclei min. 
and max. width: 6 and 20 µm resp.; intensity of granules and nuclei above background: 300 and 40 
gray levels resp.) of MetaXpress Cell Analysis Software (Molecular Devices). Inhibition of 
autophagy was quantified by calculating the number of granules per nucleus and normalized to the 
compound-free controls.  
 
b) Medium-Throughput High-Content Screening for Autophagy Inhibitors 
This screening was performed by the Compound Management and Screening Center (COMAS). 
The phenotypic autophagy screen utilizes MCF7-eGFP-LC3 cells. 4,000 cells per well were seeded 
in 25 µL medium in a 384-well Greiner µclear plate (cat# 781080, lid cat# 656191) and incubated 
overnight. Cells were then washed using a plate washer (Biotek, ELx405) three times with PBS 
followed by a final aspiration of the washing buffer. The addition of 25 nL of compound solution 
(10 mM stock solution in DMSO) was then carried out with an echo dispenser (Labcyte, Echo 520 
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dispenser). Addition of medium to induce autophagy was carried out with a Multidrop Combi 
(Thermo Scientific). 25 µL EBSS (Sigma Aldrich, cat# E3024-500mL) containing 50 µM 
chloroquine (Sigma Aldrich, cat# C6628-25g) was used for starvation-induced autophagy and 
25 µL MEM containing 50 µL chloroquine and 100 nM rapamycin (Biomol, cat# Cay13346-1) was 
used for rapamycin-induced autophagy screening. After incubation for 3 h, cells were fixed by 
addition of 25 µL 1:4 formaldehyde in PBS + 1:500 Hoechst (stock: 1 mg/mL, Sigma Aldrich cat# 
B2261) and incubation for 20 min at room temperature. Cells were then washed three times with 
PBS. Four images per well were taken with ImageXpress Micro XL (Molecular Devices) at 20x. 
Automated image analysis was performed using the granularity setting of MetaXpress Software 
(Molecular Devices). The most significant analysis parameter was granule area, with resulting 
signal-to-background ratios around 40 and Z’ values around 0.7.  
 
c) Confocal Live-Cell Imaging of MCF7-mCherry-eGFP-LC3 Cells 
This experiment was performed by Dr. Georgios Konstantinidis 
After seeding of 400,000 MCF7-mCherry-eGFP-LC3 (kind gift of Sharon Tooze) cells in glass 
bottom dishes (MatTek, Ashland) and overnight incubation, media was removed and replaced with 
2 mL of the indicated treatment media containing appropriate compounds. After incubation for 3 h, 
live cell imaging was performed in MEM without phenol red (Invitrogen) or EBSS (Sigma) by 
using an inverted confocal microscope Leica SP5 AOBS equipped with a 63x/1.4 HCX Plan Apo 
oil immersion lens and a temperature-controlled hood at 37 °C and 5% CO2. Green and Red Puncta 
Colocalization macro was used to analyze mCherry-eGFP-LC3 puncta (Ruben K. Dagda, 
University of Nevada School of Medicine, Pharmacology Department; Daniel Shiwarski, 
Carneggie Mellon University; Charleen T Chu, University of Pittsburgh). 
 
d) Immunoblotting for Autophagy Inhibition 
MCF7-eGFP-LC3 cells (2 mL for 6-well, 1 mL for 12-well plates; 100,000 cells/mL) were seeded 
in 6- or 12-well plates and incubated overnight. The medium was replaced by fresh MEM, EBSS, 
or the respective compounds MEM or EBSS. The cells were then incubated for 3 h, the medium 
was removed, and the cells washed with PBS (1 mL for 6-well plates, 0.5 mL for 12-well plates). 
Cell lysis was performed by adding Laemmli buffer (1X), followed by stringent scraping with Cell 
Scrapers. The mixture was collected and homogenized by sonification. The protein concentration 
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was determined using the DC assay (Chapter 6.2.5), and all samples were diluted to the same 
concentration. SDS sample buffer was added (20% v/v), and the proteins were denatured by heating 
at 95 °C for 5 min. The samples were snap-frozen and stored at -80 °C until further use. The proteins 
were then separated by SDS-PAGE and the LC3-B and p62 levels analyzed by western blot using 
β-actin as a loading control.  
 
e) Selective Viability Assay 
This experiment was performed by Dr. Luca Laraia 
For fed conditions, 4,000 MCF7-eGFP-LC3 cells in 100 µL medium were seeded in a clear flat-
bottom 96-well plate and incubated overnight. For starved conditions, 7,000 cells in 100 µL medium 
were used. The media was removed gently, and cells were washed with PBS (100 µL). The PBS 
was replaced with 100 µL of normal media (fed conditions) or EBSS (starved). Test compounds at 
a concentration of 6x the desired final concentration in 20 µL of the appropriate medium were 
added. Cells were incubated for 48 h. At this point 10 µL of WST-1 reagent (Roche) was added to 
each well. The absorbance was measured with a Beckman DTX-880 (Beckman Coulter, Germany) 
plate reader at 450/690 nm. Absorbance measurements were performed after 20, 30, 40, 50, 60 min 
of addition of 1a. Good measurements are considered when absorbance of the DMSO control is 
around 1.00. IC50 values were calculated using GraphPad Prism using DMSO (negative) and 
nocodazole (10 µM, positive) as controls.  
 
f) Induction of Apoptosis 
MCF7 cells in 100 µL medium (3,000 for fed conditions or 10,000 for starved conditions) were 
seeded in a clear flat-bottom 96-well plate and incubated overnight. The media was removed 
carefully, and cells were washed with PBS (50 µL), and 100 µL of medium (DMEM for fed, EBSS 
for starved conditions) containing 1.2 v/v% IncuCyte® Kinetic Caspase-3/7 Apoptosis Assay 
Reagent. Test compounds in a DMSO stock solution were prediluted in the appropriate medium 
(MEM or EBSS) at a concentration of 6x the desired final concentration, while keeping the DMSO 
content constant. Of this solution, 20 µL were added to the cells, and the cells were incubated for 
72 h in the IncuCyte® ZOOM. Images were acquired at 10X magnification in both the phase and 
green channel every hour. Images were analyzed using automated image analysis with the 
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IncuCyte® ZOOM Control Software. The key parameter was green fluorescence confluence as a 
percentage of phase contrast confluence (%). Data was normalized to the DMSO control. 
 
6.2.3. Affinity-Based Proteomics 
i. Cell Lysate Preparation 
MCF7-eGFP-LC3 cells were grown until reaching ca. 90% confluence in growing medium (Eagle's 
MEM). After washing with PBS and trypsinization for 5 min at 37 °C, they were resuspended in 
PBS. The cell suspension was centrifuged (150 x g, 5 min, 4 °C) and the supernatant discarded. The 
cell pellet was washed twice by resuspension into PBS, followed by centrifugation (150 g, 5 min, 
4 °C) and resuspension in lysis buffer (prepared according to a standard procedure[164]). The 
suspension was incubated for 30 min at 4 °C, with gentle vortexing every 10 min. The lysate was 
homogenized by passing it 10 times through a 20 G needle and centrifuged for 20 °C at 18,500 x g 
and 4 °C. The supernatant was collected, the protein concentration determined, and the lysate stored 
at -80 °C. 
 
ii. Generation of MCF7-eGFP-LC3-SILAC Cell Line 
In order to label MCF7-eGFP-LC3 cells with heavy amino acids for SILAC, the cells were grown 
in two different MEM SILAC media. Each medium was supplied with amino acids consisting of 
either light (12C6-L-lysine and 12C614N4-L-arginine) or heavy isotopes (13C6-L-lysine and 13C615N4-
L-arginine). Both media contained dialyzed FBS, and were else prepared as normal MEM medium 
(Chapter 6.2.1). To verify the incorporation efficiency, samples of light, heavy, and a 1:1 (protein 
ratio) mixture of light and heavy lysates, together with a BSA control (5 pmol) were subjected to 
in-gel digest and subsequently analyzed by MS/MS.  
 
iii. Pull-Down 
NHS Mag Sepharose beads (GE Healthcare®, cat# 28951380, 25 µL) were equilibrated with ice-
cold aq. HCl solution (1 mM) and incubated with the amines 93 or 94 in coupling buffer (0.15 M 
triethanolamine, 0.5 M NaCl, pH 7.4, 500 µL; compound concentration: 10 µM) overnight at 4 °C 
in a rotation wheel. Residual active groups were quenched in an alternating blocking and alkylation 
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sequence with block A (0.5 M ethanolamine, 0.5 M NaCl, pH 7.4) and B solutions (0.5 M NaOAc, 
0.5 M NaCl, pH 4) three times respectively (500 µL, rt, 15 min the second time with A, else 2 min, 
in a rotation wheel). The beads were equilibrated with lysis buffer (500 µL, 2 min), and bulk protein 
lysate was added (500 µL, protein concentration = 6 mg/mL, for competitive pull-down, the lysate 
was pre-treated with 10 µM compound), and the suspension incubated at 4 °C for 2 h in a rotation 
wheel. The supernatant was removed and the beads washed with lysis buffer with increasing MgCl2 
concentrations in order to remove unspecific binding (5 min, 4 °C). The beads were washed with 
PBS (3 x 500 µL, 5 min, 4 °C). For SILAC-based pull-down, the beads were combined as follows: 
heavy/active with light/control and heavy/control with light/active. The samples were further 
processed by for on-bead digest or SDS-PAGE.  
 
iv. SILAC Incorporation Test: In-Gel Digest 
SDS loading buffer (5 µL, 5X) was added to each SILAC-lysate (20 µL) and the BSA control 
(20 µL, 5 pmol). Denaturation of the proteins was achieved by heating the samples at 95 °C for 
5 min. The samples were loaded onto a 4–20% mini-PROTEAN® TGX precast protein gel and the 
proteins allowed to come into the gel by applying 120 V for 10 min.  
The protein gel bands were cut out and cut into 1–2 mm squares. The gel slices were 
incubated with fixation solution (H2O/EtOH/AcOH = 5:4:1, 500 µL, 350 rpm, rt) for 5 min, and the 
solution replaced by fresh fixation solution. The samples were incubated overnight at 25 °C and 
350 rpm. The fixation solution was replaced by washing solution 1 (200 µL, 25 mM 
NH4HCO3/acetonitrile [3:1] at 37 °C and 600 rpm for 30 min), then washing solution 2 (200 µL, 
25 mM NH4HCO3/ACN [1:1] at 37 °C and 600 rpm for 15 min), then reducing solution (200 µL, 
50 mM DTT in 25 mM NH4HCO3 at 37 °C and 600 rpm for 45 min), and finally alkylation solution 
(200 µL, 55 mM iodoacetamide in 25 mM NH4HCO3 at 25 °C and 600 for 1 h in the dark). The gels 
were washed with washing solution 2 (200 µL, 25 °C and at 600 rpm for 15 min). The supernatant 
was removed and the gel dehydrated by washing with acetonitrile (100 µL). The gels were left to 
air-dry for 30 min at room temperature, and incubated with digest solution (75 µL, 10 µg/mL trypsin 
in 25 mM NH4HCO3 at 25 °C and 600 rpm for 15 min). A NH4HCO3 solution (25 mM, 75 µL) was 
added and the mixture incubated overnight for the digestion reaction to take place (30 °C, 350 rpm).  
TFA (10%, 10 µL) was added to stop the digestion, the mixture was centrifuged shortly 
and the tryptic peptides mobilized by sonification (30 min, 0 °C, max. amplitude). The supernatant 
was collected, and the gels were incubated with ACN (75 µL, 15 min, 25 °C, 350 rpm). The 
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supernatants were combined and this step was repeated once more. The samples were concentrated 
by vacuum centrifugation (30 °C, 3 h, max. speed) and analyzed by MS/MS.  
 
v. On-Bead Digest 
Proteins immobilized to the beads through affinity purification were denatured and reduced by 
incubation in reducing/denaturing buffer (8 M urea, 1 mM DTT in 50 mM Tris, pH 7.9, rt, 350 rpm, 
30 min). Cysteine side chains were alkylated by incubation in alkylation solution (5 µL, 50 mM 
chloroacetamide in reducing/denaturing buffer, rt, 350 rpm, 30 min). The proteins were digested 
using Lys-C (4 µL, 0.25 µg/µL in H2O, 37 °C, 350 rpm, 1 h) and the supernatant transferred into a 
new vessel. Additional tryptic digest was accomplished by incubation with trypsin (1 µg in 150 µL 
Tris [50 mM, pH 7.5] at 37 °C and 350 rpm for 1 h). The supernatants from both digestion steps 
were combined, trypsin was added (2 µg in 5 µL H2O), and the samples were incubated overnight 
(37 °C, 350 rpm). The digest was stopped by addition of TFA (2 µL, conc.).  
 
vi. Stop and Go Extraction Tip (STAGE)-Based Peptide Purification 
To purify the soluble on-bead-digested peptides, self-packed micro-columns in pipet tips with 3M 
Empore™ SPE Extraction Disks (2215-C18) were used according to a known procedure.[165] The 
C18 material was activated by washing with MeOH (100 µL) and equilibrated with elution buffer 
(100 µL, H2O/acetonitrile (1:4) + 0.1% v/v HCOOH) and equilibration buffer (2 x 100 µL, H2O + 
0.1% v/v HCOOH). The samples were loaded onto the tips and after 1 min filtered through the C18 
material by centrifugation (rt, 2500 rpm, 3 min). Salts and detergents were washed off using 
equilibration buffer (100 µL), and the peptides were eluted with elution buffer (2 x 20 µL, 1 min 
incubation) by centrifugation (rt, 2500 rpm, 30 s) into a new reaction vessel. The samples were 
concentrated by vacuum centrifugation (30 °C, 1.5 h) and submitted to nano-LC-MS/MS analysis. 
 
vii. Peptide Identification by Nano-LC-MS/MS 
This part of the experiment was performed by the mass spectrometry group. 
The resulting peptides from the tryptic digest were separated by nano-HPLC and subsequently 
identified by MS and MS/MS.  
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The dried peptides were re-suspended in 20 µL TFA and dissolved by sonication (15 min, 
max. amplitude). Insoluble particles were separated by centrifugation (15000x g, 1min). A fraction 
(10 µL) was desalted and concentrated in a nano-(U)HPLC system suitable for flow-rates of 
300 nL/min using the UltiMateTM 3000 RSLCnano system (Dionex) equipped with a nano-HPLC 
Acclaim PepMap RSLC C18 (2 µm, 100 Å, 75 µm ID × 25 cm, nanoViper, Dionex), a pre-column 
cartridges (Acclaim PepMap100 C18, 5 µm, 100 Å, 300 µm ID × 5 mm, Dionex), and a nano-spray 
emitter (Standard Coated SilicaTipTM Emitter, 360 µm OD, 20 µm ID, 10 µm Tip ID, 10.5 cm, New 
Objective, USA) in a linear gradient (start: 96.8% formic acid (0.1%), 3.2% formic acid (0.1%) in 
acetonitrile, end: 62% formic acid (0.1%), 38% formic acid (0.1%) in acetonitrile) at a constant 
flow rate of 300 nL/ min at a column temperature of 40°C.  
The MS and MS/MS experiments were carried out on a Q Exactive™ Plus Hybrid 
Quadrupole-Orbitrap Mass Spectrometer equipped with a nanospray source (Nanospray Flex Ion 
Source, Thermo Scientific). All solvents were LC-MS grade. The lyophilized tryptic peptides were 
dissolved in 20 mL 0.1% v/v TFA in water. 3 mL of sample were injected onto a pre-column 
cartridge (5 mm, 100 Å, 300 mm ID * 5 mm, Dionex, Germany) using 0.1% v/v TFA in water as 
eluent at a flow rate of 30 mL/min. Desalting was performed for 5 min with eluent flow to waste 
followed by back-flushing of the sample during the whole analysis from the pre-column to the 
PepMap100 RSLC C18 nano-HPLC column (2 mm, 100 Å, 75 mm ID × 50 cm, nanoViper, Dionex, 
Germany) using a linear gradient of water/ACN (containing 0.1% v/v HCOOH) 95:5 ® 70:30 
during 95 min using a flow rate of 300 nL/min. 
The nano-HPLC was coupled online to the Quadrupole-Orbitrap Mass Spectrometer using 
a standard coated SilicaTip (ID 20 µm, Tip-ID 10 µM, New Objective, Woburn, MA, USA). Mass 
range of m/z = 300–1650 was acquired with a resolution of 70,000 for full scan, followed by up to 
ten high energy collision dissociation (HCD) MS/MS scans of the most intense at least doubly 
charged ion peaks. 
 
viii. MS-Data Evaluation 
This part of the experiment was performed by the mass spectrometry group. 
Data evaluation was performed using MaxQuant software[42] (v.1.5.3.30) including the Andromeda 
search algorithm and searching the human reference proteome of the Uniprot database. The search 
was performed for full enzymatic trypsin cleavages allowing two miscleavages. For protein 
modifications, carbamidomethylation was chosen as fixed and oxidation of methionine and 
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acetylation of the N-terminus as variable modifications. The mass accuracy for full mass spectra 
was set to 4.5 ppm and for MS/MS spectra 20 ppm. The false discovery rates for peptide and protein 
identification were set to 1%. Only proteins for which at least two peptides were quantified were 
chosen for further validation. Relative quantification of proteins was carried out using the label-
free quantification algorithm implemented in MaxQuant. All experiments were performed in 
technical triplicates. Label-free quantification (LFQ) intensities were logarithmized (log2) and 
proteins which were not three times quantified in at least one of the groups were filtered off. Missing 
values were imputed using small normal distributed values and a t-test was performed. Proteins 
which were statistically significant outliers in at least one of the three experiments were considered 
as hits. 
 
6.2.4. Cellular Thermal Shift and Thermal Proteome Profiling 
i. Lysate Preparation 
For CETSA and TPP experiments, MCF7-eGFP-LC3 cells were cultured according to the 
procedures described in Chapter 6.2.1. For one T175 flask, the cells were tripsinized with 3 mL 
trypsin/EDTA, resuspended in MEM medium (10 mL), and centrifuged at 150 x g and 4 °C for 
5 min. The medium was removed and the cell pellet washed with ice-cold PBS (2 x 25 mL and 1 x 
10 mL, centrifugation at 150 x g and 4 °C for 5 min each time). The pellet was resuspended in PBS 
containing the nonylphenyl polyethylene glycol (NP-40 alternative, 1.5 mL, 0.4% v/v), used to 
enhance membrane protein solubilization. The cells were lysed via a freeze-thaw cycle (4 x). The 
insoluble components were separated by centrifugation for 20 min 4 °C and 100,000 x g using 
polycarbonate tubes in an ultra-centrifuge. Protein concentration was determined using the 
Bradford method[166] with the Bradford reagent (Bio-Rad laboratories). After dilution to 2 mg/mL, 
the lysate was snap-frozen and stored at -80 °C until further use.  
 
ii. Thermal Shift Assay 
The cell lysate was thawed and split into two vials (1.4 mL each). One sample was treated with 1a 
in DMSO and the other only with DMSO, resulting in a final concentration of 2.5 µM and 1% v/v 
DMSO. The samples were incubated at rt for 30 min, each split into 10 aliquots of 120 µL and 
subjected to heating at different temperatures in a gradient PCR cycler (Eppendorf Mastercycler ep 
gradient S) for 3 min. The temperature gradient ranged from 37–67 °C, while one vehicle sample 
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was always heated in parallel with one compound sample. The samples were then cooled to 4 °C, 
centrifuged for 20 min at 4 °C and 100,000 x g. The supernatant (100 µL) was transferred into low-
binding Eppendorf tubes.  
 
iii. Trypsin Digest 
After the thermal shift assay, 75 µL of each aliquot were treated with freshly prepared TEAB buffer 
(75 µL, 100 mM) and reducing buffer (200 mM TCEP, 0.2 mM TEAB, 7.5 µL) and incubated for 
1 h at 55 °C and 350 rpm. The remaining 25 µL were snap-frozen, stored at -80 °C for 
immunoblotting. A freshly prepared alkylation solution (iodoacetamide in reducing buffer, 375 mM, 
7.5 µL) was added to each sample, and incubation was continued for 30 min in darkness. 
Afterwards, pre-chilled acetone (ca. 900 µL) was added, and the proteins were allowed to 
precipitate overnight at -20 °C. The samples were centrifuged for 10 min at 4 °C and 8,000 x g, and 
the supernatant was removed carefully. The pellets were air-dried for 45 min and resuspended in 
TEAB buffer (100 µL, 100 mM) and digestion solution (0.4 µg/mL trypsin in 10 mM HCl, 7.5 µL). 
The digestion was performed at 37 °C overnight.  
 
iv. TMT-labeling 
This part of the experiment was performed by the mass spectrometry group. 
The tryptic peptide solution was centrifuged and labeled with TMT according to the manufacturer’s 
description, but using half the amount of labeling reagent. Briefly, 82 µL of anhydrous acetonitrile 
were added to each 0.8 mg of TMT label reagent aliquot (TMT10plex, Thermo Fisher Scientific, 
cat# 90110). Of the respective TMT reagent solution, 41 µL were transferred to the peptide sample 
of the respective DMSO control (V1-10). Directly after addition, samples were briefly vortexed. 
For the compound-treated samples, 100 µL were transferred to the respective remaining TMT 
reagent. Directly after addition, samples are briefly vortexed. Samples were incubated for 2 h at rt 
Afterwards, 8 µL of 5% hydroxylamine were added to the samples, and the reaction was quenched 
by incubating the samples for 15 min. Of each compound-treated, labeled sample, 120 µL were 
combined into one sample, and 120 µL of each DMSO-treated, labeled sample were combined to a 
second one. Both samples were concentrated by vacuum centrifugation (30 °C, max. speed) until a 
dry white pellet was visible.  
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v. Peptide Identification by Nano-LC-MS/MS 
This part of the experiment was performed by the mass spectrometry group. 
Prior to nanoHPLC-MS/MS analysis, samples were divided into 10 fractions on a C18 column 
using high pH conditions to reduce the complexity of the samples and thereby increase the number 
of quantified proteins. For this purpose, both samples were dissolved in 120 µL 20 mM NH4HCO2 
solution at pH 11, followed by incubation in an ultra-sonicator for ca. 2 min, vortexing for 1 min, 
and centrifugation at 13,000 rpm and rt for 3 min. Subsequently, 50 µL of supernatant were injected 
onto an XBridge C18 column (130 Å, 3.5 µm, 1 mm x 150 mm) using a U3000 capHPLC- System 
(Thermo Fisher Scientific, Germany). Separation was performed at a flow rate of 50 µL/min using 
20 mM aq. NH4HCO2 solution (pH 11) as solvent A and a mixture of aq. 20 mM NH4HCO2 solution 
(pH 11) with acetonitrile (2:3) as solvent B. Separation conditions were 95% solvent A / 5% solvent 
B for 15 min, to desalt the samples, followed by a linear gradient up to 25% for 5 min and a second 
linear gradient up to 100% solvent B for 60 min. Afterwards, the column was washed with 100% 
solvent B for 20 min and re-equilibrated to the starting conditions. Detection was carried out at a 
valve length of 214 nm. The eluate between 10 and 80 min was fractionated into 10 (1st fraction 20 
min, 2nd fraction 10 min, 3rd–8th fraction 5 min each, 9th fraction 10 min, 10th fraction 25 min). Each 
fraction was concentrated by vacuum centrifugation (30 °C, max. speed) until complete dryness 
and subsequently subjected to nanoHPLC-MS/MS analysis.  
For nanoHPLC-MS/MS analysis, samples were dissolved in 10 µL of 0.1% aq. TFA. Of 
this solution, 4 µL were injected into a UltiMateTM 3000 RSLCnano system (Thermo Fisher 
Scientific, Germany) online-coupled to a Q ExactiveTM Plus Hybrid Quadrupole-Orbitrap Mass 
Spectrometer, which was equipped with a nanospray source (Nanospray Flex Ion Source, Thermo 
Fisher Scientific), using a standard coated SilicaTip (ID 20 µm, Tip-ID 10 µM, New Objective, 
Woburn, MA, USA). All solvents were LC-MS grade. For desalting, samples were injected into a 
pre-column cartridge (5 µm, 100 Å, 300 µm ID * 5 mm, Dionex, Germany) using 0.1% TFA in 
water as eluent at a flow rate of 30 µL/min. Desalting was performed for 5 min with eluent flow to 
waste followed by back-flushing of the sample during the whole analysis from the pre-column to 
the PepMap100 RSLC C18 nano-HPLC column (2 mm, 100 Å, 75 mm ID × 50 cm, nanoViper, 
Dionex, Germany) using a linear gradient of water/ACN (containing 0.1% v/v HCOOH) 95:5 ® 
60:40 during 125 min using a flow rate of 300 nL/min. Afterwards, the column was washed (95% 
solvent B) and re-equilibrated to starting conditions.  
Mass range of m/z = 300–1650 was acquired with a resolution of 70,000 for full scan, 
followed by up to ten high energy collision dissociation (HCD) MS/MS scans of the most intense 
at least doubly charged ion peaks using a resolution of 35,000 and a NCE energy of 35%.  
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vi. MS-Data Evaluation 
This part of the experiment was performed by the mass spectrometry group. 
Data evaluation was performed using MaxQuant software[163] (v.1.5.3.30) including the Andromeda 
search algorithm and searching the human reference proteome of the Uniprot database. The search 
was performed for full enzymatic trypsin cleavages allowing two miscleavages. For protein 
modifications carbamidomethylation was chosen as fixed and oxidation of methionine and 
acetylation of the N-terminus as variable modifications. For relative quantification, the type 
“reporter ion MS2” was chosen and for all lysines and peptide N-termini 10plex TMT labels were 
defined. The mass accuracy for first and second search of full mass spectra was set to 20 ppm and 
4.5 ppm, respectively and to 20 ppm for MS/MS spectra. The false discovery rates for peptide and 
protein identification were set to 1%. Only proteins for which at least two peptides were quantified 
were chosen for further validation. Relative quantification of proteins was carried out using the 
reporter ion MS2 algorithm implemented in MaxQuant. All experiments were performed in 
biological triplicates.  
 
vii. Melting Curve Calculation 
This part of the experiment was performed by the mass spectrometry group. 
To determine the melting point shifts between compound- and DMSO-treated samples of each 
protein, an in-house developed Excel-Macro was used. Briefly, denaturation changes at different 
temperatures were tracked using the reporter ion intensity and observed in relation to the lowest 
temperature; the reporter ion intensity for lowest temperature was normalized to 1.  
The relative fold changes of melting temperatures were calculated as a function of 
temperature using the Boltzmann equation:  
 
y	=	bottom plateau	+	 top plateau	- bottom plateau
1+e-
a
T  - b
 
Equation 1. The sigmoidal trend of the measured intensities was fitted with the following equation using an 
iterative working macro in Microsoft Excel. Top plateau is fixed to one; bottom plateau is a protein specific 
constant that defines the maximal denaturation; a and b are constants which describe the curve progression.  
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The melting point of a protein is defined as the temperature at which half of the protein has 
been denatured. This point corresponds to the inflection point of the curve, the highest slope of the 
curve which is defined as the value of the first derivative.  
For hit identification, following requirements were defined and had to be fulfilled for all 
replicates: (1) the protein is identified with at least two unique peptides, (2) the average shift of the 
melting point is at least 2 °C, while displaying either a stabilization of destabilization for all 
replicates, and/or (3) the relative difference in the peak intensities of the two highest temperatures 
between the DMSO control and the compound-treated sample is at least 10% of the maximum 
intensity.  
 
6.2.5. Methods in Protein Biochemistry 
a) Protein Concentration Determination 
Routine determination of protein concentration was performed using the Bradford method[166] with 
the Bradford reagent (Bio-Rad laboratories) in the linear range of a BSA control (0.3–10 mg/mL). 
The absorbance was measured at 595 nm using a BioPhotometer (Eppendorf).  
For a large number of samples or low protein concentrations, a DC protein assay (Bio-Rad 
laboratories) was performed in 96-well plates according to the manufacturer's instructions. The 
absorbance was measured at 650–750 nm using a Tecan microplate reader and the concentration 
calculated using a BSA standard curve.  
 
b) SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE)  
Protein separation was performed by SDS-PAGE according to a standard procedure[167] using the 
Mini-PROTEAN® Tetracell Electrophoresis System (Bio-Rad). SDS loading buffer was added to 
the protein mixtures, reaching a final DTT concentration of 100 mM in each sample. The proteins 
were denatured by heating the samples at 95 °C for 5 min prior to loading. Separation was 
performed in running buffer at 80 V for 15 min, then 120 V at rt and stopped when the desired 
separation was observed in the protein marker. Protein size was estimated by comparison to the 
marker PageRulerTM Plus Prestained Protein Ladder (Thermo Fisher Scientific, cat# 26619). For 
in-gel digestion during proteomics experiments, Mini-PROTEAN®TGXTM Gels (4–20%) were 
used. 
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c) Coomassie Protein Staining  
The SDS gel was incubated in fixing solution for 15 min, transferred into Coomassie staining 
solution, and stained for 2 h. Destaining of the gel was performed in destaining solution until the 
background was clear. The gel was then imaged using the Gellogic 200 Imaging System (KODAK) 
and KODAK-Mi software.  
 
d) Electrophoretic Transfer of Proteins (Western Blot) 
Proteins separated in SDS-PAGE were transferred to a PVDF membrane using an electrical field. 
All components of the sandwich were presoaked in freshly prepared transfer buffer, whereas the 
membrane was equilibrated in MeOH and then with miliQ H2O prior to soaking in transfer buffer.  
Wet transfer was performed in a Mini Trans-Blot® Cell (Bio-Rad). A sandwich containing 
the gel and the membrane was assembled according to the manufacturer’s instructions. The transfer 
was conducted at 0 °C and 100 V for 1 h. Alternatively, a semi-dry transfer was performed in a 
Trans-Blot® SD Semi-Dry Transfer Cell (Bio-Rad) according to the manufacturer’s instructions. 
Transfer was conducted at rt and 25 V for 1 h.  
 
e) Immunodetection of Immobilized Proteins 
The PVDF membrane was blocked for 1 h at rt with blocking buffer. The primary antibody was 
added at the concentration and in the buffer described by the manufacturers (Chapter 6.1.2). The 
membrane was then incubated overnight at 4 °C and constant agitation. Unbound antibody was 
removed and the membrane washed thrice with TBS-T for 5 min at rt and constant agitation. Then, 
the second antibody was added at the concentration and in the buffer described by the manufacturer. 
The membrane was incubated for 1 h at rt and constant agitation and washed thrice with TBS-T.  
 The enzymatic HRP signal was detected using SuperSignal West Pico/Femto 
Chemiluminescent Substrate (Pierce) according to the manufacturer’s instructions. The resulting 
chemiluminescence was quantified using the Odyssey® Fc Imaging System (Li-COR® Bioscience) 
with adequate exposure times.  
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6.2.6. Methods to Study Small Molecule–Target Binding 
a) Thermal Shift Assay 
Protein thermostability was measured in a DSF assay using the fluorescent dye SYPRO® Orange 
Protein Gel Stain (5,000X, Thermo Fischer Scientific, cat# S6651). In a 96-well PCR plate (Hard-
Shell®, Bio-Rad, cat# HSP960), protein melt buffer (phosphate buffer, 100 mM, pH 8, 8.5 µL) was 
added to each well, followed by a bGDH solution (5X in protein melt buffer, 4 µL, Sigma Aldrich, 
cat# G2626), a solution of compound in protein melt buffer (4X, 5 µL), and a solution of the dye in 
protein melt buffer (40X) sequentially. The plate was centrifuged shortly and subjected to a thermal 
gradient scan (20–90 °C) in a CFX96 Touch™ Real-Time PCR Detection System. The fluorescence 
was measured after each increment of 0.5 °C at excitation and emission wavelengths of 490 and 
575 nm resp. Melting temperatures were derived using the CFX ManagerTM software.  
 
b) Pyruvate Kinase Assay 
Pyruvate kinase activity was measured in a fluorescence-based assay using the Pyruvate Kinase 
Activity Colorimetric/Fluorometric Assay Kit (BioVision, cat# K709-100) according to the 
manufacturer’s instructions. Briefly, a solution containing an enzyme mix, a substrate mix, and 
OxiRed™ Probe in assay buffer was added to a solution of the compound or DMSO control in assay 
buffer. The absorbance was monitored using a Tecan microplate reader. The amount of pyruvate 
generated in the presence of compound was calculated using a standard curve.  
 
c) Glutamate Dehydrogenase Assay 
The activity of glutamate dehydrogenase was measured in a colorimetric assay using the GDH 
Assay Kit (Sigma-Aldrich, cat# MAK099) and bGDH (Sigma Aldrich, cat# G2626) according to 
the manufacturer’s instructions. Briefly, a solution of glutamate and GDH developer in assay buffer 
was added to a solution of compound or controls in assay buffer, and the samples were incubated 
at 37 °C for 3 min. The absorbance was measured in a Tecan microplate reader at 450 nm and 37 °C 
every 5 min. The amount of NADH generated in the presence of compound was calculated using a 
standard curve. To be able to observe a potential increase in activity, the concentration was chosen 
so that the reaction rate was lower than the one of the control provided. Hence, the assay was 
performed at [bGDH] = 2–4 µg/mL and the measurement time adjusted accordingly.  
 122 
d) Calpain Assay 
Calpain-1 activity was measured in a fluorescence-based assay using the Human Calpain 1 Inhibitor 
Screening Kit (Sigma-Aldrich, cat# MAK210) according to the manufacturer’s instructions. 
Briefly, a solution of calpain-1 in assay buffer was added to the compound and DMSO control in 
assay buffer and the mixture was incubated at 37 °C for 5 min. A solution of substrate in assay 
buffer was added to the mixture prepared above, and the fluorescence (λex = 400/λem = 505 nm) was 
measured at 37 °C every minute in a Tecan microplate reader. The enzymatic activity was defined 
as the percentage of the control provided in the kit.  
 
6.2.7. Profiling Services 
a) Functional Assay Against AMPK 
This experiment was performed by SignalChem. 
Briefly, to a mixture of AMPKα1β1γ1 or AMPKα2β1γ1 (10–50 nM), kinase substrate, and 
compound (10 µM) in assay buffer, 33P-ATP (10 µM) was added, and the reaction was incubated 
for 20–30 min. A volume of the mixture was spotted onto a Multiscreen phosphocellulose P81 plate 
and the plate washed in a 1% phosphoric acid solution. The radioactivity was measured in the 
presence of scintillation fluid in a Trilux scintillation counter. 
 
b) Functional Assay Against Phosphatase Targets 
This experiment was performed by SignalChem. 
For DUSP22, PTPN1, PTPN2, PTPN7, PTPRC, PTPN13, PTPRS, and PTPRA, a mixture of the 
phosphatase, pNPP substrate (5 mM), and compound (10 µM) in assay buffer was incubated at 37 °C 
for 15 min. The reaction as stopped by adding an aq. NaOH solution and the absorbance measured 
at 405 nm. 
 For PTPN6, PTPN12, PTPRF, and PTPN11, a mixture of the phosphatase, tyrosine 
phosphopeptide-2 substrate (89 µM), and compound (10 µM) in assay buffer was incubated at 37 °C 
for 15 min. The reaction as stopped by adding Biomol Green reagent and the absorbance measured 
at 650 nm. 
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c) Functional Assay Against RAF1, BRAF, and ABL Kinases 
This experiment was performed by Eurofins, Cerep®.  
Briefly, a mixture of human recombinant kinase, kinase substrate (ULightTM-Histone H3 
(Thr3/Ser10) Peptide (50 nM), inactive MEK1 (15 nM), and ULightTM-TK peptide (100 nM) for 
RAF1, BRAF, and ABL, respectively), ATP, and compound (10 µM) was incubated at rt for 60, 30, 
or 180 min, resp. The phosphorylated substrate was detected by LANCE® Ultra time-resolved 
fluorescence resonance energy transfer (TR-FRET). 
 
d) Measurement of Agonist and Antagonist Effects on Serotonin Receptors 
This experiment was performed by Cerep®.  
Briefly, human recombinant cells or cells endogenously overexpressing the receptor of interest were 
treated with compound. To determine an antagonistic effect, the receptors were simultaneously 
stimulated with a known agonist. Depending on the receptor subtype, either impedance, IP1, or 
cAMP levels were measured (Table 20). 
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Table 20. Functional assays employed to determine a possible agonist/antagonist effect of indoline 1a on 
serotonin receptors. 
Receptor Cell line Effect Stimulus Measured  Component 
Detection 
Method 
5-HT1A 
human recombinant  
(HEK-293 cells) 
agonist none impedance CDS 
antagonist 8-OH-DPAT (100 nM) impedance CDS 
5-HT1B 
CHO cells  
(endogenous) 
agonist none impedance CDS 
antagonist serotonin (10 nM) impedance CDS 
5-HT1D 
rat recombinant  
(CHO cells) 
agonist none impedance CDS 
antagonist serotonin (3 nM) impedance CDS 
5-HT2A 
human recombinant  
(HEK-293 cells) 
agonist none IP1 HTRF 
antagonist serotonin (100 nM) IP1 HTRF 
5-HT2B 
human recombinant  
(CHO cells) 
agonist none IP1 HTRF 
antagonist serotonin (30 nM) IP1 HTRF 
5-HT2C 
human recombinant  
(HEK-293 cells) 
agonist none IP1 HTRF 
antagonist serotonin (10 nM) IP1 HTRF 
5-HT4e 
human recombinant  
(CHO cells) 
agonist none cAMP HTRF 
antagonist serotonin (30 nM) cAMP HTRF 
5-HT6 
human recombinant  
(CHO cells) 
agonist none cAMP HTRF 
antagonist serotonin (300 nM) cAMP HTRF 
5-HT7 
human recombinant  
(CHO cells) 
agonist none cAMP HTRF 
antagonist serotonin (300 nM) cAMP HTRF 
CDS: Cellular dielectric spectroscopy; HTRF: Homogeneous Time Resolved Fluorescence 
 
e) Unselective Binding Assay Against Rat GPCRs 
This experiment was performed by Eurofins, Panlabs ®.  
The assays were performed in whole Wistar Rat brain membranes using radiolabeled ligands, which 
are specific for each receptor family (Table 21). Non-specific binding was determined by measuring 
displacement of the respective radioligand.  
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Table 21. Radioligands used for each binding assay. 
Receptor Radioligand 
Adrenergic α1 [3H] Prazosin (0.25 nM) 
Adrenergic α2 [3H] Rauwolscine (0.70 nM) 
Adrenergic β [3H] Dihydroalprenolol (0.25 nM) 
Bombesin [125I] (Tyr4)-Bombesin (10 pM) 
Muscarinic [3H] Quinuclidinyl benzilate (0.15 nM) 
Opiate [3H] Naloxone (1.0 nM) 
Purinergic [35S] ATP-αS (0.10 nM) 
 
f) Functional Assay Against on Purinergic Receptors 
This experiment was performed by Eurofins, Cerep ®.  
Briefly, human recombinant 1321N1 cells or cells endogenously overexpressing the receptor of 
interest were treated with compound. To determine an antagonistic effect, the receptors were 
simultaneously stimulated with a known agonist. Intracellular calcium levels were measured and 
detected by fluorimetry (Table 22). 
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Table 22. Stimuli used in functional assays to determine a possible agonist/antagonist effect of indoline 1a 
on P2Y receptors. 
Receptor Effect Stimulus 
P2Y1 
agonist none 
antagonist 2MeSATP (1 nM) 
P2Y2 
agonist none 
antagonist UTP (300 nM) 
P2Y4 
agonist none 
antagonist UTP (10 nM) 
P2Y6 
agonist none 
antagonist UDP (10 nM) 
P2Y11 
agonist none 
antagonist ATP (60 µM) 
 
g) Binding Assay against P2X 
This experiment was performed by Eurofins, Panlabs®. 
The assay was performed in whole membranes of New Zealand-derived albino rabbit urinary 
bladder using the P2X-specific radiolabeled ligand [3H] α,β-methylene-ATP (8 mM). Non-specific 
binding was determined by measuring displacement of the radioligand. 
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6.3. Materials in Chemical Synthesis 
 All reactions involving air or moisture sensitive reagents or intermediates were carried out 
under an argon atmosphere, and all the glassware was dried by heat gun under high vacuum prior 
to use. Commercial reagents were used without further purification. Dry solvents were received 
from Acros in anhydrous quality and used without any further purification. All other solvents or 
reagents were purified according to standard procedures or were used as received from Sigma 
Aldrich, Alfa Aesar, Acros, Activate Scientific, Matrix Scientific, Combi Blocks, Fisher Scientific, 
Merck and TCI.  
 Analytical thin-layer chromatography (TLC) was performed on Merck silica gel aluminium 
plates with F-254 indicator. Detection of compounds was performed by UV254 light or staining 
with a solution of KMnO4 (1.5 g in 400 mL H2O, 5 g NaHCO3) followed by heating with a heat 
gun. Flash column chromatography was performed using silica gel from Acros Organics (40–
65 µm, 230–400 mesh). Flash master chromatography was performed using a Reveleris® X2 Flash 
System (Büchi) and GraceResolveTM cartridges.  
 Preparative HPLC-MS: Separations were carried out using a preparative mass-directed 
HPLC (Agilent Series, 1100/LC/MSD VL, Agilent Series) with a reversed-phase C18 column (RP 
C4, flow 20.0 mL/min, solvent A: 0.1% TFA in water, solvent B: 0.1% TFA in acetonitrile). 
 1H NMR and 13C NMR were recorded on spectrometers from Bruker (AMX 400, AMX 
500 MHz, AMX 600 MHz, Avance DRX 400, and Avance DRX 500) and Varian (Mercury 
400 MHz or Unity Inova 600) using CDCl3, DMSO-d6, or CD3OD as solvent. The NMR spectra 
are reported as follows: chemical shift (δ) in ppm relative to TMS (δ = 0 ppm), multiplicity, 
coupling constant (J) in Hertz (Hz), number of protons. Chemical shift values are reported with the 
solvent resonance as internal standard (CDCl3: δH = 7.26 ppm, δC = 77.16 ppm; DMSO-d6: δH = 
2.50 ppm, δC = 39.52 ppm; CD3OD: δH = 3.31 ppm, δC = 49.00 ppm). Multiplicities are indicated 
as br. (broad signal), s (singlet), d (doublet), t (triplet), q (quartet), sept (septet), combinations 
thereof, or m (multiplet). Unless stated otherwise all NMRs were measured at room temperature. 
Where possible, structural assignments were attempted using standard 2-D NMR techniques 
(gCOSY, gHSQC, gHMBC). 
 HR-MS spectra were recorded on a LTQ Orbitrap (Thermo Fisher) mass spectrometer 
coupled to an Accela HPLC-System (HPLC column: Hypersyl GOLD, 50 mm x 1 mm, particle size 
1.9 µm), ionization method: electron spray ionization (ESI). 
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6.4. Synthesis of Indoline-Based Analogs 
Analogs of indoline 1a that are not described in this section were purchased from ChemDiv. 
Cyclopropyl(indolin-1-yl)methanone (3) 
 
To a solution of indoline (4, 1.50 mL, 13.4 mmol) and Et3N (7.18 mL, 40.1 mmol, 3.0 eq.) in CH2Cl2 
(25 mL) under an argon atmosphere, DMAP (33 mg, 0.3 mmol, 0.02 eq.) was added. The solution 
was cooled to 0 °C, and cyclopropanecarbonyl chloride (1.37 mL, 14.7 mmol, 1.1 eq.) was added 
dropwise. The mixture was stirred for 10 min at 0 °C and 2 h at rt, EtOAc was added (30 mL), and 
the organic phase was washed with an aq. 1 M HCl solution (2 x 10 mL), sat. aq. NaHCO3 solution 
(1 x 10 mL), and brine (1 x 10 mL). The organic layer was dried over MgSO4 and concentrated 
under reduced pressure. The crude product was purified by flash chromatography (SiO2; 
cyclohexane/EtOAc 1:0 ® 9:1) to afford 3 (2.479 g, 99%) as an off-white amorphous solid.  
1H NMR (400 MHz, CDCl3): δ = 8.17 (s, 1H), 7.24–7.11 (m, 2H), 6.99 (t, J = 7.4 Hz, 1H), 4.26 (t, 
J = 8.7 Hz, 2H), 3.21 (t, J = 8.7 Hz, 2H), 1.88–1.65 (m, 1H), 1.19–1.07 (m, 2H), 0.96–0.79 (m, 2H); 
HR-ESI-MS: m/z = 188.1069 ([M + H]+, calcd. for C12H14NO+: 188.1070). 
 
General Procedure I – C5-Bromination of N-Acylated Indolines 
To a solution of the acyl indoline (9.3 mmol) in CH2Cl2 (40 mL) at rt under an argon atmosphere, 
NBS (1.1 eq.) was added. The mixture was stirred at rt for 2–16 h and poured into sat. aq. NaHCO3 
(20 mL). The layers were separated, and the aq. layer was extracted with EtOAc (3 x 10 mL). The 
combined organic layers were washed with brine (1 x 50 mL), dried over MgSO4, filtered, and 
concentrated under reduced pressure. The crude product was purified by flash chromatography 
(SiO2; cyclohexane/EtOAc mixture). 
 
N
O
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1-(5-Bromoindolin-1-yl)ethan-1-one (SI-1)  
 
Bromoindoline SI-1 was synthesized according to GP I, using 1-(indolin-1-yl)ethan-1-one (1.500 g, 
9.3 mmol), which was reacted for 2 h. Purification of the product by flash chromatography (SiO2; 
cyclohexane/EtOAc 4:1 ® 3:2) afforded SI-1 (2.123 g, 85%) as a white amorphous solid.  
1H NMR (500 MHz, DMSO-d6): δ = 7.95 (d, J = 8.6 Hz, 1H), 7.40 (s, 1H), 7.30 (d, J = 8.5 Hz, 
1H), 4.09 (t, J = 8.6 Hz, 2H), 3.14 (t, J = 8.5 Hz, 2H), 2.14 ppm (s, 3H); 13C NMR (126 MHz, 
DMSO-d6): δ = 168.8, 142.3, 134.8, 129.6, 127.6, 117.3, 114.4, 48.3, 27.1, 23.9 ppm; HR-ESI-
MS: m/z = 240.00166 ([M + H]+, calcd. for C10H1179BrNO+: 240.0019), 241.99886 ([M + H]+, calcd. 
for C10H1181BrNO+: 241.9998). 
 
(5-Bromoindolin-1-yl)(cyclopropyl)methanone (6) 
 
Bromoindoline 6 was synthesized according to GP I, using 3 (300 mg, 1.6 mmol), which was 
reacted for 2 h. Purification of the product by flash chromatography (SiO2; cyclohexane/EtOAc 1:0 
® 9:1) afforded 6 (379 mg, 89%) as an off-white amorphous solid.  
1H NMR (400 MHz, CDCl3): δ = 8.05 (s, 1H), 7.29 (s, 1H), 7.28–7.26 (m, 1H), 4.28 (t, J = 8.2 Hz, 
2H), 3.21 (t, J = 8.1 Hz, 2H), 1.74 (s, 1H), 1.13 (m, 2H), 0.98–0.81 ppm (m, 2H); 13C NMR 
(126 MHz, DMSO-d6): δ = 142.6, 135.0, 129.5, 127.6, 117.4, 114.4, 47.9, 27.1, 13.1, 7.9 ppm; HR-
ESI-MS: m/z = 266.0173 ([M + H]+, calcd. for C12H1379BrNO+: 266.0175), 268.0145([M + H]+, 
calcd. for C12H1381BrNO+: 268.0155). 
 
N
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General Procedure II – Chlorosulfonylation of N-Acylindolines 
To chlorosulfonic acid (12.0 eq.), the N-acylindoline (0.9 mmol) was added slowly at 0 °C under 
an argon atmosphere. The mixture was stirred at 0 °C for 20 min, and at 70 °C for 5 h. The mixture 
was quenched by pipetting it carefully onto ice (10 mL) under vigorous stirring. The precipitated 
crude product was extracted with EtOAc (5 x 20 mL). The combined organic layers were dried over 
MgSO4, filtered, and concentrated under reduced pressure. The crude product was used without 
purification in the next step. Due to its poor stability in water, no ESI-MS data could be obtained. 
 
5-Bromo-1-(cyclopropanecarbonyl)indoline-6-sulfonyl chloride (SI-2) 
 
Chlorosulfonyl SI-2 was synthesized according to GP II using 6 (100 mg, 0.4 mmol). 
1H NMR (400 MHz, CDCl3): δ = 9.11–8.90 (m, 1H), 7.61 (s, 1H), 4.38 (t, J = 8.8 Hz, 2H), 3.33 (t, 
J = 8.3 Hz, 2H), 1.80–1.70 (m, 1H), 1.21–1.14 (m, 2H), 1.02–0.90 ppm (m, 2H). 
 
1-(Cyclopropanecarbonyl)indoline-5-sulfonyl Chloride (SI-3) 
 
Chlorosulfonyl SI-3 was synthesized according to GP II using 3 (100 mg, 0.5 mmol). 
1H NMR (400 MHz, CDCl3): δ = 8.42–8.20 (m, 1H), 7.88 (dd, J = 8.8, 2.1 Hz, 1H), 7.82 (s, 1H), 
4.40 (t, J = 8.7 Hz, 2H), 3.33 (t, J = 8.7 Hz, 2H), 1.86–1.68 (m, 1H), 1.21–1.15 (m, 2H), 1.01–
0.94 ppm (m, 2H). 
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1-Acetyl-5-bromoindoline-6-sulfonyl Chloride (SI-4)[108] 
 
Chlorosulfonyl SI-4 was synthesized according to GP II using SI-1 (500 mg, 2.1 mmol). 
1H NMR (400 MHz, CDCl3): δ = 9.01 (s, 1H), 7.60 (s, 1H), 4.17 (t, J = 8.6 Hz, 2H), 3.30 (s, 2H), 
2.25 ppm (s, 3H). 
 
General Procedure III – Synthesis of Sulfonamides 
A mixture of the sulfonyl chloride (82 µmol) and the aniline (1.0–1.1 eq.) in pyridine (2 mL) was 
heated to 60 °C under an argon atmosphere for 16 h. The solution was concentrated under reduced 
pressure, and the residue dissolved in EtOAc, and washed with an aq. 1 M HCl solution (1 x). The 
aq. phase was extracted with EtOAc, and the combined organic layers were dried over MgSO4, 
filtered, and concentrated under reduced pressure. The product was purified by flash 
chromatography (SiO2; cyclohexane/EtOAc mixture). Yields are reported over two steps. 
 
5-Bromo-N-(4-chloro-3-(trifluoromethyl)phenyl)-1-(cyclopropanecarbonyl)indoline-6-
sulfonamide (1a) 
 
Sulfonamide 1a was synthesized according to GP III using SI-2 (300 mg, 823 µmol) and 4-chloro-
3-(trifluoromethyl)aniline (169 mg, 864 µmol, 1.1 eq.). Purification of the product by flash column 
chromatography (SiO2; cyclohexane/EtOAc 4:1 ® 2:1) afforded 1a (329 mg, 76%) as an off-white 
amorphous solid.  
1H NMR (500 MHz, DMSO-d6): δ = 11.13 (s, 1H), 8.80 (s, 1H), 7.66 (s, 1H), 7.60 (d, J = 8.8 Hz, 
1H), 7.55 (d, J = 2.6 Hz, 1H), 7.34 (dd, J = 8.8, 2.6 Hz, 1H), 4.32 (t, J = 8.5 Hz, 2H), 3.22 (t, J = 
8.6 Hz, 2H), 1.93 (tt, J = 7.2, 5.4 Hz, 1H), 0.95–0.84 ppm (m, 4H); 13C NMR (126 MHz, DMSO-
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d6): δ = 172.0, 142.9, 140.0, 136.8, 136.1, 132.7, 131.4, 127.2 (q, J = 30.8 Hz), 124.8 (q, J = 1.9 Hz), 
123.3, 122.3 (q, J = 273.3 Hz), 117.8, 117.6 (q, J = 5.8 Hz), 111.9, 48.1, 27.0, 13.1, 8.3 ppm; 
19F NMR (377 MHz, DMSO-d6): δ = -61.77 ppm; HR-ESI-MS: m/z = 522.9708 ([M + H]+, calcd. 
for C19H1679BrClF3N2O3S+: 522.9700), 524.9682 ([M + H]+, calcd. for C19H1681BrClF3N2O3S+: 
524.9680), 526.9652 ([M + H]+, calcd. for C19H1681Br37ClF3N2O3S+: 526.9650). 
 
5-Bromo-1-(cyclopropanecarbonyl)-N-(3-(trifluoromethyl)phenyl)indoline-6-sulfonamide 
(1b) 
 
Sulfonamide 1b was synthesized according to GP III using SI-2 (50 mg, 137 µmol) and 3-
(trifluoromethyl)aniline (17 µL, 137 µmol, 1.0 eq.). Purification of the product by flash column 
chromatography (SiO2; cyclohexane/EtOAc 4:1 ® 2:1) afforded 1b (61 mg, 90%) as an off-white 
amorphous solid.  
1H NMR (600 MHz, DMSO-d6): δ = 11.00 (s, 1H), 8.81 (s, 1H), 7.65 (s, 1H), 7.47 (t, J = 8.0 Hz, 
1H), 7.41 (s, 1H), 7.37–7.31 (m, J = 8.0, 1.6 Hz, 2H), 4.32 (t, J = 8.2 Hz, 2H), 3.21 (t, J = 8.5 Hz, 
2H), 1.93 (tt, J = 7.2, 5.4 Hz, 1H), 0.94–0.84 ppm (m, 4H); 13C NMR (151 MHz, DMSO-d6): δ = 
142.9, 139.9, 138.1, 136.2, 131.4, 130.6, 129.9 (q, J = 31.8 Hz), 123.7 (q, J = 272.4 Hz), 122.1, 
120.0, 118.1, 115.0, 112.0, 48.1, 27.0, 13.2, 8.3 ppm; 19F NMR (565 MHz, DMSO-d6): 
δ = -61.51 ppm; HR-ESI-MS: m/z = 489.0093 ([M + H]+, calcd. for C19H1779BrF3N2O3S+: 
489.0090), 491.0069 ([M + H]+, calcd. for C19H1781BrF3N2O3S+: 491.0069). 
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5-Bromo-N-(4-bromo-3-(trifluoromethyl)phenyl)-1-(cyclopropanecarbonyl)indoline-6-
sulfonamide (1c) 
 
Sulfonamide 1c was synthesized according to GP III using SI-2 (30 mg, 82 µmol) and 4-bromo-3-
(trifluoromethyl)aniline (20 mg, 82 µmol, 1.0 eq.). Purification of the product by flash column 
chromatography (SiO2; cyclohexane/EtOAc 4:1 ® 2:1) afforded 1c (43 mg, 91%) as an off-white 
amorphous solid.  
1H NMR (600 MHz, DMSO-d6): δ = 11.16 (s, 1H), 8.80 (s, 1H), 7.75 (d, J = 8.7 Hz, 1H), 7.66 (s, 
1H), 7.54 (d, J = 2.6 Hz, 1H), 7.25 (dd, J = 8.7, 2.5 Hz, 1H), 4.32 (t, J = 8.3 Hz, 2H), 3.22 (t, J = 
8.5 Hz, 2H), 1.99–1.88 (m, 1H), 0.95–0.84 ppm (m, 4H); 13C NMR (151 MHz, DMSO-d6): δ = 
172.1, 142.9, 140.1, 136.1, 136.1, 131.5, 129.0 (q, J = 30.8 Hz), 123.3, 122.5 (q, J = 273.4 Hz), 
118.2–117.7 (m); 117.9, 117.8, 112.4, 111.9, 48.2, 27.1, 13.1, 8.3 ppm; 19F NMR (565 MHz, 
DMSO-d6): δ = -61.84 ppm; HR-ESI-MS: m/z = 566.9206 ([M + H]+, calcd. for 
C19H1679Br2F3N2O3S+: 566.9195), 568.9181 ([M + H]+, calcd. for C19H1679Br81BrF3N2O3S+: 
568.9175), 570.9158 ([M + H]+, calcd. for C19H1681Br2F3N2O3S+: 570.9154). 
 
5-Bromo-1-(cyclopropanecarbonyl)-N-(4-methyl-3-(trifluoromethyl)phenyl)indoline-6-
sulfonamide (1d) 
 
Sulfonamide 1d was synthesized according to GP III using SI-2 (36 mg, 96 µmol) and 4-methyl-3-
(trifluoromethyl)aniline (15 µL, 108 µmol, 1.1 eq.). Purification of the product by flash column 
chromatography (SiO2; cyclohexane/EtOAc 4:1 ® 2:1) afforded 1d (45 mg, 92%) as an off-white 
amorphous solid.  
1H NMR (700 MHz, DMSO-d6): δ = 10.79 (br. s, 1H), 8.78 (br. s, 1H), 7.64 (s, 1H), 7.40 (s, 1H), 
7.29 (d, J = 8.4 Hz, 1H), 7.24 (d, J = 8.5 Hz, 1H), 4.32 (t, J = 8.0 Hz, 2H), 3.21 (t, J = 8.5 Hz, 2H), 
2.29 (s, 3H), 1.97–1.87 (m, 1H), 0.99–0.77 ppm (m, 4H); 13C NMR (176 MHz, DMSO-d6): δ = 
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172.0, 142.8, 139.7, 136.4, 135.4, 133.2, 131.3, 131.0, 127.9 (q, J = 29.5 Hz), 124.0 (q, J = 
273.8 Hz), 122.4, 118.0, 116.4 (d, J = 5.3 Hz), 111.9, 48.1, 27.0, 18.0, 17.9, 13.1, 8.3 ppm; 19F 
NMR (377 MHz, DMSO-d6): δ = -60.76 ppm; HR-ESI-MS: m/z = 503.0261 ([M + H]+, calcd. for 
C20H1979BrF3N2O3S+: 503.0246), 505.0235 ([M + H]+, calcd. for C20H1981BrF3N2O3S+: 505.0226). 
 
5-Bromo-N-(3-chloro-5-(trifluoromethyl)phenyl)-1-(cyclopropanecarbonyl)indoline-6-
sulfonamide (1e) 
 
Sulfonamide 1e was synthesized according to GP III using SI-2 (35 mg, 96 µmol) and 3-chloro-5-
(trifluoromethyl)aniline (21 mg, 106 µmol, 1.1 eq.). Purification of the product by flash column 
chromatography (SiO2; cyclohexane/EtOAc 4:1 ® 2:1) afforded 1e (28 mg, 56%) as an off-white 
amorphous solid.  
1H NMR (600 MHz, DMSO-d6): δ = 11.33 (s, 1H), 8.82 (s, 1H), 7.67 (s, 1H), 7.48 (s, 1H), 7.37 
(dd, J = 3.1, 1.4 Hz, 2H), 4.32 (t, J = 8.2 Hz, 2H), 3.22 (t, J = 8.5 Hz, 2H), 1.93 (dq, J = 7.0, 5.6 Hz, 
1H), 0.89 ppm (dd, J = 10.8, 5.9 Hz, 4H); 13C NMR (151 MHz, DMSO-d6): δ = 172.1, 143.0, 140.2, 
139.7, 135.8, 134.7, 131.6, 131.5 (q, J = 32.7 Hz), 122.9 (q, J = 273.0 Hz), 121.4, 119.9, 117.9, 
113.3, 111.9, 48.1, 27.1, 13.1, 8.4 ppm; 19F NMR (565 MHz, DMSO-d6): δ = -61.82 ppm; HR-
ESI-MS: m/z = 522.9707 ([M + H]+, calcd. for C19H1679BrClF3N2O3S+: 522.9700), 524.9680 
([M + H]+, calcd. for C19H1681BrClF3N2O3S+: 524.9680), 526.9652 ([M + H]+, calcd. for 
C19H1681Br37ClF3N2O3S+: 526.9650). 
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N-(3,5-Bis(trifluoromethyl)phenyl)-5-bromo-1-(cyclopropanecarbonyl)indoline-6-
sulfonamide (1f) 
 
Sulfonamide 1f was synthesized according to GP III using SI-2 (30 mg, 83 µmol) and 3,5-
bis(trifluoromethyl)aniline (19.3 µL, 123 µmol, 1.5 eq.). Purification of the product by flash column 
chromatography (SiO2; cyclohexane/EtOAc 2:1® 1:0) afforded 1f (24 mg, 52%) as an off-white 
amorphous solid.  
1H NMR (400 MHz, CD3OD): δ = 8.94 (s, 1H), 7.67 (s, 2H), 7.57 (s, 1H), 7.54 (s, 1H), 4.36 (t, J = 
8.6 Hz, 2H), 3.25 (t, J = 8.6 Hz, 2H), 1.97–1.88 (m, 1H), 1.08–1.00 (m, 2H), 1.01–0.93 ppm (m, 
2H); HR-ESI-MS: m/z = 556.9973 ([M + H]+, calcd. for C20H1679BrF6N2O3S+: 556.9964), 558.9949 
([M + H]+, calcd. for C20H1681BrF6N2O3S+: 558.9943). 
 
5-Bromo-1-(cyclopropanecarbonyl)-N-(4-methoxy-3-(trifluoromethyl)phenyl)indoline-6-
sulfonamide (1h) 
 
Sulfonamide 1h was synthesized according to GP III using SI-2 (34 mg, 93 µmol) and 4-methoxy-
3-(trifluoromethyl)aniline (19 mg, 98 µmol, 1.1 eq.). Purification of the product by flash column 
chromatography (SiO2; cyclohexane/EtOAc 4:1 ® 2:1) afforded 1h (37 mg, 77%) as an off-white 
amorphous solid.  
1H NMR (600 MHz, DMSO-d6): δ = 10.50 (s, 1H), 8.71 (s, 1H), 7.66 (s, 1H), 7.37–7.30 (m, 2H), 
7.17 (d, J = 8.9 Hz, 1H), 4.32 (t, J = 8.3 Hz, 2H), 3.79 (s, 3H), 3.21 (t, J = 8.5 Hz, 2H), 1.96–1.87 
(m, 1H), 0.95-0.76 ppm (m, 4H); 13C NMR (151 MHz, DMSO-d6): δ = 172.0, 153.8, 142.8, 139.6, 
136.6, 131.3, 129.5, 126.1, 123.2 (q, J = 272.4 Hz), 119.4 (q, J = 5.2 Hz), 117.9, 117.1 (q, J = 
30.4 Hz), 113.9, 112.0, 56.3, 48.1, 27.0, 13.1, 8.3 ppm; 19F NMR (565 MHz, DMSO-d6): 
δ = -61.23 ppm; HR-ESI-MS: m/z = 519.0211 ([M + H]+, calcd. for C20H1979BrF3N2O4S+: 
519.0196), 521.0187 ([M + H]+, calcd. for C20H1981BrF3N2O4S+: 521.0175). 
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5-Bromo-1-(cyclopropanecarbonyl)-N-(4-fluoro-3-(trifluoromethyl)phenyl)indoline-6-
sulfonamide (1i) 
 
Sulfonamide 1i was synthesized according to GP III using SI-2 (35 mg, 96 µmol) and 4-fluoro-3-
(trifluoromethyl)aniline (12 µL, 96 µmol, 1.0 eq.). Purification of the product by flash column 
chromatography (SiO2; cyclohexane/EtOAc 4:1 ® 2:1) afforded 1i (32 mg, 66%) as an off-white 
amorphous solid.  
1H NMR (600 MHz, DMSO-d6): δ = 10.95 (s, 1H), 8.77 (s, 1H), 7.66 (s, 1H), 7.50–7.34 (m, 3H), 
4.32 (t, J = 8.4 Hz, 2H), 3.22 (t, J = 8.6 Hz, 2H), 1.95–1.86 (m, 1H), 0.88 ppm (dd, J = 10.5, 6.4 Hz, 
4H); 13C NMR (151 MHz, DMSO-d6): δ = 172.0, 155.1 (d, J = 250.6 Hz), 142.9, 139.9, 136.2, 
134.0 (d, J = 2.8 Hz), 131.4, 125.3 (d, J = 8.6 Hz), 122.1 (q, J = 272.2 Hz), 118.4 (d, J = 21.8 Hz), 
117.8, 117.6 (d, J = 4.4 Hz), 117.0 (qd, J = 32.5, 13.5 Hz), 111.9, 48.1, 27.0, 13.1, 8.3 ppm; 
19F NMR (565 MHz, DMSO-d6): δ = -60.52 (d, J = 12.4 Hz), -121.98–-122.12 ppm (m); HR-ESI-
MS: m/z = 507.0001 ([M + H]+, calcd. for C19H1679BrF4N2O3S+: 506.9996), 508.9975 ([M + H]+, 
calcd. for C19H1681BrF4N2O3S+: 508.9975). 
 
5-Bromo-N-(4-chloro-2-(trifluoromethyl)phenyl)-1-(cyclopropanecarbonyl)indoline-6-
sulfonamide (1j) 
 
Sulfonamide 1j was synthesized according to GP III using SI-2 (35 mg, 96 µmol) and 4-chloro-2-
(trifluoromethyl)aniline (15 µL, 106 µmol, 1.0 eq.). Purification of the product by flash column 
chromatography (SiO2; cyclohexane/EtOAc 1:0 ® 9:1) afforded 1j (4 mg, 7%) as an off-white 
amorphous solid.  
1H NMR (400 MHz, CDCl3): δ = 9.08–8.81 (m, 1H), 7.64–7.56 (m, 1H), 7.50 (s, 1H), 7.43–7.36 
(m, 2H), 4.34 (t, J = 8.3 Hz, 2H), 3.26 (t, J = 8.8 Hz, 2H), 1.88–1.65 (m, 1H), 1.00–0.79 ppm (m, 
4H); ESI-MS: m/z = 522.8 ([M + H]+, calcd. for C19H1679BrClF3N2O3S+: 523.0), 524.8 ([M + H]+, 
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calcd. for C19H1581BrClF3N2O3S+: 525.0), 526.8 ([M + H]+, calcd. for C19H1581Br37ClF3N2O3S+: 
527.0). 
 
5-Bromo-1-(cyclopropanecarbonyl)-N-(1-methyl-1H-indol-5-yl)indoline-6-sulfonamide (1n) 
 
Sulfonamide 1n was synthesized according to GP III using SI-2 (37 mg, 101 µmol) and 1-methyl-
1H-indol-5-amine (16 mg, 111 µmol, 1.1 eq.). Purification of the product by flash column 
chromatography (SiO2; cyclohexane/EtOAc 4:1 ® 2:1) afforded 1n (32 mg, 67%) as an off-white 
amorphous solid.  
1H NMR (700 MHz, DMSO-d6): δ = 9.98 (br. s, 1H), 8.63 (s, 1H), 7.63 (d, J = 16.0 Hz, 1H), 7.30–
7.25 (m, 3H), 6.96 (d, J = 8.9 Hz, 1H), 6.31 (d, J = 2.9 Hz, 1H), 4.25 (t, J = 7.9 Hz, 2H), 3.69 (s, 
3H), 3.16 (t, J = 8.5 Hz, 2H), 1.92–1.82 (m, J = 32.5 Hz, 1H), 0.89–0.78 ppm (m, 4H); 13C NMR 
(176 MHz, DMSO-d6): δ = 171.8, 142.6, 139.0, 137.0, 134.1, 130.9, 130.5, 128.3, 127.9, 118.3, 
116.9, 114.0, 112.2, 110.0, 100.2, 48.0, 32.5, 26.9, 13.1, 8.2 ppm; HR-ESI-MS: m/z = 474.0502 
([M + H]+, calcd. for C21H2179BrN3O3S+: 474.0482), 476.0479 ([M + H]+, calcd. for 
C21H2181BrN3O3S+: 476.0461). 
 
5-Bromo-1-(cyclopropanecarbonyl)-N-(3,4,5-trifluorophenyl)indoline-6-sulfonamide (1o) 
 
Sulfonamide 1o was synthesized according to GP III using SI-2 (33 mg, 91 µmol) and 3,4,5-
trifluoroaniline (13 mg, 91 µmol, 1.0 eq.). Purification of the product by flash column 
chromatography (SiO2; cyclohexane/EtOAc 4:1 ® 2:1) afforded 1o (25 mg, 58%) as an off-white 
amorphous solid.  
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1H NMR (600 MHz, DMSO-d6): δ = 11.09 (s, 1H), 8.78 (s, 1H), 7.68 (s, 1H), 6.90 (dd, J = 9.4, 
6.1 Hz, 2H), 4.34 (t, J = 8.5 Hz, 2H), 3.23 (t, J = 8.6 Hz, 2H), 1.94 (ddt, J = 14.5, 12.0, 5.9 Hz, 1H), 
0.99–0.81 ppm (m, 4H); 13C NMR (151 MHz, DMSO-d6): δ = 172.2, 150.3 (ddd, J = 246.4, 10.1, 
5.2 Hz), 142.9, 140.2, 135.9, 135.3 (dt, J = 245.5, 15.6 Hz), 133.7 (td, J = 11.3, 3.2 Hz), 131.5, 
117.9, 112.0, 103.3 (dd, J = 19.9, 5.1 Hz), 48.2, 27.1, 13.2, 8.4 ppm; 19F NMR (565 MHz, DMSO-
d6): δ = -133.42 (dd, J = 22.4, 9.6 Hz), -167.50 ppm (t, J = 22.2 Hz); HR-ESI-MS: m/z = 474.9937 
([M + H]+, calcd. for C18H1579BrF3N2O3S+: 474.9933), 476.9909 ([M + H]+, calcd. for 
C18H1581BrF3N2O3S +: 476.9913). 
 
5-Bromo-1-(cyclopropanecarbonyl)-N-(3-fluorophenyl)indoline-6-sulfonamide (1p) 
 
Sulfonamide 1p was synthesized according to GP III using SI-2 (30 mg, 82 µmol) and 3-
fluoroaniline (8 µL, 82 µmol, 1.0 eq.). Purification of the product by flash column chromatography 
(SiO2; cyclohexane/EtOAc 4:1 ® 2:1) afforded 1p (35 mg, 98%) as an off-white amorphous solid.  
1H NMR (600 MHz, DMSO-d6): δ = 10.85 (s, 1H), 8.81 (s, 1H), 7.65 (s, 1H), 7.26 (td, J = 8.2, 
6.9 Hz, 1H), 6.91 (dd, J = 8.2, 0.7 Hz, 1H), 6.87 (dt, J = 11.0, 2.2 Hz, 1H), 6.82 (td, J = 8.3, 2.0 Hz, 
1H), 4.33 (t, J = 8.4 Hz, 2H), 3.22 (t, J = 8.5 Hz, 2H), 1.98–1.88 (m, 1H), 0.96–0.83 ppm (m, 4H); 
13C NMR (151 MHz, DMSO-d6): δ = 172.1, 162.2 (d, J = 243.0 Hz), 142.9, 139.9, 139.0 (d, J = 
10.7 Hz), 136.3, 131.4, 131.0 (d, J = 9.6 Hz), 118.1, 114.5 (d, J = 2.4 Hz), 112.0, 110.2 (d, J = 
20.9 Hz), 105.5 (d, J = 25.6 Hz), 48.2, 27.0, 13.2, 8.3 ppm; 19F NMR (565 MHz, DMSO-d6): 
δ = -111.49 ppm; HR-ESI-MS: m/z = 439.0125 ([M + H]+, calcd. for C18H1779BrFN2O3S+: 
439.0122), 441.0098 ([M + H]+, calcd. for C18H1781BrFN2O3S+: 441.0101). 
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5-Bromo-1-(cyclopropanecarbonyl)-N-(4-fluorophenyl)indoline-6-sulfonamide (1q) 
 
Sulfonamide 1q was synthesized according to GP III using SI-2 (30 mg, 82 µmol) and 4-
fluoroaniline (8 µL, 82 µmol, 1.0 eq.). Purification of the product by flash column chromatography 
(SiO2; cyclohexane/EtOAc 4:1 ® 2:1) afforded 1q (7 mg, 20%) as an off-white amorphous solid.  
1H NMR (600 MHz, DMSO-d6): δ = 10.47 (s, 1H), 8.72 (s, 1H), 7.64 (s, 1H), 7.18–7.00 (m, 4H), 
4.32 (t, J = 8.4 Hz, 2H), 3.21 (t, J = 8.5 Hz, 2H), 1.99–1.87 (m, 1H), 0.93–0.83 ppm (m, 4H); 
13C NMR (151 MHz, DMSO-d6): δ = 172.0, 158.8 (d, J = 240.6 Hz), 142.8, 139.6, 136.6, 133.3, 
131.2, 121.9 (d, J = 8.3 Hz), 118.1, 115.9 (d, J = 22.7 Hz), 112.0, 48.1, 27.0, 13.2, 8.3 ppm; 
19F NMR (565 MHz, DMSO-d6): δ = -118.72 ppm; HR-ESI-MS: m/z = 439.0121 ([M + H]+, calcd. 
for C18H1779BrFN2O3S+: 439.0122), 441.0099 ([M + H]+, calcd. for C18H1781BrFN2O3S+: 441.0101). 
 
5-Bromo-1-(cyclopropanecarbonyl)-N-(3,5-difluorophenyl)indoline-6-sulfonamide (1r) 
 
Sulfonamide 1r was synthesized according to GP III using SI-2 (30 mg, 82 µmol) and 3,5-
difluoroaniline (11 mg, 82 µmol, 1.0 eq.). Purification of the product by flash column 
chromatography (SiO2; cyclohexane/EtOAc 4:1 ® 2:1) afforded 1r (30 mg, 79%) as an off-white 
amorphous solid.  
1H NMR (600 MHz, DMSO-d6): δ = 11.17 (s, 1H), 8.81 (s, 1H), 7.67 (s, 1H), 6.86 (tt, J = 9.3, 
2.1 Hz, 1H), 6.81–6.66 (m, 2H), 4.34 (t, J = 8.4 Hz, 2H), 3.23 (t, J = 8.6 Hz, 2H), 1.99–1.89 (m, 
1H), 0.98–0.84 ppm (m, 4H); 13C NMR (151 MHz, DMSO-d6): δ = 172.2, 163.4 (dd, J = 17.0, 
6.4 Hz), 142.9, 140.2, 140.1, 136.0, 131.5, 118.0, 112.0, 101.6–101.1 (m), 98.7 (t, J = 26.0 Hz), 
48.2, 27.1, 13.2, 8.4 ppm; 19F NMR (565 MHz, DMSO-d6): δ = -108.26 ppm; HR-ESI-MS: m/z = 
457.0031 ([M + H]+, calcd. for C18H1679BrF2N2O3S+: 457.0028), 459.0004 ([M + H]+, calcd. for 
C18H16N281BrF2O3S+: 459.0007). 
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5-Bromo-1-(cyclopropanecarbonyl)-N-(perfluorophenyl)indoline-6-sulfonamide (1s) 
 
Sulfonamide 1s was synthesized according to GP III using SI-2 (35 mg, 96 µmol) and 2,3,4,5,6-
pentafluoroaniline (19 mg, 101 µmol, 1.0 eq.). Purification of the product by flash column 
chromatography (SiO2; cyclohexane/EtOAc 4:1 ® 2:1) afforded 1s (8 mg, 16%) as an off-white 
amorphous solid.  
1H NMR (400 MHz, CD3OD): δ = 8.68 (s, 1H), 7.68 (s, 1H), 4.40 (t, J = 8.5 Hz, 2H), 3.34 (t, J = 
8.5 Hz, 2H), 1.98–1.88 (m, 1H), 1.03–0.97 (m, 2H), 0.97–0.91 ppm (m, 2H); HR-ESI-MS: m/z = 
510.9745 ([M + H]+, calcd. for C18H1379BrF5N2O3S+: 510.9745), 512.9723 ([M + H]+, calcd. for 
C18H1381BrF5N2O3S+: 512.9725). 
 
5-Bromo-N-(3-cyanophenyl)-1-(cyclopropanecarbonyl)indoline-6-sulfonamide (1t) 
 
 
 
Sulfonamide 1t was synthesized according to GP III using SI-2 (30 mg, 82 µmol) and 3-
aminobenzonitrile (10 mg, 82 µmol, 1.0 eq.). Purification of the product by flash column 
chromatography (SiO2; cyclohexane/EtOAc 4:1 ® 2:1) afforded 1t (34 mg, 93%) as an off-white 
amorphous solid.  
1H NMR (600 MHz, DMSO-d6): δ = 11.05 (s, 1H), 8.80 (s, 1H), 7.65 (s, 1H), 7.51–7.43 (m, 2H), 
7.43–7.40 (m, 1H), 7.40–7.35 (m, 1H), 4.33 (t, J = 8.3 Hz, 2H), 3.22 (t, J = 8.5 Hz, 2H), 1.96–1.88 
(m, 1H), 0.99–0.81 ppm (m, 4H); 13C NMR (151 MHz, DMSO-d6): δ = 172.1, 142.9, 140.0, 138.2, 
136.2, 131.5, 130.8, 127.3, 123.2, 121.5, 118.2, 117.9, 112.0, 112.0, 48.2, 27.0, 13.2, 8.4 ppm; HR-
ESI-MS: m/z = 446.0173 ([M + H]+, calcd. for C19H1779BrN3O3S+: 446.0169), 448.0145 ([M + H]+, 
calcd. for C19H1781BrN3O3S+: 448.0148). 
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3-((5-Bromo-1-(cyclopropanecarbonyl)indoline)-6-sulfonamido)benzoic Acid (1u) 
 
Sulfonamide 1u was synthesized according to GP III using SI-2 (32 mg, 88 µmol) and 3-
aminobenzoic acid (12 µL, 88 µmol, 1.0 eq.). Purification of the product by flash column 
chromatography (SiO2; cyclohexane/EtOAc/HOAc 1:1:0 ® 49.5:49.5:1) afforded 1u as an off-
white amorphous solid (38 mg, 92%).  
1H NMR (600 MHz, DMSO-d6): δ = 13.00 (s, 1H), 10.75 (s, 1H), 8.77 (s, 1H), 7.71 (d, J = 1.6 Hz, 
1H), 7.63 (s, 1H), 7.56 (dt, J = 7.5, 1.4 Hz, 1H), 7.33 (tt, J = 4.7, 3.5 Hz, 2H), 4.30 (t, J = 7.6 Hz, 
2H), 3.19 (t, J = 8.5 Hz, 2H), 1.96–1.84 (m, 1H), 0.95–0.80 ppm (m, 4H); 13C NMR (151 MHz, 
DMSO-d6): δ = 172.0, 166.7, 142.8, 139.7, 137.4, 136.6, 131.8, 131.3, 129.5, 124.6, 123.1, 120.1, 
118.1, 112.0, 48.1, 27.0, 13.2, 8.3 ppm; HR-ESI-MS: m/z = 465.0117 ([M + H]+, calcd. for 
C19H1879BrN2O5S+: 465.0114), 467.0092 ([M + H]+, calcd. for C19H1881BrN2O5S+: 467.0094). 
 
5-Bromo-1-(cyclopropanecarbonyl)-N-(1H-indol-5-yl)indoline-6-sulfonamide (1w) 
 
Sulfonamide 1w was synthesized according to GP III using SI-2 (35 mg, 96 µmol) and 1H-indol-
5-amine (13 mg, 101 µmol, 1.1 eq.). Purification of the product by flash column chromatography 
(SiO2; cyclohexane/EtOAc 4:1 ® 2:1) afforded 1w (44 mg, 99%) as an off-white amorphous solid.  
1H NMR (700 MHz, DMSO-d6): δ = 11.06 (s, 1H), 9.93 (s, 1H), 8.68–8.58 (m, 1H), 7.62 (s, 1H), 
7.28 (s, 1H), 7.22 (d, J = 8.6 Hz, 1H), 6.94–6.87 (m, 1H), 6.31 (s, 1H), 4.26 (s, 2H), 3.17 (t, J = 
8.3 Hz, 2H), 3.11–3.01 (m, 1H), 1.91–1.83 (m, 1H), 0.90–0.78 ppm (m, 4H); 13C NMR (176 MHz, 
DMSO-d6): δ = 171.8, 142.6, 139.0, 137.1, 133.6, 130.9, 128.0, 127.5, 126.3, 118.3, 117.0, 113.8, 
112.2, 111.6, 101.1, 48.0, 26.9, 13.1, 8.2 ppm; HR-ESI-MS: m/z = 460.0337 ([M + H]+, calcd. for 
C20H1979BrO3N3S+: 460.0325), 462.0315 ([M + H]+, calcd. for C20H1981BrO3N3S+: 462.0305). 
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5-Bromo-1-(cyclopropanecarbonyl)-N-(1H-indol-6-yl)indoline-6-sulfonamide (1x) 
 
Sulfonamide 1x was synthesized according to GP III using SI-2 (35 mg, 96 µmol) and 1H-indol-6-
amine (13 mg, 101 µmol, 1.1 eq.). Purification of the product by flash column chromatography 
(SiO2; cyclohexane/EtOAc 4:1 ® 2:1) afforded 1x (44 mg, 99%) as an off-white amorphous solid.  
1H NMR (600 MHz, DMSO-d6): δ = 11.02 (s, 1H), 10.12 (s, 1H), 8.69 (s, 1H), 7.61 (s, 1H), 7.34 
(d, J = 8.5 Hz, 1H), 7.23 (t, J = 2.8 Hz, 1H), 7.20 (t, J = 0.8 Hz, 1H), 6.82 (dd, J = 8.5, 1.9 Hz, 1H), 
6.29 (t, J = 2.0 Hz, 1H), 4.25 (t, J = 8.2 Hz, 2H), 3.16 (t, J = 8.5 Hz, 2H), 1.89 (m, 1H), 0.92–
0.76 ppm (m, 4H); 13C NMR (151 MHz, DMSO- d6): δ = 171.8, 142.7, 139.1, 137.0, 135.7, 131.0, 
130.4, 125.5, 124.9, 120.2, 118.4, 114.0, 112.1, 104.1, 100.9, 48.1, 26.9, 13.1, 8.2 ppm; HR-ESI-
MS: m/z = 460.0334 ([M + H]+, calcd. for C20H1979BrN3O3S+: 460.0325), 462.0312 ([M + H]+, calcd. 
for C20H1981BrN3O3S+: 462.0305). 
 
1-(Cyclopropanecarbonyl)-N-(3-(trifluoromethyl)phenyl)indoline-5-sulfonamide (7) 
 
Sulfonamide 7 was synthesized according to GP III using SI-3 (50 mg, 137 µmol) and 3-
(trifluoromethyl)aniline (22 µL, 137 µmol, 1.0 eq.). Purification of the product by flash column 
chromatography (SiO2; cyclohexane/EtOAc 4:1 ® 2:1) afforded 7 (53 mg, 74%) as an off-white 
amorphous solid.  
1H NMR (600 MHz, DMSO-d6): δ = 10.62 (s, 1H), 8.07 (d, J = 5.9 Hz, 1H), 7.64–7.57 (m, 2H), 
7.47 (t, J = 7.9 Hz, 1H), 7.40–7.33 (m, 3H), 4.31 (t, J = 7.5 Hz, 2H), 3.19 (t, J = 8.5 Hz, 2H), 1.93 
(dq, J = 12.5, 6.2 Hz, 1H), 0.86 ppm (t, J = 8.5 Hz, 4H); 13C NMR (151 MHz, DMSO-d6): δ = 
172.21, 146.9, 138.9, 133.5, 132.6, 130.6, 129.8 (q, J = 31.8 Hz), 127.1, 123.8 (q, J = 272.4 Hz), 
123.3, 122.8, 120.1, 115.3, 115.2 (q, J = 3.8 Hz); 48.3, 26.8, 13.4, 8.3 ppm; 19F NMR (565 MHz, 
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DMSO-d6): δ = -61.47 ppm; HR-ESI-MS: m/z = 411.0982 ([M + H]+, calcd. for C19H18F3N2O3S+: 
411.0985). 
 
1-Acetyl-5-bromo-N-(4-chloro-3-(trifluoromethyl)phenyl)indoline-6-sulfonamide (9) 
  
Sulfonamide 15k was synthesized according to GP III using SI-4 (750 mg, 2.2 mmol) and 4-chloro-
3-(trifluoromethyl)aniline (455 mg, 2.3 mmol, 1.1 eq.). Purification of the product by flash column 
chromatography (SiO2; cyclohexane/EtOAc 4:1 ® 1:4) afforded 15k (1.046 g, 95%) as an off-
white amorphous solid.  
1H NMR (400 MHz, DMSO-d6): δ = 11.17 (s, 1H), 8.79 (s, 1H), 7.66 (s, 1H), 7.62 (d, J = 8.8 Hz, 
1H), 7.55 (d, J = 2.6 Hz, 1H), 7.34 (dd, J = 8.8, 2.5 Hz, 1H), 4.13 (t, J = 8.6 Hz, 2H), 3.18 (t, J = 
8.6 Hz, 2H), 2.16 ppm (s, 3H); 13C NMR (126 MHz, DMSO-d6): δ = 169.3, 142.8, 139.9, 136.8, 
136.1, 132.7, 131.5, 127.20 (q, J = 30.8 Hz), 124.7, 123.2, 122.32 (q, J = 273.1 Hz), 117.6, 117.4 
(q, J = 5.3 Hz), 112.0, 48.5, 27.1, 23.8 ppm; 19F NMR (377 MHz, DMSO-d6): δ = -61.76 ppm; 
HR-ESI-MS: m/z = 496.9549 ([M + H]+, calcd. for C17H1479BrClF3N2O3S+: 496.9544), 498.9524 
([M + H]+, calcd. for C17H1481BrClF3N2O3S+: 498.9523), 500.9493 ([M + H]+, calcd. for 
C17H1481BrClF3N2O3S+: 500.9494). 
 
1-Acetyl-5-bromo-N-(3-(trifluoromethyl)phenyl)indoline-6-sulfonamide (13k) 
 
Sulfonamide 13k was synthesized according to GP III using SI-4 (70 mg, 206 µmol) and 3-
(trifluoromethyl)aniline (26 µL, 206 µmol, 1.0 eq.). Purification of the product by flash column 
chromatography (SiO2; cyclohexane/EtOAc 4:1 ® 2:1) afforded 13k (83 mg, 83%) as an off-white 
amorphous solid.  
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1H NMR (600 MHz, DMSO-d6): δ = 11.02 (s, 1H), 8.80 (s, 1H), 7.65 (s, 1H), 7.64–7.57 (m, 1H), 
7.47 (dd, J = 10.8, 5.2 Hz, 2H), 7.42 (s, 1H), 7.36 (dd, J = 15.0, 8.3 Hz, 4H), 4.12 (t, J = 8.6 Hz, 
2H), 3.17 (t, J = 8.7 Hz, 2H), 2.16 ppm (s, 3H); 13C NMR (151 MHz, DMSO-d6): δ = 169.4, 142.8, 
139.9, 138.8, 138.1, 136.3, 132.6, 131.4, 130.6, 130.0, 129.7, 127.1, 124.6, 123.3, 122.8, 122.1, 
120.1, 117.8, 114.9, 112.0, 48.5, 27.1, 23.9 ppm; 19F NMR (565 MHz, DMSO-d6): δ = -61.49 ppm; 
HR-ESI-MS: m/z = 462.9936 ([M + H]+, calcd. for C17H1579BrF3N2O3S+: 462.9933), 464.9911 
([M + H]+, calcd. for C17H1581BrF3N2O3S+: 464.9913). 
 
1-Acetyl-5-bromo-N-(3,5-difluorophenyl)indoline-6-sulfonamide (SI-5) 
 
Sulfonamide SI-5 was synthesized according to GP III using SI-4 (500 mg, 1.5 mmol) and 3,5-
difluoroaniline (286 mg, 2.2 mmol, 1.5 eq.). Purification of the product by flash column 
chromatography (SiO2; cyclohexane/EtOAc 4:1 ® 1:4) afforded SI-5 (450 g, 71%) as an off-white 
amorphous solid.  
1H NMR (600 MHz, DMSO-d6) δ 11.20 (s, 1H), 8.80 (s, 1H), 7.66 (s, 1H), 6.86 (tt, J = 9.2, 2.1 Hz, 
1H), 6.73 (dd, J = 7.7, 6.0 Hz, 2H), 4.13 (t, J = 8.6 Hz, 2H), 3.18 (t, J = 8.6 Hz, 2H), 2.16 ppm (s, 
3H); 13C NMR (151 MHz, DMSO-d6): δ = 169.5, 162.6 (dd, J = 244.9, 15.4 Hz), 142.8, 140.1, 
140.0 (t, J = 13.5 Hz), 136.0, 131.6, 117.7, 112.1, 101.6–100.9 (m), 98.7 (t, J = 26.1 Hz), 48.5, 
27.1, 23.9 ppm; 19F NMR (565 MHz, DMSO-d6) δ -108.21 ppm (t, J = 8.9 Hz); HR-ESI-MS: m/z = 
430.9862([M + H]+, calcd. for C16H1479BrF2N2O3S+: 430.9871), 432.9838([M + H]+, calcd. for 
C16H1481BrF2N2O3S+: 432.9851). 
 
General Procedure IV – Saponification of N-Acetylated Indolines 
To a solution of the N-acetylindoline (2 mmol) in MeOH (10 mL) under an argon atmosphere, a 
40% w/v aq. NaOH solution (10 mL) was added. The mixture was heated to reflux for 8 h and the 
organic solvent evaporated. The resulting solution was neutralized with an aq. 1 M HCl solution 
and extracted with EtOAc (5 x 30 mL). The combined organic layers were dried over MgSO4, 
filtered, and concentrated under reduced pressure. The crude product was either used in the next 
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step without further purification of purified by flash column chromatography (SiO2; 
cyclohexane/EtOAc mixture).  
 
5-Bromo-N-(4-chloro-3-(trifluoromethyl)phenyl)indoline-6-sulfonamide (11) 
 
Indoline 11 was prepared according to GP IV using 15k (1.000 g, 2.0 mmol). Purification by flash 
column chromatography (SiO2; EtOAc in cyclohexane 14%) afforded 11 (803 mg, 88%) as an off-
white amorphous solid. 
1H NMR (600 MHz, DMSO-d6) δ 10.97 (br. s, 1H), 7.61 (d, J = 8.8 Hz, 1H), 7.52 (d, J = 2.6 Hz, 
1H), 7.36–7.29 (m, 2H), 7.13 (s, 1H), 6.17 (br. s, 1H), 3.48 (t, J = 8.8 Hz, 2H), 2.96 ppm (t, J = 
8.7 Hz, 2H); 13C NMR (151 MHz, DMSO-d6): δ = 152.5, 137.1, 136.9, 135.9, 132.7, 130.5, 127.14 
(q, J = 30.8 Hz), 124.4, 123.0, 122.41 (q, J = 273.2 Hz), 117.08 (q, J = 5.5 Hz), 109.2, 103.7, 46.5, 
28.6 ppm; 19F NMR (565 MHz, DMSO-d6) δ -61.73 ppm; HR-ESI-MS: m/z = 454.9437([M + H]+, 
calcd. for C15H1279BrClF3N2O2S+: 454.9438), 456.9411 ([M + H]+, calcd. for 
C15H1281BrClF3N2O2S+: 456.9409), 458.9381 ([M + H]+, calcd. for C15H1281Br37ClF3N2O2S+: 
458.9388). 
 
5-Bromo-N-(3-(trifluoromethyl)phenyl)indoline-6-sulfonamide (12) 
 
Indoline 12 was prepared according to GP IV using 13k (200 mg, 432 µmol), and used in the next 
step without further purification. 
1H NMR (400 MHz, CDCl3): δ = 7.37–7.31 (m, J = 1.5 Hz, 5H), 7.30 (s, 1H), 3.64 (t, J = 8.6 Hz, 
2H), 3.05 ppm (t, J = 8.5 Hz, 2H); HR-ESI-MS: m/z = 419.9750([M + H]+, calcd. for 
C15H1279BrF3N2O2S+: 419.9750), 422.9801([M + H]+, calcd. for C15H1281BrF3N2O2S+: 422.9807). 
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5-Bromo-N-(3,5-difluorophenyl)indoline-6-sulfonamide (SI-6) 
 
Indoline SI-6 was prepared according to GP IV using SI-5 (200 mg, 464 µmol). Purification by 
flash column chromatography (SiO2; EtOAc in cyclohexane 14%) afforded SI-6 (177 mg, 98%) as 
an off-white amorphous solid. 
1H NMR (400 MHz, DMSO-d6): δ = 10.97 (br. s, 1H), 7.34 (s, 1H), 7.17 (s, 1H), 6.85 (tt, J = 9.4, 
2.3 Hz, 1H), 6.77–6.66 (m, 2H), 6.16 (br. s, 1H), 3.49 (t, J = 8.7 Hz, 2H), 2.97 ppm (t, J = 8.7 Hz, 
2H); 13C NMR (101 MHz, DMSO-d6): δ = 161.4, 152.5, 136.9, 135.9, 130.5, 109.3, 103.8, 101.1, 
100.9, 98.7, 98.4, 46.5, 28.6 ppm; ESI-MS: m/z = 389.0([M + H]+, calcd. for C14H1279BrF2N2O2S+: 
389.0); 391.0([M + H]+, calcd. for C14H1281BrF2N2O2S+: 391.0). 
 
General Procedure V-A – N-Acylation of Sulfonamido Indolines 
To a solution of the indoline (0.66 µmol), the acid (1.5–3.0 eq.), and DIPEA (2–5 eq.) in EtOAc 
(1 mL) at 0 °C under an argon atmosphere, a solution of T3P in EtOAc (50% v/v, 1.5–3.0 eq.) was 
added. The solution was allowed to warm to rt and stirred for 16 h. The mixture was diluted with 
EtOAc (15 mL) and washed with sat. aq. NaHCO3 (1 x 15 mL), an aq. 1 M HCl solution (1 x 15 mL), 
and brine (2 x 15 mL). The organic layer was dried over MgSO4, filtered, and concentrated under 
reduced pressure. The product was purified by flash column chromatography (SiO2; 
cyclohexane/EtOAc mixture).  
 
General Procedure V-B – N-Acylation of Sulfonamido Indolines 
To a solution of the acid (4.0 eq.) in DMF (1 mL), PyBOP (2.2 eq.), DMAP (2.2 eq.) and DIPEA 
(8.0 eq.) were successively added. After 10 min preactivation, the mixture was added to a solution 
of the indoline (59 µmol) in DMF (1 mL). The mixture was stirred at rt for 16 h. The mixture was 
concentrated to a minimum volume in vacuo, diluted in EtOAc (15 mL), and washed with sat. aq. 
NaHCO3 (1 x 15 mL), an aq. 1 M HCl solution (1 x 15 mL), and brine (2 x 15 mL). The organic 
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layer was dried over MgSO4, concentrated, and the product was purified by flash column 
chromatography or preparative HPLC. 
 
5-Bromo-1-isobutyryl-N-(3-(trifluoromethyl)phenyl)indoline-6-sulfonamide (13c) 
 
Acyl indoline 13c was prepared according to GP V-B using 12 (10 mg, 24 µmol) and isobutyric 
acid (9 µL, 95 µmol, 4.0 eq.). Purification of the product by preparative HPLC afforded 13c (7 mg, 
57%) as an off-white amorphous solid.  
1H NMR (600 MHz, DMSO-d6): δ = 11.01 (s, 1H), 8.90 (s, 1H), 7.65 (s, 1H), 7.48 (t, J = 8.0 Hz, 
1H), 7.42 (s, 1H), 7.36 (t, J = 8.7 Hz, 2H), 4.20 (t, J = 8.5 Hz, 2H), 3.18 (t, J = 8.5 Hz, 2H), 2.85–
2.76 (m, 1H), 1.09 ppm (d, J = 6.7 Hz, 6H); 13C NMR (151 MHz, DMSO-d6): δ = 175.8, 143.1, 
140.0, 138.1, 136.2, 131.3, 130.6, 129.8 (q, J = 31.9 Hz), 123.7 (q, J = 272.4 Hz), 122.2, 120.0 (q, 
J = 3.5 Hz), 118.3, 115.0, 112.1, 47.8, 32.5, 27.2, 18.8 ppm; 19F NMR (565 MHz, DMSO-d6): δ = 
-61.53 ppm; HR-ESI-MS: m/z = 491.0254 ([M + H]+, calcd. for C19H1979BrF3N2O3S+: 491.0246), 
493.0229 ([M + H]+, calcd. for C19H1981BrF3N2O3S+: 493.0226). 
 
5-Bromo-1-(cyclobutanecarbonyl)-N-(3-(trifluoromethyl)phenyl)indoline-6-sulfonamide 
(13d) 
 
Acyl indoline 13d was prepared according to GP V-A using 12 (25 mg, 59 µmol), cyclobutane 
carboxylic acid (9 µL, 89 µmol, 1.5 eq.), DIPEA (21 µL, 119 µmol, 2.0 eq.), and T3P (53 µL, 
89 µmol, 1.5 eq.). Purification by preparative HPLC afforded 13d (14 mg, 44%) as an off-white 
amorphous solid. 
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1H NMR (600 MHz, DMSO-d6): δ = 11.01 (s, 1H), 8.87 (s, 1H), 7.64 (s, 1H), 7.48 (t, J = 8.0 Hz, 
1H), 7.42 (s, 1H), 7.35 (t, J = 9.1 Hz, 2H), 4.02 (t, J = 8.6 Hz, 2H), 3.43 (p, J = 8.4 Hz, 1H), 3.16 
(t, J = 8.5 Hz, 2H), 2.30–2.21 (m, 2H), 2.20–2.12 (m, 2H), 2.00–1.90 (m, 1H), 1.85–1.75 ppm (m, 
1H); 13C NMR (151 MHz, DMSO-d6): δ = 173.0, 143.0, 139.8, 138.1, 136.3, 131.4, 130.6, 129.8 
(q, J = 31.8 Hz), 123.8 (q, J = 272.4 Hz), 122.1, 120.0, 118.0, 115.0 (q, J = 3.8 Hz), 112.0, 47.2, 
38.4, 27.2, 23.9, 17.3 ppm; 19F NMR (565 MHz, DMSO-d6): δ = -61.50 ppm; HR-ESI-MS: m/z = 
503.0249 ([M + H]+, calcd. for C20H1979BrF3N2O3S+: 503.0247), 505.0223 ([M + H]+, calcd. for 
C20H1981BrF3N2O3S+: 505.0226). 
 
5-Bromo-1-(cyclopentanecarbonyl)-N-(3-(trifluoromethyl)phenyl)indoline-6-sulfonamide 
(13f) 
 
Acyl indoline 13f was prepared according to GP V-A using 12 (25 mg, 59 µmol), cyclopentane 
carboxylic acid (19 µL, 178 µmol, 3.0 eq.), DIPEA (52 µL, 297 µmol, 5.0 eq.), and T3P (106 µL, 
178 µmol, 3.0 eq.). Purification by preparative HPLC afforded 13f (14 mg, 45%) as an off-white 
amorphous solid. 
1H NMR (600 MHz, DMSO-d6): δ = 11.00 (s, 1H), 8.88 (s, 1H), 7.64 (s, 1H), 7.47 (t, J = 8.0 Hz, 
1H), 7.41 (d, J = 14.8 Hz, 1H), 7.35 (t, J = 8.3 Hz, 2H), 4.19 (t, J = 8.5 Hz, 2H), 3.18 (t, J = 8.5 Hz, 
2H), 3.00 (p, J = 7.8 Hz, 1H), 1.87 (td, J = 12.0, 7.5 Hz, 2H), 1.79–1.71 (m, 2H), 1.70–1.62 (m, 
2H), 1.61–1.52 ppm (m, 2H); 13C NMR (151 MHz, DMSO-d6): δ = 174.9, 143.1, 140.0, 138.1, 
136.2, 131.3, 130.6, 129.8 (q, J = 31.8 Hz), 123.7 (q, J = 272.4 Hz), 122.2, 120.0 (q, J = 3.7 Hz), 
118.2, 115.0 (q, J = 3.8 Hz), 112.0, 48.0, 43.1, 29.3, 27.1, 25.7 ppm; 19F NMR (565 MHz, DMSO-
d6): δ = -64.66 ppm; HR-ESI-MS: m/z = 517.0404 ([M + H]+, calcd. for C21H2179BrF3N2O3S+: 
517.0403), 519.0383 ([M + H]+, calcd. for C21H2181BrF3N2O3S+: 519.0382). 
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5-Bromo-1-(2-cyclopropylacetyl)-N-(3-(trifluoromethyl)phenyl)indoline-6-sulfonamide (13i) 
 
Acyl indoline 13i was prepared according to GP V-B using 12 (25 mg, 59 µmol) and 2-
cyclopropylacetic acid (44 µL, 474 µmol, 4.0 eq.). After 16 h, only partial conversion was observed, 
hence a further 4.0 eq of 2-cyclopropylacetic acid, 2.2 eq. of PyBOP, 2.2 eq. of DMAP, and 8 eq. 
of DIPEA were added, and the mixture was stirred for a further 24 h. Purification of the product by 
preparative HPLC afforded 13i (13 mg, 42%) as an off-white amorphous solid.  
1H NMR (600 MHz, DMSO-d6): δ = 11.01 (s, 1H), 8.87 (s, 1H), 7.64 (s, 1H), 7.48 (t, J = 8.0 Hz, 
1H), 7.43 (s, 1H), 7.36 (t, J = 8.6 Hz, 2H), 4.08 (t, J = 8.6 Hz, 2H), 3.16 (t, J = 8.5 Hz, 2H), 2.40 
(d, J = 6.7 Hz, 2H), 1.11–0.97 (m, 1H), 0.54–0.44 (m, 2H), 0.21–0.09 ppm (m, 2H); 13C NMR (151 
MHz, DMSO-d6): δ = 171.5, 142.9, 139.8, 138.1, 136.3, 131.4, 130.6, 129.9 (q, J = 31.8 Hz), 123.7 
(q, J = 272.4 Hz), 122.1, 120.0 (q, J = 3.6 Hz), 117.9, 115.0, 111.9, 47.8, 39.9, 27.1, 6.3, 4.2 ppm; 
19F NMR (565 MHz, DMSO-d6): δ = -61.49 ppm; HR-ESI-MS: m/z = 503.0235([M + H]+, calcd. 
for C20H1979BrF3N2O3S+: 503.0246), 505.0211 ([M + H]+, calcd. for C20H1981BrF3N2O3S+: 
505.0226). 
 
5-Bromo-1-propionyl-N-(3-(trifluoromethyl)phenyl)indoline-6-sulfonamide (13l) 
 
To a solution of 12 (25 mg, 59 µmol) and Et3N (43 µL, 237 µmol, 4.0 eq.) in CH2Cl2 (1.5 mL) 
under an argon atmosphere, DMAP (1 mg, 7 µmol, 0.1 eq.) was added. The solution was cooled to 
0 °C and propionic acid anhydride (15 µL, 0.1 mmol, 2.0 eq.) was added. After stirring for 10 min 
at 0 °C and 16 h at rt, EtOAc was added (30 mL), and the mixture was washed with sat. aq. NaHCO3 
(1 x 15 mL), an aq. 1 M HCl solution (1 x 15 mL) and brine (2 x 15 mL). The organic layer was 
dried over MgSO4, filtered, and concentrated under reduced pressure. Purification of the product 
by flash column chromatography (SiO2; cyclohexane/EtOAc 4:1 ® 2:1) afforded 13l (6 mg, 20%) 
as an off-white amorphous solid. 
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1H NMR (400 MHz, CD3OD): δ = 8.96 (s, 1H), 7.57 (s, 1H), 7.46–7.39 (m, 2H), 7.37 (t, J = 7.7 Hz, 
1H), 7.27 (d, J = 7.3 Hz, 1H), 4.14 (t, J = 8.6 Hz, 2H), 3.22 (t, J = 8.6 Hz, 2H), 2.51 (q, J = 7.2 Hz, 
2H), 1.18 ppm (t, J = 7.4 Hz, 3H); HR-ESI-MS: m/z = 477.0093 ([M + H]+, calcd. for 
C18H1779BrF3N2O3S+: 477.0090), 479.0072 ([M + H]+, calcd. for C18H1781BrF3N2O3S+: 479.0069). 
 
1-Benzoyl-5-bromo-N-(4-chloro-3-(trifluoromethyl)phenyl)indoline-6-sulfonamide (15b) 
 
Acyl indoline 15b was prepared according to GP V-A using 11, (30 mg, 66 µmol), benzoic acid 
(12 mg, 99 µmol, 1.5 eq.), DIPEA (23 µL, 132 µmol, 2.0 eq.), and T3P (59 µL, 99 µmol, 1.5 eq.). 
Purification by flash column chromatography (SiO2; EtOAc in cyclohexane 15.0 ® 17.5%) 
afforded 15b (24 mg, 65%) as an off-white amorphous solid. 
1H NMR (600 MHz, DMSO-d6): δ = 11.19 (s, 1H), 7.74 (s, 1H), 7.65 (d, J = 8.8 Hz, 1H), 7.64–
7.45 (m, 7H), 7.44– 7.24 (m, 1H), 4.05 (t, J = 8.4 Hz, 2H), 3.14 ppm (t, J = 8.3 Hz, 2H); 19F NMR 
(565 MHz, DMSO-d6): δ = -61.75 ppm; HR-ESI-MS: m/z = 558.9717 ([M + H]+, calcd. for 
C22H1679BrClF3N2O3S+: 558.9700), 560.9693([M + H]+, calcd. for C22H1681BrClF3N2O3S+: 
560.9680), 562.9657([M + H]+, calcd. for C22H1681Br37ClF3N2O3S+: 562.9650). 
 
5-Bromo-N-(4-chloro-3-(trifluoromethyl)phenyl)-1-isobutyrylindoline-6-sulfonamide (15c) 
 
Acyl indoline 15c was prepared according to GP V-A using 11, (30 mg, 66 µmol), isobutyric acid 
(9 µL, 99 µmol, 1.5 eq.), DIPEA (23 µL, 132 µmol, 2.0 eq.), and T3P (59 µL, 99 µmol, 1.5 eq.). 
Purification by flash column chromatography (SiO2; cyclohexane/EtOAc 4:1 ® 2:1) afforded 15c 
(13 mg, 39%) as an amorphous off-white solid. 
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1H NMR (400 MHz, DMSO-d6): δ = 11.15 (br. s, 1H), 8.88 (br. s, 1H), 7.67 (s, 1H), 7.62 (d, J = 
8.8 Hz, 1H), 7.56 (d, J = 2.6 Hz, 1H), 7.35 (dd, J = 8.8, 2.6 Hz, 1H), 4.21 (t, J = 8.5 Hz, 2H), 3.19 
(t, J = 8.5 Hz, 2H), 2.80 (sep, J = 6.7 Hz, 1H), 1.10 ppm (d, J = 6.7 Hz, 6H); 13C NMR (101 MHz, 
DMSO-d6): δ = 175.8, 143.1, 140.2, 136.9, 136.1, 132.8, 131.4, 127.4, 127.1, 124.8, 123.4, 118.1, 
117.6, 117.6, 112.0, 47.8, 32.5, 27.2, 18.8 ppm; 19F NMR (377 MHz, DMSO-d6) : δ = -61.79 ppm; 
HR-ESI-MS: m/z = 524.98652 ([M + H]+, calcd. for C19H1879BrClF3N2O3S+: 524.98566), 526.9838 
([M + H]+, calcd. for C19H1881BrClF3N2O3S+: 526.9836), 528.9808 ([M + H]+, calcd. for 
C19H1881Br37ClF3N2O3S+: 528.9807). 
 
5-Bromo-N-(4-chloro-3-(trifluoromethyl)phenyl)-1-(cyclobutanecarbonyl)indoline-6-
sulfonamide (15d) 
 
Acyl indoline 15d was prepared according to GP V-A using 11 (30 mg, 66 µmol), cyclobutane 
carboxylic acid (9 µL, 99 µmol, 1.5 eq.), DIPEA (23 µL, 132 µmol, 2.0 eq.), and T3P (59 µL, 
99 µmol, 1.5 eq.). After 16 h, only partial conversion was observed, so a further 1.5 eq. of 
cyclobutane carboxylic acid, 4.0 eq. of DIPEA, and 1.5 eq. of T3P were added, and the mixture was 
stirred for a further 24 h. Purification by preparative HPLC afforded 15d (25 mg, 72%) as an off-
white amorphous solid. 
1H NMR (600 MHz, DMSO-d6): δ = 11.16 (s, 1H), 8.85 (s, 1H), 7.65 (s, 1H), 7.62 (d, J = 8.8 Hz, 
1H), 7.56 (d, J = 2.6 Hz, 1H), 7.36 (dd, J = 8.8, 2.6 Hz, 1H), 4.02 (t, J = 8.6 Hz, 2H), 3.43 (p, J = 
8.3 Hz, 1H), 3.17 (t, J = 8.5 Hz, 2H), 2.25 (qd, J = 9.1, 2.1 Hz, 2H), 2.21–2.12 (m, 2H), 2.03–1.89 
(m, 1H), 1.86–1.75 ppm (m, 1H); 13C NMR (151 MHz, DMSO-d6): δ = 173.1, 143.1, 140.0, 136.9, 
136.1, 132.8, 131.5, 127.9-126.6 (q, J = 30.9 Hz), 124.8, 123.3, 122.4 (q, J = 272.9 Hz), 117.8, 
117.6 (q, J = 5.3 Hz), 112.0, 47.2, 38.4, 27.2, 23.9, 17.3 ppm; 19F NMR (565 MHz, DMSO-d6): 
δ = -61.78 ppm; HR-ESI-MS: m/z = 536.9865 ([M + H]+, calcd. for C20H1879BrClF3N2O3S+: 
536.9857), 538.9841 ([M + H]+, calcd. for C20H1881BrClF3N2O3S+: 538.9836), 540.9807 ([M + H]+, 
calcd. for C20H1881Br37ClF3N2O3S+: 540.9807). 
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5-Bromo-N-(4-chloro-3-(trifluoromethyl)phenyl)-1-(furan-2-carbonyl)indoline-6-
sulfonamide (15e) 
 
Acyl indoline 15e was prepared according to GP V-A using 11, (30 mg, 66 µmol), furan-2-
carboxylic acid (11 mg, 99 µmol, 1.5 eq.), DIPEA (23 µL, 132 µmol, 2.0 eq.), and T3P (59 µL, 
99 µmol, 1.5 eq.). Purification by flash column chromatography (SiO2; EtOAc in cyclohexane 15 
® 30%) afforded 15e (26 mg, 73%) as a brown amorphous solid. 
1H NMR (600 MHz, DMSO- d6): δ = 11.22 (br. s, 1H), 8.89 (s, 1H), 8.00 (dd, J = 1.6, 0.6 Hz, 1H), 
7.74 (s, 1H), 7.62 (d, J = 8.8 Hz, 1H), 7.57 (d, J = 2.6 Hz, 1H), 7.36 (dd, J = 8.8, 2.6 Hz, 1H), 7.33 
(dd, J = 3.6, 0.5 Hz, 1H), 6.74 (dd, J = 3.6, 1.7 Hz, 1H), 4.48 (t, J = 8.5 Hz, 2H), 3.26 (t, J = 8.4 Hz, 
2H); 13C NMR (151 MHz, DMSO- d6): δ = 157.0, 146.8, 146.4, 143.2, 140.4, 136.9, 136.1, 132.8, 
131.6, 127.2 (q, J = 30.8 Hz), 124.7, 123.2, 122.4 (q, J = 273.2 Hz), 118.9, 117.9, 117.5 (q, J = 
5.4 Hz), 112.9, 112.1, 49.5, 27.8 ppm; 19F NMR (565 MHz, DMSO- d6): δ = -61.76 ppm; HR-ESI-
MS: m/z = 548.9508 ([M + H]+, calcd. for C20H14O4N279BrClF3S+: 548.9493), 550.9483 ([M + H]+, 
calcd. for C20H14O4N281BrClF3S+: 550.9472), 552.9454 ([M + H]+, calcd. for 
C20H14O4N281Br37ClF3S+: 552.9443). 
 
5-Bromo-N-(4-chloro-3-(trifluoromethyl)phenyl)-1-(cyclopentanecarbonyl)indoline-6-
sulfonamide (15f) 
 
Acyl indoline 15f was prepared according to GP V-A using 11, (30 mg, 66 µmol), cyclopentane 
carboxylic acid (11 µL, 99 µmol, 1.5 eq.), DIPEA (23 µL, 132 µmol, 2.0 eq.), and T3P (59 µL, 
99 µmol, 1.5 eq.). After 16 h, only partial conversion was observed, hence a further 1.5 eq. of 
cyclopentane carboxylic acid, 2.0 eq. of DIPEA, and 1.5 eq. of T3P were added, and the mixture 
was stirred for a further 24 h. Purification by flash column chromatography (SiO2; 
cyclohexane/EtOAc 4:1 ® 2:1) afforded 15f (18 mg, 50%) as an off-white amorphous solid. 
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1H NMR (400 MHz, DMSO-d6): δ = 11.15 (s, 1H), 8.86 (s, 1H), 7.66 (s, 1H), 7.61 (d, J = 8.8 Hz, 
1H), 7.55 (d, J = 2.6 Hz, 1H), 7.35 (dd, J = 8.8, 2.6 Hz, 1H), 4.20 (t, J = 8.5 Hz, 2H), 3.19 (t, J = 
8.5 Hz, 2H), 3.09–2.94 (m, 1H), 1.95–1.83 (m, 2H), 1.81–1.63 (m, 4H), 1.63–1.51 ppm (m, 2H); 
13C NMR (101 MHz, DMSO-d6): δ = 175.0, 143.2, 140.1, 136.9, 136.1, 132.8, 131.4, 127.2 (q, J = 
31.0 Hz), 124.7, 123.4, 122.4 (q, J = 273.1 Hz), 118.0, 117.6 (q, J = 6.0 Hz), 112.0, 48.0, 43.1, 
29.3, 27.2, 25.7 ppm; 19F NMR (377 MHz, DMSO-d6): δ = -61.79 ppm; HR-ESI-MS: m/z = 
520.9540 ([M + H]+, calcd. for C19H1479BrClF3N2O3S+: 520.9544), 522.9517 ([M + H]+, calcd. for 
C19H1481BrClF3N2O3S+: 522.9514), 524.9487 ([M + H]+, calcd. for C19H1481Br37ClF3N2O3S+: 
524.9494). 
 
5-Bromo-N-(4-chloro-3-(trifluoromethyl)phenyl)-1-(furan-3-carbonyl)indoline-6-
sulfonamide (15g) 
 
Acyl indoline 15g was prepared according to GP V-A using 11, (30 mg, 66 µmol), 1H-pyrrole-2-
carboxylic acid (11 mg, 99 µmol, 1.5 eq.), DIPEA (23 µL, 132 µmol, 2.0 eq.), and T3P (59 µL, 
99 µmol, 1.5 eq.). Purification by flash column chromatography (SiO2; EtOAc in cyclohexane 15 
® 30%) afforded 15g (25 mg, 70%) as a brown amorphous solid. 
1H NMR (600 MHz, DMSO-d6): δ = 11.20 (br. s, 1H), 8.89 (br. s, J = 34.1 Hz, 1H), 8.35 (s, 1H), 
7.83 (t, J = 1.6 Hz, 1H), 7.72 (s, 1H), 7.63 (d, J = 8.8 Hz, 1H), 7.57 (d, J = 2.6 Hz, 1H), 7.37 (dd, 
J = 8.8, 2.6 Hz, 1H), 6.89 (d, J = 1.1 Hz, 1H), 4.34 (t, J = 8.5 Hz, 2H), 3.24 ppm (t, J = 8.4 Hz, 2H); 
13C NMR (151 MHz, DMSO-d6): δ = 161.7, 145.7, 143.8, 143.1, 140.5, 136.9, 136.1, 132.8, 131.6, 
127.3 (q, J = 30.9 Hz), 124.8, 122.4 (q, J = 273.2 Hz), 123.2, 121.9, 118.6, 117.6 (q, J = 5.4 Hz), 
112.7, 110.8, 49.5, 27.6 ppm; 19F NMR (565 MHz, DMSO-d6): δ = -61.76 ppm; HR-ESI-MS: 
m/z = 548.9510 ([M + H]+, calcd. for C20H14O4N279BrClF3S+: 548.9493), 550.9486 ([M + H]+, calcd. 
for C20H14O4N281BrClF3S+: 550.9472), 552.9455 ([M + H]+, calcd. for C20H14O4N281Br37ClF3S+: 
552.9443) 
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5-Bromo-N-(4-chloro-3-(trifluoromethyl)phenyl)-1-(2-cyclopropylacetyl)indoline-6-
sulfonamide (15i) 
 
Acyl indoline 15i was prepared according to GP V-A using 11, (30 mg, 66 µmol), 2-
cyclopropylacetic acid (9 µL, 99 µmol, 1.5 eq.), DIPEA (23 µL, 132 µmol, 2.0 eq.), and T3P (59 µL, 
99 µmol, 1.5 eq.). Purification by flash column chromatography (SiO2; cyclohexane/EtOAc 4:1 ® 
2:1) afforded 15i (22 mg, 63%) as an off-white amorphous solid. 
1H NMR (400 MHz, DMSO-d6): δ = 11.16 (s, 1H), 8.86 (s, 1H), 7.66 (s, 1H), 7.62 (d, J = 8.8 Hz, 
1H), 7.56 (d, J = 2.6 Hz, 1H), 7.35 (dd, J = 8.8, 2.6 Hz, 1H), 4.09 (t, J = 8.6 Hz, 2H), 3.17 (t, J = 
8.5 Hz, 2H), 2.40 (d, J = 6.7 Hz, 2H), 1.12–0.97 (m, 1H), 0.60–0.42 (m, 2H), 0.24–0.07 ppm (m, 
2H); 13C NMR (101 MHz, DMSO-d6): δ = 171.5, 143.0, 139.9, 136.9, 136.1, 132.8, 131.5, 127.2 
(q, J = 31.0 Hz), 124.8, 123.3, 122.4 (q, J = 273.2 Hz), 117.7, 117.6 (q, J = 5.4 Hz), 111.9, 47.8, 
39.9, 27.1, 6.3, 4.1 ppm; 19F NMR (377 MHz, DMSO-d6): δ = -61.76 ppm; HR-ESI-MS: m/z = 
536.98667 ([M + H]+, calcd. for C20H1879BrClF3N2O3S+: 536.9857), 538.9840 ([M + H]+, calcd. for 
C20H1881BrClF3N2O3S+: 538.9836), 540.9810 ([M + H]+, calcd. for C20H1881Br37ClF3N2O3S+: 
540.9807). 
 
5-Bromo-N-(4-chloro-3-(trifluoromethyl)phenyl)-1-(1H-pyrrole-2-carbonyl)indoline-6-
sulfonamide (15j) 
 
Acyl indoline 15j was prepared according to GP V-A using 11, (30 mg, 66 µmol), 1H-pyrrole-2-
carboxylic acid (11 mg, 99 µmol, 1.5 eq.), DIPEA (23 µL, 132 µmol, 2.0 eq.), and T3P (59 µL, 
99 µmol, 1.5 eq.). Purification by flash column chromatography (SiO2; EtOAc in cyclohexane 14 
® 25%) afforded 15j (21 mg, 58%) as a brown amorphous solid. 
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1H NMR (600 MHz, DMSO- d6): δ = 11.76 (br. s, 1H), 11.19 (br. s, 1H), 8.98 (s, 1H), 7.70 (s, 1H), 
7.61 (d, J = 8.8 Hz, 1H), 7.55 (d, J = 2.5 Hz, 1H), 7.35 (dd, J = 8.8, 2.5 Hz, 1H), 7.10–7.04 (m, 
1H), 6.86–6.80 (m, 1H), 6.24 (dt, J = 3.7, 2.4 Hz, 1H), 4.43 (t, J = 8.5 Hz, 2H), 3.27 ppm (t, J = 
8.4 Hz, 2H); 13C NMR (151 MHz, DMSO- d6): δ = 159.8, 143.9, 140.2, 136.9, 136.0, 132.8, 131.4, 
127.2 (q, J = 30.9 Hz), 124.7, 124.6, 123.5, 123.1, 122.4 (q, J = 273.1 Hz), 118.8, 117.3 (q, J = 
5.3 Hz), 113.9, 112.0, 109.7, 49.6, 27.9 ppm; 19F NMR (565 MHz, DMSO- d6): δ = -61.74 ppm; 
HR-ESI-MS: m/z = 547.9674 ([M + H]+, calcd. for C20H15O3N379BrClF3S+: 547.9653), 549.9648 
([M + H]+, calcd. for C20H15O3N381BrClF3S+: 549.96322), 551.9618 ([M + H]+, calcd. for 
C20H15O3N381Br37ClF3S+: 551.9603). 
 
General Procedure VI – Oxidation of Sulfonamidylindolines 
A suspension of the indoline (100 µmol) and MnO2 (10.0 eq.) in CH2Cl2 or toluene (5 mL) was 
heated to reflux and stirred for 4 h. The crude mixture was concentrated and the product purified 
by flash column chromatography (SiO2; CH2Cl2/MeOH mixture). 
 
5-Bromo-N-(4-chloro-3-(trifluoromethyl)phenyl)-1-(cyclopropanecarbonyl)-1H-indole-6-
sulfonamide (16a) 
 
Indole 16a was prepared according to GP VI using 1a (50 mg, 96 µmol) in toluene (5 mL). 
Purification by flash column chromatography (SiO2; pentane/CH2Cl2 2:3 ® 0:1) afforded 16a 
(46 mg, 92%) as an off-white amorphous solid. 
1H NMR (400 MHz, DMSO-d6): δ = 11.18 (s, 1H), 9.18 (s, 1H), 8.53 (d, J = 3.8 Hz, 1H), 8.11 (s, 
1H), 7.56 (t, J = 5.9 Hz, 2H), 7.35 (dd, J = 8.8, 2.6 Hz, 1H), 6.85 (d, J = 3.7 Hz, 1H), 2.81–2.70 (m, 
1H), 1.23–1.07 ppm (m, 4H); 13C NMR (151 MHz, DMSO-d6): δ = 172.8, 136.9, 135.0, 132.7, 
132.6, 132.4, 131.9, 127.3, 127.2 (q, J = 30.9 Hz), 124.7, 123.2, 122.3 (q, J = 273.2 Hz), 119.8, 
117.4 (q, J = 5.5 Hz), 112.2, 107.3, 13.4, 10.4 ppm; 19F NMR (377 MHz, DMSO-d6): 
δ = -61.87 ppm; HR-ESI-MS: m/z = 520.9540 ([M + H]+, calcd. for C19H1479BrClF3N2O3S+: 
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520.9544), 522.9517 ([M + H]+, calcd. for C19H1481BrClF3N2O3S+: 522.9514), 524.9487 ([M + H]+, 
calcd. for C19H1481Br37ClF3N2O3S+: 524.9494). 
 
5-Bromo-1-(cyclopropanecarbonyl)-N-(3-(trifluoromethyl)phenyl)-1H-indole-6-sulfonamide 
(16b) 
 
Indole 16b was prepared according to GP VI using 1b (10 mg, 10 µmol) in toluene (2 mL). 
Purification by flash column chromatography afforded 16b (9 mg, 94%) as an off-white amorphous 
solid. 
1H NMR (600 MHz, DMSO-d6): δ = 11.04 (s, 1H), 9.19 (s, 1H), 8.52 (d, J = 3.8 Hz, 1H), 8.10 (s, 
1H), 7.46–7.40 (m, 2H), 7.36 (d, J = 8.1 Hz, 1H), 7.30 (d, J = 7.7 Hz, 1H), 6.85 (d, J = 3.7 Hz, 1H), 
2.81–2.68 (m, 1H), 1.20–1.08 ppm (m, 4H); 13C NMR (151 MHz, DMSO-d6): δ = 172.8, 138.2, 
134.9, 132.6, 131.8, 130.6, 130.1, 129.8 (q, J = 31.8 Hz), 127.2, 123.7 (q, J = 272.4 Hz), 122.2, 
119.9, 119.9, 114.8 (q, J = 4.0 Hz), 112.3, 107.3, 13.4, 10.4 ppm; 19F NMR (565 MHz, DMSO-d6): 
δ = -61.61 ppm; HR-ESI-MS: m/z = 486.9937 ([M + H]+, calcd. for C19H1579BrF3N2O3S+: 
486.9933), 488.9916 ([M + H]+, calcd. for C19H1581BrF3N2O3S+: 488.9913). 
 
5-Bromo-N-(4-chloro-3-(trifluoromethyl)phenyl)-1H-indole-6-sulfonamide (17) 
 
Indole 17 was prepared according to GP VI using 11 (50 mg, 110 µmol) in CH2Cl2 (5 mL). 
Purification by flash column chromatography (SiO2; EtOAc in cyclohexane 15%) afforded 17 
(27 mg, 54%) as an off-white amorphous solid. 
1H NMR (600 MHz, DMSO): δ = 11.80 (s, 1H), 11.01 (s, 1H), 8.28 (s, 1H), 7.97 (s, 1H), 7.71 (t, 
J = 2.8 Hz, 1H), 7.58–7.53 (m, 2H), 7.35 (dd, J = 8.8, 2.6 Hz, 1H), 6.56–6.50 ppm (m, 1H); 
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13C NMR (151 MHz, DMSO): δ = 137.2, 133.2, 132.7, 132.2, 131.6, 128.2, 127.1 (q, J = 30.7 Hz), 
126.2, 124.3, 122.9, 122.4 (q, J = 273.1 Hz), 116.8 (q, J = 5.6 Hz), 116.4, 107.0, 101.4 ppm; 
19F NMR (565 MHz, DMSO): δ = -61.79 ppm; HR-ESI-MS: m/z = 452.9277 ([M + H]+, calcd. for 
C15H1079BrClF3N2O2S+: 452.92815), 454.9256 ([M + H]+, calcd. for C15H1081BrClF3N2O2S+: 
454.9252), 456.9230 ([M + H]+, calcd. for C15H1081Br37ClF3N2O2S+: 456.9232). 
 
5-Bromo-N-(3,5-difluorophenyl)-1H-indole-6-sulfonamide (95) 
 
Indole 95 was prepared according to GP VI using SI-6 (174 mg, 447 µmol) in CH2Cl2 (20 mL). 
Purification by flash column chromatography (SiO2; EtOAc in cyclohexane 15%) afforded 95 
(148 mg, 85%) as an off-white amorphous solid. 
1H NMR (600 MHz, DMSO-d6): δ = 11.76 (br. s, 1H), 11.02 (br. s, 1H), 8.31 (s, 1H), 7.98 (s, 1H), 
7.72 (t, J = 2.8 Hz, 1H), 6.79 (tt, J = 9.3, 2.2 Hz, 1H), 6.77–6.72 (m, 2H), 6.53 ppm (t, J = 2.0 Hz, 
1H); 13C NMR (151 MHz, DMSO-d6): δ = 162.6 (dd, J = 244.5, 15.4 Hz), 140.4 (t, J = 13.5 Hz), 
133.2, 132.2, 131.6, 128.3, 126.2, 116.4, 107.1, 101.4, 101.2–100.6 (m), 98.3 ppm (t, J = 26.1 Hz); 
19F NMR (565 MHz, DMSO d6): δ = -108.51 ppm (t, J = 8.9 Hz); HR-ESI-MS: m/z = 
386.9612([M + H]+, calcd. for C14H1079BrF2N2O2S+: 386.9609), 388.9590([M + H]+, calcd. for 
C14H1081BrF2N2O2S+: 388.9589). 
 
General Procedure VII – Dehalogenation of Bromoindolines 
To a solution of the bromoindoline (61 µmol) in DMF (1 mL), Et3N (1.2 eq.) and Pd/C (10% w/w 
loading, 2 mol%) were added, and the resulting suspension was stirred under a H2 atmosphere for 
16 h. The mixture was filtered through a pad of Celite® and concentrated under reduced pressure. 
The product was purified by flash column chromatography. 
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N-(4-Chloro-3-(trifluoromethyl)phenyl)-1-(cyclopropanecarbonyl)indoline-6-sulfonamide 
(18a) 
 
Indoline 18a was prepared according to GP VII using 1a (30 mg, 57 µmol). Purification by flash 
column chromatography (SiO2; cyclohexane/EtOAc 4:1 → 2:1) afforded 18a (25 mg, 96%) as an 
off-white amorphous solid.  
1H NMR (600 MHz, DMSO-d6): δ = 10.85 (s, 1H), 8.49 (s, 1H), 7.59 (dd, J = 10.3, 7.0 Hz, 1H), 
7.51 (d, J = 2.6 Hz, 1H), 7.42–7.31 (m, 3H), 4.31 (t, J = 8.3 Hz, 2H), 3.21 (t, J = 8.5 Hz, 2H), 2.00–
1.86 (m, 1H), 0.97–0.79 ppm (m, 4H); 13C NMR (151 MHz, DMSO-d6): δ = 172.0, 143.0, 138.2, 
137.5 (q, J = 3.7 Hz), 132.7, 127.2 (q, J = 30.9 Hz), 125.4, 124.9, 123.97, 122.8, 122.4 (q, J = 
273.2 Hz), 121.8, 117.8 (q, J = 5.3 Hz), 113.5, 48.0, 27.3, 13.2, 8.2 ppm; 19F NMR (565 MHz, 
DMSO-d6): δ = -61.78 ppm; HR-ESI-MS: m/z = 445.0603 ([M + H]+, calcd. for C19H17ClF3N2O3S+: 
445.0595), 447.0571 ([M + H]+, calcd. for C19H1737ClF3N2O3S+: 447.0566). 
 
1-(Cyclopropanecarbonyl)-N-(3-(trifluoromethyl)phenyl)indoline-6-sulfonamide (18b) 
 
Indoline 18b was prepared according to GP VII using 1b (30 mg, 61 µmol). Purification by flash 
column chromatography (SiO2; cyclohexane/EtOAc 4:1 → 2:1) afforded 18b (24 mg, 95%) as an 
off-white amorphous solid.  
1H NMR (600 MHz, DMSO-d6): δ = 10.73 (s, 1H), 8.51 (s, 1H), 7.47 (t, J = 7.9 Hz, 1H), 7.42–
7.31 (m, 5H), 4.30 (t, J = 8.2 Hz, 2H), 3.27–3.10 (m, 2H), 1.97–1.82 (m, 1H), 0.95–0.78 ppm (m, 
4H); 13C NMR (151 MHz, DMSO-d6): δ = 171.9, 143.8, 138.8, 138.0, 137.8, 130.6, 129.8 (q, J = 
31.8 Hz), 125.3, 123.8 (q, J = 272.4 Hz), 122.8, 121.9, 120.1 (q, J = 3.3 Hz) 115.2, 113.6, 48.0, 
27.3, 13.2, 8.2 ppm; 19F NMR (565 MHz, DMSO-d6): δ = -61.49 ppm; HR-ESI-MS: m/z = 
411.0992 ([M + H]+, calcd. for C19H18F3N2O3S+: 411.0985). 
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Preparation of Further Analogs of Indoline 1a 
5-Bromo-N-(4-chloro-3-(trifluoromethyl)phenyl)-1-pivaloylindoline-6-sulfonamide (15h) 
 
To a solution of 11, (30 mg, 66 µmol), DMAP (1 mg, 8 µmol, 0.1 eq.), and Et3N (35 µL, 198 µmol, 
3.0 eq.) in pyridine (1 mL) under an argon atmosphere at 0 °C, pivalic acid chloride (9 µL, 72 µmol, 
1.1 eq.) was added. The solution was heated to 60 °C. Only partial conversion was observed after 
16 h, hence a further 10.0 eq. of pivalic acid chloride were added, and the solution was stirred for a 
further 8 h at 60 °C and for 16 h at 100 °C. The mixture was concentrated under reduced pressure, 
diluted with EtOAc (20 mL), and washed with an aq. 1 M HCl solution (1 x 20 mL). The aq. phase 
was extracted with EtOAc (2 x 20 mL). The combined organic layers were dried over MgSO4, 
filtered, and concentrated under reduced pressure. Purification by flash column chromatography 
(EtOAc in cyclohexane 10% → 20%) afforded 15h (23 mg, 65%) as an off-white amorphous solid. 
1H NMR (600 MHz, DMSO-d6): δ = 11.13 (br. s, 1H), 8.89 (s, 1H), 7.67 (s, 1H), 7.62 (d, J = 
8.8 Hz, 1H), 7.56 (d, J = 2.6 Hz, 1H), 7.36 (dd, J = 8.8, 2.6 Hz, 1H), 4.29 (t, J = 8.4 Hz, 2H), 3.18 
(t, J = 8.2 Hz, 2H), 1.28 ppm (s, 9H); 13C NMR (151 MHz, DMSO-d6): δ = 176.5, 144.6, 139.6, 
136.9, 135.9, 132.8, 131.1, 127.2 (q, J = 30.9 Hz), 124.8, 123.4, 122.4 (q, J = 273.1 Hz), 119.5, 
117.7 (q, J = 5.4 Hz), 112.2, 49.5, 40.0, 28.4, 27.2 ppm; 19F NMR (565 MHz, DMSO-d6): 
δ = -61.80 ppm; HR-ESI-MS: m/z = 539.0020([M + H]+, calcd. for C20H20O3N279BrClF3S+: 
539.0013), 540.9996([M + H]+, calcd. for C20H20O3N281BrClF3S+: 540.9993), 
542.9967([M + H]+, calcd. for C20H20O3N281Br37ClF3S+: 542.9963). 
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5-Bromo-N-(4-chloro-3-(trifluoromethyl)phenyl)-1-(oxetan-3-yl)indoline-6-sulfonamide (19) 
and 5-Bromo-N-(4-chloro-3-(trifluoromethyl)phenyl)-1-ethylindoline-6-sulfonamide (20) 
 
To a solution of 11 (50 mg, 110 µmol) in CH2Cl2 (2 mL) under an argon atmosphere, 3-oxetanone 
(40 mg, 549 µmol, 5.0 eq.) was added, and the solution was stirred at reflux for 10 min. 
NaB(OAc)3H (75 mg, 351 µmol, 3.2 eq.) was added, and the mixture was stirred for a further 
90 min. The mixture was cooled to rt and quenched by adding H2O (2 mL), followed by sat. aq. 
NaHCO3 (2 mL). The aqueous phase was extracted with CH2Cl2, (3 x 20 mL) and the combined 
organic layers were dried over MgSO4, filtered, and concentrated under reduced pressure. 
Purification by flash column chromatography (SiO2; cyclohexane/EtOAc 9:1 ® 4:1) afforded 19 
(47 mg, 84%) and 20 (6 mg, 12%) as colorless oils.  
19: 
1H NMR (500 MHz, DMSO-d6): δ = 11.05 (s, 1H), 7.60 (d, J = 8.8 Hz, 1H), 7.51 (d, J = 2.4 Hz, 
1H), 7.40 (s, 1H), 7.35 (dd, J = 8.8, 2.4 Hz, 1H), 7.00 (s, 1H), 4.81–4.64 (m, 5H), 3.63 (t, J = 8.5 Hz, 
2H), 2.99 ppm (t, J = 8.4 Hz, 2H); 13C NMR (126 MHz, DMSO-d6): δ = 150.3, 138.3, 137.0, 136.0, 
132.7, 130.8, 127.1 (d, J = 30.8 Hz), 124.4, 123.1, 122.4 (q, J = 273.2 Hz), 116.7 (q, J = 5.5 Hz), 
108.2, 105.9, 73.6, 50.8, 48.6, 27.2 ppm; HR-ESI-MS: m/z = 510.9697([M + H]+, calcd. for 
C18H16O3N279BrClF3S+: 510.97001), 512.9673([M + H]+, calcd. for C18H16O3N281BrClF3S+: 
512.9671), 514.9643([M + H]+, calcd. for C18H16O3N281Br37ClF3S+: 514.9650). 
20: 
1H NMR (500 MHz, DMSO-d6): δ = 11.01 (s, 1H), 7.60 (d, J = 8.8 Hz, 1H), 7.53 (d, J = 2.7 Hz, 
1H), 7.36 (dd, J = 8.8, 2.7 Hz, 1H), 7.33 (t, J = 1.1 Hz, 1H), 7.01 (s, 1H), 3.42 (t, J = 8.6 Hz, 2H), 
3.15 (q, J = 7.1 Hz, 2H), 2.94 (t, J = 8.3 Hz, 2H), 1.04 ppm (t, J = 7.2 Hz, 3H); HR-ESI-MS: m/z = 
482.9747([M + H]+, calcd. for C17H16O2N279BrClF3S+: 482.9751), 484.9723([M + H]+, calcd. for 
C17H16O2N281BrClF3S+: 484.9722), 486.9694 ([M + H]+, calcd. for C17H16O2N281Br37ClF3S+: 
486.9701). 
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6.5. Synthesis of Pull-Down Probes 
i. Linker Synthesis 
tert-Butyl (3-(2-(2-(3-aminopropoxy)ethoxy)ethoxy)propyl)carbamate (91)[168] 
 
To a vigorously stirred solution of 3,3'-((oxybis(ethane-2,1-diyl))bis(oxy))bis(propan-1-amine) 
(9.837 mL, 44 mmol, 1.9 eq.) in CH2Cl2 (200 mL) at rt, a solution of Boc2O (5.000 g, 23 mmol) in 
CH2Cl2 (100 mL) was added using a dropping funnel over a period of 1 h. The solution was stirred 
at rt for 16 h and washed with an aq. 0.1 M HCl solution (2 x 100 mL). The aqueous layer was 
extracted with CH2Cl2 (5 x 50 mL). The combined organic layers were dried over Na2SO4, 
concentrated under reduced pressure and dried in vacuo. The crude, containing the desired product 
in 62% purity with bis-Boc-protected diamino-PEG as side product, was used without further 
purification (5 g). 
 
tert-Butyl (1-bromo-2-oxo-7,10,13-trioxa-3-azahexadecan-16-yl)carbamate (52) 
 
To a solution of bromoacetylbromide (668 µL, 3.9 mmol, 1.0 eq.) in THF (50 mL) at 0 °C, a solution 
of Boc-NH-PEG3-NH2 (91 [62% purity], 2.000 g, 3.9 mmol) and DIPEA (687 µL, 3.9 mmol, 
1.0 eq.) in THF (20 mL) was added over 1 h. The solution was stirred for 1 h at rt and diluted with 
EtOAc (50 mL). The organic layer was washed with a NH4Cl solution (50 mL sat. aq. NH4Cl2 + 
50 mL water, 1 x), a NaHCO3 solution (50 mL sat. aq. NaHCO3 + 50 mL water, 1 x), and brine (2 
x 50 mL). The organic layer was dried over MgSO4, and concentrated under reduced pressure. 
Purification by flash chromatography (SiO2; EtOAc/cyclohexane 1:1 ® 1:0) afforded 52 (1.471 g, 
86%) as a colorless oil. 
1H NMR (400 MHz, CDCl3): δ = 7.17 (br. s, 1H), 4.91 (br. s, 1H), 3.82 (s, 2H), 3.67–3.53 (m, 
10H), 3.51 (t, J = 6.0 Hz, 2H), 3.39 (dd, J = 12.1, 5.8 Hz, 2H), 3.24–3.13 (m, J = 4.8 Hz, 2H), 1.79 
(dt, J = 11.7, 5.9 Hz, 2H), 1.76–1.67 (m, 2H), 1.41 ppm (s, 9H); HR-ESI-MS: m/z = 441.1604 
([M + H]+, calcd. for C17H3479BrN2O6+: 441.1600), 443.1579 ([M + H]+, calcd. for C17H3481BrN2O6+: 
443.1580). 
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ii. Synthesis of 1st Generation Active Probe for Pull-Down 
(E)-5-(3-((tert-Butyldimethylsilyl)oxy)prop-1-en-1-yl)-N-(4-chloro-3-
(trifluoromethyl)phenyl)-1-(cyclopropanecarbonyl)indoline-6-sulfonamide (51) 
 
To a solution of 1a (70 mg, 134 µmol) in DMF (1 mL) under an argon atmosphere, (E)-3-(tert-
butyldimethylsilyloxy)propene-1-yl-boronic acid pinacol ester (50, 88 µL, 267 µmol, 2.0 eq.), 
Na2CO3 (43 mg, 401 µmol, 3.0 eq.) and water (100 µL) were added. The mixture was bubbled with 
argon for 10 min, Pd(PPh3)4 (6 mg, 5 µmol, 4 mol%) was added, and the mixture was heated to 
105 °C for 20 h. The mixture was concentrated in vacuo, and the crude product was diluted in 
EtOAc (20 mL) and washed with brine (1 x 20 mL). The aq. phase was extracted with EtOAc (3 x 
20 mL), and the combined organic layers were dried over MgSO4, filtered, and concentrated under 
reduced pressure. Purification by flash column chromatography (SiO2; CH2Cl2/pentane 9:1 ® 
cyclohexane/EtOAc 4:1) afforded 51 (55 mg, 66%) as an off-white amorphous solid. 
1H NMR (400 MHz, CDCl3): δ = 8.72 (br. s, 1H), 7.42 (d, , J = 15.7 Hz, 1H), 7.39–7.31 (m, 1H), 
7.29 (d, J = 8.5 Hz, 2H), 7.22 (s, 1H), 7.09 (s, 1H), 6.08 (dt, J = 15.4, 4.8 Hz, 1H), 4.37 (dd, J = 
4.8, 1.7 Hz, 2H), 4.29 (t, J = 8.3 Hz, 2H), 3.22 (t, J = 8.2 Hz, 2H), 1.77–1.69 (m, 1H), 1.25 (d, J = 
4.7 Hz, 2H), 1.17–1.09 (m, 2H), 0.97–0.95 (m, 9H), 0.17–0.12 ppm (m, 6H); HR-ESI-MS: m/z = 
615.1736 ([M + H]+, calcd. for C28H35ClF3N2O4SSi+: 615.1722), 617.1712 ([M + H]+, calcd. for 
C28H3537ClF3N2O4SSi+: 617.1692). 
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(E)-N-(4-Chloro-3-(trifluoromethyl)phenyl)-1-(cyclopropanecarbonyl)-5-(3-hydroxyprop-1-
en-1-yl)indoline-6-sulfonamide (34) 
 
To a solution of 51 (40 mg, 65 µmol) in THF (1.5 mL) under an argon atmosphere, a solution of 
TBAF in THF (1 M, 195 µL, 3.0 eq.) was added and the mixture was stirred for 5 h at rt. The 
solution was concentrated under reduced pressure and re-dissolved in EtOAc (25 mL). The organic 
layer was washed with an aq. 1 M HCl solution (1 x 25 mL) and brine (1 x 10 mL), dried over 
MgSO4, filtered, and concentrated under reduced pressure. Purification by flash column 
chromatography (SiO2; cyclohexane/EtOAc (1% AcOH) 2:1 ® 2:3) afforded 34 (24 mg, 73%) as 
a thick colorless oil. 
1H NMR (400 MHz, CD3OD): δ = 8.73 (br. s, 1H), 7.48 (s, 1H), 7.41–7.38 (m, 1H), 7.36 (s, 2H), 
7.26 (dd, J = 8.8, 2.3 Hz, 1H), 6.21 (dt, J = 15.9, 5.0 Hz, 1H), 4.35 (t, J = 8.6 Hz, 2H), 4.28 (d, J = 
5.2 Hz, 2H), 3.26 (t, J = 8.1 Hz, 2H), 1.96–1.89 (m, 1H), 1.10–1.00 (m, 2H), 1.00–0.92 ppm (m, 
2H); HR-ESI-MS: m/z = 501.0862 ([M + H]+, calcd. for C22H21ClF3N2O4S+: 501.0863), 503.0832 
([M + H]+, calcd. for C22H2137ClF3N2O4S+: 503.0833). 
 
N-(4-Chloro-3-(trifluoromethyl)phenyl)-1-(cyclopropanecarbonyl)-5-(3-
hydroxypropyl)indoline-6-sulfonamide (35) 
 
A suspension of TBDMS-alkenyl indoline 51 (15 mg, 24 µmol) and Pd/C (1 mg, 1.2 µmol, 10% 
loading, 5 mol%) in MeOH (1 mL) under a H2 atmosphere (balloon) was stirred for 24 h. The 
mixture was filtered through a pad of Celite®, concentrated under reduced pressure, and the product 
purified by flash column chromatography to afford 35 (5 mg, 44%) as a thick colorless oil. 
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1H NMR (400 MHz, CD3OD): δ = 8.79–8.62 (m, 1H), 7.48–7.44 (m, 1H), 7.44–7.39 (m, 1H), 7.34–
7.29 (m, 1H), 7.30–7.25 (m, 1H), 4.35 (t, J = 8.1 Hz, 2H), 3.63 (t, J = 6.1 Hz, 2H), 3.25 (t, J = 
8.3 Hz, 2H), 3.08–2.97 (m, 2H), 1.98–1.88 (m, 1H), 1.88–1.78 (m, 2H), 1.08–0.99 (m, 2H), 0.99–
0.89 ppm (m, 2H); HR-ESI-MS: m/z = 503.1020 ([M + H]+, calcd. for C22H23ClF3N2O4S+: 
503.1019), 505.0990 ([M + H]+, calcd. for C22H2337ClF3N2O4S+: 505.0990). 
 
tert-Butyl (E)-(20-(6-(N-(4-Chloro-3-(trifluoromethyl)phenyl)sulfamoyl)-1-
(cyclopropanecarbonyl)indolin-5-yl)-15-oxo-4,7,10,17-tetraoxa-14-azaicos-19-en-1-
yl)carbamate (53) 
 
A mixture of the alcohol 34 (10 mg, 19 µmol), linker 52 (13 mg, 29 µmol, 1.5 eq.), and K2CO3 
(4 mg, 29 µmol, 1.5 eq.) in acetone (2 mL) under an argon atmosphere was heated to reflux for 8 h. 
The solvent was evaporated under reduced pressure and the product purified by flash column 
chromatography (SiO2; CH2Cl2/MeOH 99:1 ® 97.5:2.5 ® 95:5) to afford 53 (11 mg, 65%) as a 
thick colorless oil. 
1H NMR (400 MHz, CD3OD): δ = 8.52 (br. s, 1H), 7.64–7.59 (m, 1H), 7.55 (s, 1H), 7.54–7.47 (m, 
2H), 7.07 (d, J = 15.7 Hz, 1H), 6.14 (dt, J = 11.0, 5.7 Hz, 1H), 4.39 (t, J = 9.0 Hz, 2H), 4.31 (s, 2H), 
4.07 (d, J = 4.6 Hz, 2H), 3.66–3.45 (m, 12H), 3.39 (s, 2H), 3.22 (s, 2H), 3.12 (dd, J = 12.0, 6.5 Hz, 
2H), 2.00–1.91 (m, 1H), 1.71 (s, 2H), 1.69–1.57 (m, 2H), 1.42 (s, 9H), 1.05–0.99 (m, 2H), 0.99–
0.93 ppm (m, 2H); HR-ESI-MS: m/z = 861.3147 ([M + H]+, calcd. for C39H53O10N4ClF3S+: 
861.3118), 863.3131 ([M + H]+, calcd. for C39H53O10N437ClF3S+: 863.3088). 
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(E)-N-(3-(2-(2-(3-Aminopropoxy)ethoxy)ethoxy)propyl)-2-((3-(6-(N-(4-chloro-3-
(trifluoromethyl)phenyl)sulfamoyl)-1-(cyclopropanecarbonyl)indolin-5-
yl)allyl)oxy)acetamide (54) 
 
Boc-protected positive probe 53 (20 mg, 23 µmol) was dissolved in dioxane (200 µL) and a drop 
of conc. HCl was added. The mixture was stirred for 3 h at rt and freeze-dried in vacuo. Purification 
by preparative HPLC (in the absence of TFA) afforded 54 (10 mg, 57%) as a thick colorless oil. 
1H NMR (400 MHz, CD3OD) δ 8.52 (br. s, 1H), 7.61 (d, J = 1.7 Hz, 1H), 7.58–7.43 (m, 3H), 7.07 
(d, J = 15.5 Hz, 1H), 6.15 (dt, J = 15.7, 5.2 Hz, 1H), 4.39 (t, J = 8.0 Hz, 2H), 4.34 (s, 2H), 4.09 (d, 
J = 4.8 Hz, 2H), 3.67 (t, J = 5.5 Hz, 2H), 3.66–3.61 (m, 6H), 3.57–3.52 (m, 2H), 3.42 (s, 2H), 3.32–
3.30 (m, 2H), 3.25 (s, 2H), 3.11 (s, 2H), 1.92 (s, 3H), 1.74–1.62 (m, 2H), 1.09–0.77 ppm (m, 4H); 
ESI-MS: m/z = 761.2 ([M + H]+, calcd. for C34H45O8N4ClF3S+: 761.2). 
 
iii. Synthesis of 1st Generation Control Probe for Pull-Down 
(E)-5-(3-((tert-Butyldimethylsilyl)oxy)prop-1-en-1-yl)-1-(cyclopropanecarbonyl)-N-(3,5-
difluorophenyl)indoline-6-sulfonamide (SI-7) 
 
Silyl ester SI-7 was prepared following the procedure employed in the synthesis of 51, using 1r 
(65 mg, 142 µmol), 50 (93 µL, 284 µmol, 2.0 eq.), Na2CO3 (45, 426 µmol, 3.0 eq.), and Pd(PPh3)4 
(13 mg, 11 µmol, 8 mol%). Purification by flash column chromatography (SiO2; EtOAc in 
cyclohexane 20 ® 25 ® 30%) afforded SI-7 (25 mg, 33%) as thick colorless oil. 
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1H NMR (400 MHz, CDCl3): δ = 8.73 (br. s, 1H), 7.40 (d, J = 15.9 Hz, 1H), 7.10 (s, 1H), 6.68–
6.56 (m, 2H), 6.43 (tt, J = 8.8, 2.0 Hz, 1H), 6.11 (dt, J = 15.7, 5.1 Hz, 1H), 4.37 (dd, J = 5.0, 1.7 Hz, 
2H), 4.34–4.21 (m, 2H), 3.31–3.10 (m, 2H), 1.84–1.59 (m, 1H), 1.19–1.07 (m, 2H), 0.96 (s, 9H), 
0.95–0.88 (m, 2H), 0.15 ppm (s, 6H); ESI-MS: m/z = 571.0 ([M + Na]+, calcd. for 
C27H34F2N2NaO4SSi+: 571.2). 
 
(E)-1-(Cyclopropanecarbonyl)-N-(3,5-difluorophenyl)-5-(3-hydroxyprop-1-en-1-yl)indoline-
6-sulfonamide (SI-8) 
 
Alcohol SI-8was prepared following the procedure employed in the synthesis of 34, using SI-7 
(24 mg, 44 µmol). Purification by flash column chromatography (SiO2; cyclohexane/EtOAc (1% 
AcOH) 2:1 ® 1:1) afforded SI-8 (17 mg, 89%) as a thick colorless oil. 
1H NMR (400 MHz, CD3OD): δ = 8.76 (br. s, 1H), 7.49 (s, 1H), 7.38 (d, J = 15.7 Hz, 1H), 6.67–
6.55 (m, 2H), 6.50 (tt, J = 9.1, 2.2 Hz, 1H), 6.23 (dt, J = 16.0, 5.2 Hz, 1H), 4.36 (s, 2H), 4.30 (dd, 
J = 5.1, 1.8 Hz, 2H), 3.26 (t, J = 8.5 Hz, 2H), 1.97–1.89 (m, 1H), 1.08–1.01 (m, 2H), 0.96 ppm (d, 
J = 7.9 Hz, 2H); HR-ESI-MS: m/z = 435.1182([M + H]+, calcd. for C21H21F2N2O4S+: 435.1185). 
 
tert-Butyl (E)-(20-(1-(Cyclopropanecarbonyl)-6-(N-(3,5-difluorophenyl)sulfamoyl)indolin-5-
yl)-15-oxo-4,7,10,17-tetraoxa-14-azaicos-19-en-1-yl)carbamate (SI-9)  
 
The Boc-protected negative probe SI-9 was prepared following the procedure employed in the 
synthesis of 53, using SI-8 (13 mg, 29 µmol). Purification by flash column chromatography (SiO2; 
CH2Cl2/MeOH 99:1 ® 97.5:2.5 ® 95:5) afforded SI-9 (11 mg, 47%) as a thick colorless oil. 
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1H NMR (400 MHz, CD3OD): δ = 8.57 (s, 1H), 7.55 (s, 1H), 7.09 (d, J = 15.7 Hz, 1H), 7.00–6.91 
(m, 2H), 6.86 (tt, J = 9.1, 2.4 Hz, 1H), 6.18 (dt, J = 15.5, 5.4 Hz, 1H), 4.39 (t, J = 8.0 Hz, 2H), 4.32 
(s, 2H), 4.12 (dd, J = 5.3, 1.4 Hz, 2H), 3.63 (dd, J = 5.1, 3.7 Hz, 4H), 3.60–3.53 (m, 4H), 3.50 (t, 
J = 6.2 Hz, 2H), 3.41 (t, J = 6.1 Hz, 2H), 3.30–3.27 (m, 2H), 3.27–3.18 (m, 2H), 3.11 (t, J = 6.8 Hz, 
2H), 1.93 (d, J = 4.5 Hz, 1H), 1.69 (dp, J = 19.2, 6.4 Hz, 4H), 1.43 (s, 9H), 1.06–0.92 ppm (m, 4H); 
HR-ESI-MS: m/z = 795.3450([M + H]+, calcd. for C38H53F2N4O10S+: 795.3445). 
 
(E)-N-(3-(2-(2-(3-Aminopropoxy)ethoxy)ethoxy)propyl)-2-((3-(1-(cyclopropanecarbonyl)-6-
(N-(3,5-difluorophenyl)sulfamoyl)indolin-5-yl)allyl)oxy)acetamide (57) 
 
Negative probe 57 was prepared following the procedure employed in the synthesis of 54, using 
SI-9 (22 mg, 27 µmol) and 2 drops of conc. HCl in dioxane (400 µL). Purification by preparative 
HPLC (in the absence of TFA) afforded 57 (11 mg, 59%) as a thick colorless oil. 
1H NMR (500 MHz, CDCl3): δ = 8.59 (d, J = 5.5 Hz, 1H), 7.56 (s, 1H), 7.08 (s, 1H), 6.93 (d, J = 
5.7 Hz, 2H), 6.90–6.81 (m, 1H), 6.27–6.13 (m, 1H), 4.40 (s, 2H), 4.37 (s, 2H), 4.13 (dd, J = 28.0, 
5.8 Hz, 2H), 3.68 (t, J = 5.4 Hz, 2H), 3.64 (s, 6H), 3.56 (d, J = 2.4 Hz, 2H), 3.43 (t, J = 5.9 Hz, 2H), 
3.26 (d, J = 6.8 Hz, 4H), 3.12 (t, J = 6.2 Hz, 2H), 1.98–1.88 (m, 3H), 1.74–1.65 (m, 2H), 1.00 ppm 
(m, 4H); HR-ESI-MS: m/z = 695.2936 ([M + H]+, calcd. for C33H45F2N4O8S+: 695.2921). 
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iv. Synthesis of 2nd Generation Active Probe for Pull-Down 
Ethyl 2-(5-Bromo-6-(N-(4-chloro-3-(trifluoromethyl)phenyl)sulfamoyl)-1H-indol-3-yl)-2-
oxoacetate (75) 
 
To a solution of 17 (100 mg, 220 µmol) in CH2Cl2 (1 mL) at 0 °C under an argon atmosphere, ethyl 
chlorooxoacetate (238 µL, 2.2 mmol, 10.0 eq.) and AlCl3 (88 mg, 661 µmol, 3.0 eq.) were 
successively added. The resulting yellow suspension was stirred for 14 h at rt, and the excess of 
reagents were quenched with water (10 mL). The mixture was extracted with EtOAc (3 x 15 mL), 
and the combined organic layers were washed with brine (1 x 20 mL), dried over Na2SO4, and 
concentrated under reduced pressure. Purification by flash column chromatography (SiO2; 
cyclohexane/EtOAc 4:1 ® 2:3) afforded 75 (126 mg, 93%, 90% pure according to NMR) as an off-
white amorphous solid. 
1H NMR (400 MHz, DMSO-d6): δ = 12.94–12.70 (m, 1H), 11.34–11.07 (m, 1H), 8.73 (s, 1H), 8.46 
(s, 1H), 8.39 (s, 1H), 7.62–7.49 (m, 2H), 7.40–7.31 (m, 1H), 4.36 (q, J = 7.2 Hz, 2H), 1.33 ppm (t, 
J = 7.1 Hz, 3H); 13C NMR (101 MHz, DMSO-d6): δ = 178.6, 162.3, 142.2, 142.0, 136.8, 134.4, 
132.7, 131.7, 130.1, 127.0, 124.7, 123.3, 117.3, 117.1, 111.8, 111.6, 62.0, 13.8 ppm; HR-ESI-MS: 
m/z = 552.9437([M + H]+, calcd. for C19H1479BrClF3N2O5S+: 552.9442), 554.9413([M + H]+, 
calcd. for C19H1481BrClF3N2O5S+: 554.9412), 556.9384([M + H]+, calcd. for 
C19H1481Br37ClF3N2O5S+: 556.9392). 
 
Br
H
NSN
H
OO
OEt
O
Cl
CF3
O
 169 
Ethyl 2-(5-Bromo-6-(N-(4-chloro-3-(trifluoromethyl)phenyl)sulfamoyl)-1H-indol-3-
yl)acetate (SI-10) 
 
To a suspension of 75 (100 mg, 181 µmol) in TFA (332 µL, 4.3 mmol, 24.0 eq.) at 0 °C, 
triethylsilane (346 µL, 2.2 mmol, 12.0 eq.) was added. The mixture was stirred at rt for 6 h, and the 
TFA was co-evaporated with toluene (5 mL). Purification by flash column chromatography (SiO2; 
cyclohexane/EtOAc 5:1) afforded SI-10 (56 mg, 58%) as an off-white amorphous solid. 
1H NMR (400 MHz, CD3OD): δ = 8.26 (s, 1H), 7.91 (s, 1H), 7.55 (d, J = 2.0 Hz, 1H), 7.47 (s, 1H), 
7.39–7.30 (m, 2H), 4.12 (q, J = 7.2 Hz, 2H), 3.74 (s, 2H), 1.21 ppm (t, J = 7.1 Hz, 3H); 13C NMR 
(151 MHz, DMSO-d6): δ = 171.1, 137.1, 133.4, 132.7, 131.5, 130.5, 128.3, 127.1 (q, J = 30.8 Hz), 
125.2, 124.3, 122.8, 122.4 (q, J = 273.1 Hz), 116.8 (q, J = 5.5 Hz), 116.5, 107.9, 106.8, 60.2, 30.2, 
14.0 ppm; 19F NMR (565 MHz, DMSO) δ -61.77 ppm; HR-ESI-MS: m/z = 538.9656([M + H]+, 
calcd. for C19H1679BrClF3N2O4S+: 538.9649). 
 
Ethyl 2-(5-Bromo-6-(N-(4-chloro-3-(trifluoromethyl)phenyl)-N-
(cyclopropanecarbonyl)sulfamoyl)-1-(cyclopropanecarbonyl)-1H-indol-3-yl)-2-oxoacetate 
(SI-11) 
 
To a solution of 75 (20 mg, 36 µmol) and Et3N (19 µL, 108 µmol, 1.2 eq.) in CH2Cl2 (1 mL) under 
an argon atmosphere, DMAP (0.1 mg, 2 mol%) was added. The solution was cooled to 0 °C and 
cyclopropyl acyl chloride (4 µL, 43 µmol, 1.2 eq.) was added. After stirring for 10 min at 0 °C and 
16 h at rt, only partial conversion was observed, so a further 3.0 eq. of Et3N and 10.0 eq. of 
cyclopropyl acyl chloride were added, and the mixture was stirred for a further 8 h. EtOAc was 
added (10 mL), and the mixture was washed with brine (1 x 5 mL). The organic layer was dried 
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over MgSO4, filtered, and concentrated under reduced pressure. Purification by flash master 
chromatography (SiO2; EtOAc in cyclohexane 0 ® 50%) afforded SI-11 (13 mg). 
1H NMR (400 MHz, CDCl3): δ = 9.37 (s, 1H), 9.24 (s, 1H), 8.80 (s, 1H), 7.93 (d, J = 2.5 Hz, 1H), 
7.76 (dd, J = 8.5, 2.5 Hz, 1H), 7.63 (d, J = 8.5 Hz, 1H), 4.46 (q, J = 7.1 Hz, 2H), 2.41–2.31 (m, 
1H), 1.52–1.41 (m, 4H), 1.35–1.21 (m, 4H), 1.09–1.01 (m, 2H), 0.88–0.78 (m, 2H) ppm; ESI-MS: 
m/z = 689.0 ([M + H]+, calcd. for C27H22N2O779BrClF3S+: 689.0), 691.0 ([M + H]+, calcd. for 
C27H22N2O781BrClF3S+: 691.0), 693.0 ([M + H]+, calcd. for C27H22N2O781Br37ClF3S+: 693.0). 
 
Ethyl 2-(5-Bromo-6-(N-(4-chloro-3-(trifluoromethyl)phenyl)-N-
(cyclopropanecarbonyl)sulfamoyl)-1-(cyclopropanecarbonyl)-1H-indol-3-yl)acetate (SI-12) 
 
To a suspension of SI-11 (20 mg, 32 µmol) in TFA (59 µL, 772 µmol, 24.0 eq.) at 0 °C, 
triethylsilane (62 µL, 386 µmol, 12.0 eq.) was added. The mixture was stirred at rt for 6 h, and the 
TFA was co-evaporated with toluene (5 mL). Purification by flash master chromatography (SiO2; 
EtOAc in cyclohexane 0 ® 90%) afforded SI-12 (3 mg, 14%) as an off-white amorphous solid. 
1H NMR (400 MHz, CDCl3): δ = 8.77 (br. s, 1H), 8.34 (s, 1H), 7.93 (d, J = 2.7 Hz, 2H), 7.73 (dd, 
J = 8.4, 2.3 Hz, 1H), 7.60 (d, J = 8.4 Hz, 1H), 7.37 (s, 1H), 4.20 (q, J = 7.1 Hz, 2H), 3.73 (s, 2H), 
1.58–1.50 (m, 1H), 1.29 (t, J = 7.1 Hz, 3H), 1.09–0.99 (m, 2H), 0.87–0.78 ppm (m, 2H); ESI-MS: 
m/z = 675.0 ([M + H]+, calcd. for C27H24N2O679BrClF3S+: 675.0), 677.0 ([M + H]+, calcd. for 
C27H24N2O681BrClF3S+: 677.0), 679.0 ([M + H]+, calcd. for C27H24N2O681Br37ClF3S+: 679.0). 
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tert-Butyl (1-(5-Bromo-6-(N-(4-chloro-3-(trifluoromethyl)phenyl)sulfamoyl)-1-
(cyclopropanecarbonyl)-1H-indol-3-yl)-2-oxo-7,10,13-trioxa-3-azahexadecan-16-
yl)carbamate (SI-13) 
 
To a solution of SI-12 (15 mg, 25 µmol, but SI-10 should have been used instead) in 
THF/MeOH/H2O 2:1:1 (1 mL), LiOH (3 mg, 74 µmol, 3.0 eq.) was added. The mixture was stirred 
at rt for 4 h, concentrated under reduced pressure, and dried in vacuo. The hydrolysis product SI-
14 was used in the next step without further purification. 
To a solution of crude acid SI-14 in CH2Cl2 (1 mL), EDC×H2O (10 mg, 59 µmol, 1.5 eq.) and 
HOBt×H2O (1.5 mg, 10 µmol, 0.3 eq.) were successively added. After 10 min pre-activation of the 
acid, a solution of 91 (14 mg, 43 µmol, 1.1 eq.) in CH2Cl2 (500 µL) was added, followed by DIPEA 
(14 µL, 79 µmol, 2.0 eq.). The solution was stirred at rt for 16 h and diluted with EtOAc (5 mL). 
The organic layer was washed with NaHCO3 (1 x 2 mL), an aq. 1 M HCl solution (1 x 2 mL), and 
brine (1 x 2 mL). The organic layer was dried over MgSO4, filtered, and concentrated under reduced 
pressure and dried in vacuo. The crude product was used in the next step without further 
purification.  
To a solution of crude 92 and DIPEA (14 µL, 77 µmol, 2.0 eq.) in CH2Cl2 (1 mL) under an argon 
atmosphere, DMAP (0.1 mg, 2 mol%) was added. The solution was cooled to 0 °C, and a solution 
of cyclopropyl acyl chloride (4 µL, 43 µmol, 1.1 eq.) in CH2Cl2 (500 µmol) was added slowly. 
After stirring for 10 min at 0 °C and 2 h at rt, EtOAc was added (5 mL), and the organic layer was 
washed with an aq. 1 M HCl solution (1 x 2 mL), sat. aq. NaHCO3 (1 x 2 mL), and brine (1 x 2 mL). 
The organic layer was dried over MgSO4, filtered, and concentrated. Purification preparative HPLC 
afforded the TFA salt of SI-13 (17 mg, 45%) as a white powder. 
1H NMR (400 MHz, CD3OD): δ = 9.24 (s, 1H), 8.18 (s, 1H), 8.00 (s, 1H), 7.54 (d, J = 2.1 Hz, 1H), 
7.39–7.35 (m, 2H), 3.66–3.61 (m, 4H), 3.61–3.40 (m, 10H), 3.16–3.06 (m, 4H), 2.56–2.48 (m, 1H), 
1.80–1.63 (m, 4H), 1.41 (s, 9H), 1.27–1.24 (m, 2H), 1.22–1.13 ppm (m, 2H); HR-ESI-MS: m/z = 
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881.1795([M + H]+, calcd. for C36H4679Br35ClF3N4O9S+: 881.1804), 883.1768([M + H]+, calcd. 
for C36H4679Br37ClF3N4O9S+: 883.1775), 885.2 ([M + H]+, calcd. for C36H4681Br37ClF3N4O9S+: 
885.2). 
 
N-(3-(2-(2-(3-Aminopropoxy)ethoxy)ethoxy)propyl)-2-(5-bromo-6-(N-(4-chloro-3-
(trifluoromethyl)phenyl)sulfamoyl)-1-(cyclopropanecarbonyl)-1H-indol-3-yl)acetamide (93) 
 
To a solution of SI-13 (17 mg, 19 µmol) in CH2Cl2 (1 mL), TFA (7 µL, 96 µmol, 5.0 eq.) was 
added. The solution was stirred for 1 h at rt and the solvent co-evaporated with toluene. Purification 
by preparative HPLC afforded the TFA salt of 93 (10 mg, 58%) as a white amorphous solid. 
1H NMR (500 MHz, CD3OD): δ = 9.26 (s, 1H), 8.20 (s, 1H), 8.02 (s, 1H), 7.55 (d, J = 2.0 Hz, 1H), 
7.42–7.36 (m, 2H), 3.65 (s, 2H), 3.59 (t, J = 5.5 Hz, 2H), 3.57–3.53 (m, 6H), 3.50–3.46 (m, 2H), 
3.43 (t, J = 6.0 Hz, 2H), 3.27 (t, J = 6.9 Hz, 2H), 3.02 (t, J = 6.3 Hz, 2H), 2.54 (ddd, J = 12.3, 8.0, 
4.5 Hz, 1H), 1.83 (dt, J = 11.9, 6.0 Hz, 2H), 1.73 (dt, J = 12.9, 6.4 Hz, 2H), 1.30–1.24 (m, 2H), 
1.18 ppm (dt, J = 11.4, 3.7 Hz, 2H); HR-ESI-MS: m/z = 781.1291([M + H]+, calcd. for 
C31H3879BrClF3N4O7S+: 781.1280), 783.1257([M + H]+, calcd. for C31H3881BrClF3N4O7S+: 
783.1259), 785.1237 ([M + H]+, calcd. for C31H3881Br37ClF3N4O7S+: 785.1230). 
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v. Synthesis of 2nd Generation Control Probe for Pull-Down 
Ethyl 2-(5-Bromo-6-(N-(3,5-difluorophenyl)sulfamoyl)-1H-indol-3-yl)-2-oxoacetate (SI-15) 
 
Oxoacetate SI-15 was prepared following the procedure employed in the synthesis of 75, using 95 
(140 mg, 361 µmol). Purification by flash column chromatography (SiO2; cyclohexane/EtOAc 4:1 
® 2:3) afforded SI-15 (126 mg, 72%) as an off-white amorphous solid. 
1H NMR (600 MHz, DMSO-d6): δ = 12.80 (d, J = 2.9 Hz, 1H), 11.23 (s, 1H), 8.73 (d, J = 3.3 Hz, 
1H), 8.46 (s, 1H), 8.43 (s, 1H), 6.83 (tt, J = 9.2, 2.2 Hz, 1H), 6.78–6.71 (m, 2H), 4.35 (q, J = 7.1 Hz, 
2H), 1.33 ppm (t, J = 7.1 Hz, 3H); 13C NMR (151 MHz, DMSO-d6): δ = 178.7, 162.7 (dd, J = 
245.0, 15.5 Hz), 162.5, 142.3, 140.1 (t, J = 13.5 Hz), 134.4, 131.8, 130.2, 127.1, 117.5, 111.9, 
111.8, 101.6–101.1 (m), 98.83 (t, J = 26.1 Hz), 62.1, 13.9 ppm; 19F NMR (565 MHz, DMSO-d6): 
δ = -108.22 ppm; HR-ESI-MS: m/z = 486.9767([M + H]+, calcd. for C18H1479BrF2N2O5S+: 
486.97694); 488.97455([M + H]+, calcd. for C18H1481BrF2N2O5S+: 488.97489). 
 
Ethyl 2-(5-Bromo-1-(cyclopropanecarbonyl)-6-(N-(3,5-difluorophenyl)sulfamoyl)-1H-indol-
3-yl)acetate (SI-16) 
 
Indole ethyl acetate SI-16 was prepared following the procedure employed in the synthesis of 90, 
using SI-15 (185 mg, 380 µmol). Purification by flash master chromatography (SiO2; MeOH in 
CH2Cl2 0 ® 17.5%) afforded SI-16 (105 mg, 58%) as an off-white amorphous solid. 
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1H NMR (500 MHz, DMSO-d6): δ = 11.64 (d, J = 1.9 Hz, 1H), 11.02 (s, 1H), 8.28 (s, 1H), 7.94 (s, 
1H), 7.62 (d, J = 2.5 Hz, 1H), 6.91–6.68 (m, 3H), 4.06 (q, J = 7.1 Hz, 2H), 3.77 (s, 2H), 1.17 ppm 
(t, J = 7.1 Hz, 3H); ESI-MS: m/z = 475.0130([M + H]+, calcd. for C18H18BrF2N2O4S+: 475.0139). 
 
tert-Butyl (1-(5-Bromo-6-(N-(3,5-difluorophenyl)sulfamoyl)-1H-indol-3-yl)-2-oxo-7,10,13-
trioxa-3-azahexadecan-16-yl)carbamate (SI-17) 
 
Acid SI-18 was prepared following the procedure employed in the synthesis of SI-14 using SI-16 
(48 mg, 101 µmol). The crude product was used in the next step without further purification.  
To a solution of crude SI-18 (29 mg, 39 µmol) in DMF (1 mL), EDC×H2O (18 mg, 96 µmol, 1.5 eq.) 
and HOBt×H2O (3 mg, 16 µmol, 0.3 eq.) were successively added. After 10 min pre-activation of 
the acid, a solution of 91 (23 mg, 70 µmol, 1.1 eq.) in CH2Cl2 (500 µL) was added, followed by 
DIPEA (28 µL, 160 µmol, 2.0 eq.). The solution was stirred at rt for 4 h, concentrated in vacuo, and 
diluted with EtOAc (5 mL). The organic layer was washed with NaHCO3 (1 x 2 mL), an aq. 1 M 
HCl solution (1 x 2 mL), and brine (1 x 2 mL). The organic layer was dried over MgSO4, filtered, 
concentrated under reduced pressure, and dried in vacuo. Crude product SI-17 was used in the next 
step without further purification.  
1H NMR (600 MHz, CDCl3): δ = 8.21 (s, 1H), 7.86 (s, 1H), 7.37 (s, 1H), 6.74 (dd, J = 7.9, 1.8 Hz, 
2H), 6.42 (t, J = 8.8 Hz, 1H), 3.63 (s, 2H), 3.61–3.18 (m, 16H), 1.81–1.71 (m, 2H), 1.71–1.62 (m, 
2H), 1.44 ppm (s, 9H); 19F NMR (565 MHz, CDCl3): δ = -108.05 ppm; HR-ESI-MS: m/z = 
747.1869([M + H]+, calcd. for C31H4279BrF2N4O8S+: 747.1869), 749.1847([M + H]+, calcd. for 
C31H4281BrF2N4O8S+: 749.1849). 
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N-(3-(2-(2-(3-aminopropoxy)ethoxy)ethoxy)propyl)-2-(5-bromo-1-(cyclopropanecarbonyl)-
6-(N-(3,5-difluorophenyl)sulfamoyl)-1H-indol-3-yl)acetamide (94) 
 
Cyclopropyl amide SI-19 was prepared following the procedure employed in the synthesis of SI-
13, using SI-17 (30 mg, 40 µmol). The crude product was used without further purification in the 
next step.  
Boc-deprotection of SI-19 was accomplished following the procedure employed in the synthesis of 
93. Purification by preparative HPLC afforded the TFA salt of 94 (10 mg, 72%) as a white 
amorphous solid.  
1H NMR (500 MHz, CD3OD): δ = 9.27 (s, 1H), 8.20 (s, 1H), 8.02 (s, 1H), 6.79–6.70 (m, 2H), 6.52 
(tt, J = 9.1, 2.3 Hz, 1H), 3.66 (s, 2H), 3.59 (t, J = 5.5 Hz, 2H), 3.58–3.53 (m, 5H), 3.50–3.46 (m, 
2H), 3.43 (t, J = 6.0 Hz, 2H), 3.27 (t, J = 6.9 Hz, 2H), 3.02 (t, J = 6.3 Hz, 2H), 2.59–2.50 (m, 1H), 
1.87–1.80 (m, 2H), 1.79–1.71 (m, 2H), 1.31–1.25 (m, 3H), 1.22–1.14 ppm (m, 2H); HR-ESI-MS: 
m/z = 715.1609([M + H]+, calcd. for C30H3879BrF2N4O7S+: 715.1607), 717.1585([M + H]+, calcd. 
for C30H3881BrF2N4O7S+: 717.1587). 
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vi. C3-Functionalization of Indoles 
tert-Butyl (E)-3-(5-Bromo-6-(N-(4-chloro-3-(trifluoromethyl)phenyl)sulfamoyl)-1H-indol-3-
yl)acrylate (74) 
 
To a mixture of 17 (50 mg, 110 µmol), tert-butyl acrylate (32 µL, 200 µmol, 2.0 eq.), and Cu(OAc)2 
(36 mg, 198 µmol, 1.8 eq.) in DMF/DMSO (1.5 mL, 9:1) under an argon atmosphere, Pd(OAc)2 
(2.5 mg, 11 µmol, 10 mol%) was added. The mixture was stirred at 70 °C for 18 h, cooled to rt, 
partitioned between water and EtOAc (10 mL, 1:1), and filtered through a pad of Celite®. The 
organic layer was washed with brine (1 x 5 mL), dried over MgSO4, filtered, and concentrated under 
reduced pressure. Purification by flash column chromatography (SiO2; CH2Cl2/MeOH 100:0 ® 
99.5:0.5 ® 99:1) afforded 74 (20 mg, 31%) as an off-white amorphous solid. 
1H NMR (400 MHz, CDCl3): δ = 8.97 (s, 1H), 8.19 (d, J = 5.8 Hz, 2H), 7.70 (d, J = 16.1 Hz, 1H), 
7.65 (d, J = 2.8 Hz, 1H), 7.53 (d, J = 2.4 Hz, 1H), 7.44 (s, 1H), 7.32–7.26 (m, 2H), 6.33 (d, J = 
16.1 Hz, 1H), 1.55 ppm (s, 9H); HR-ESI-MS: m/z = 578.9962([M + H]+, calcd. for 
C22H20BrClF3N2O4S+: 578.9962). 
 
tert-Butyl (E)-3-(5-Bromo-1H-indol-3-yl)acrylate (77)[107] 
 
Indole acrylate 77 was prepared following the procedure employed in the synthesis of 74, using 5-
bromoindole (76, 1.000 g, 5.1 mmol) in DMF/DMSO (12 mL, 9:1). Purification by flash column 
chromatography (SiO2; cyclohexane/EtOAc 95:5® 9:1) afforded 77 (882 mg, 54%) as an off-white 
amorphous solid. 
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1H NMR (600 MHz, CDCl3): δ = 8.55 (br. s, 1H), 8.04 (s, 1H), 7.75 (d, J = 16.0 Hz, 1H), 7.45 (s, 
1H), 7.36 (d, J = 8.6 Hz, 1H), 7.28 (d, J = 8.6 Hz, 1H), 6.34 (d, J = 16.0 Hz, 1H), 1.56 ppm (s, 9H); 
13C NMR (151 MHz, CDCl3): δ = 167.5, 136.4, 135.8, 129.1, 127.1, 126.3, 123.3, 116.4, 114.9, 
113.5, 113.2, 80.3, 28.5 ppm; HR-ESI-MS: m/z = 322.0433([M + H]+, calcd. for C15H1779BrNO2+: 
322.0437), 324.0413([M + H]+, calcd. for C15H1781BrNO2+: 324.04167). 
 
Ethyl 2-(5-Bromo-1H-indol-3-yl)-2-oxoacetate (78)[169]  
 
To a solution of 5-bromoindole (1.000 g, 5.1 mmol) in Et2O (7.5 mL) at 0 °C under an argon 
atmosphere, oxalyl chloride (878 µL, 10.2 mmol, 2.0 eq.) was added. The mixture was stirred at rt 
for 4 h concentrated and concentrated under reduced pressure. EtOH (7.5 mL) was added and the 
mixture was stirred for a further 1 h and concentrated under reduced pressure. The residue was 
dissolved in EtOAc (100 mL), washed with brine (100 mL), dried over MgSO4, and concentrated 
under reduced pressure. Purification by flash chromatography (SiO2; cyclohexane/EtOAc 4:1 ® 
2:3) afforded 78 (1.300 g, 86%) as a light-brown amorphous solid  
1H NMR (400 MHz, CD3OD): δ = 8.45 (s, 1H), 8.43–8.40 (m, 1H), 7.44–7.41 (m, 2H), 4.41 (q, J = 
7.1 Hz, 2H), 1.42 ppm (t, J = 7.1 Hz, 3H); 13C NMR (151 MHz, CD3OD): δ = 173.0, 141.0, 140.0, 
132.9, 129.5, 119.5, 108.5, 62.0, 52.9, 39.5, 38.6, 14.5 ppm; HR-ESI-MS: m/z = 
295.9926([M + H]+, calcd. for C12H1179BrNO3+: 295.9917), 297.9905([M + H]+, calcd. for 
C12H1181BrNO3+: 297.9896). 
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Ethyl 2-(5-Bromoindolin-3-yl)acetate (79) 
 
To a suspension of 78 (1.044 g, 3.5 mmol) in TFA (6.5 mL, 85 µmol, 24.0 eq.) at 0 °C, Et3SiH 
(6.8 mL, 42 mmol, 12.0 eq.) was added. The mixture was stirred for 6 h and the TFA co-evaporated 
with toluene. The product was purified by flash column chromatography (SiO2; 
cyclohexane/EtOAc 9:1  ® 5:1) to afford 79 (900 mg, 90%) as a thick brownish oil. 
1H NMR (600 MHz, MeOD): δ = 7.57 (s, 1H), 7.48 (dd, J = 8.4, 1.6 Hz, 1H), 7.17 (d, J = 8.4 Hz, 
1H), 4.21–4.11 (m, 2H), 4.00 (dd, J = 11.0, 8.7 Hz, 1H), 3.94–3.86 (m, 1H), 3.56 (dd, J = 11.0, 
6.5 Hz, 1H), 2.92 (dd, J = 16.9, 5.4 Hz, 1H), 2.73 (dd, J = 16.9, 8.1 Hz, 1H), 1.25 ppm (t, J = 7.1 Hz, 
3H); 13C NMR (151 MHz, MeOD): δ = 173.0, 141.0, 140.0, 132.9, 129.5, 119.5, 108.5, 62.0, 52.9, 
39.5, 38.6, 14.5 ppm; ESI-MS: m/z = 284.0([M + H]+, calcd. for C12H1579BrNO2+: 284.0), 
286.0([M + H]+, calcd. for C12H1581BrNO2+: 286.0). 
 
Ethyl 2-(5-Bromo-1-(cyclopropanecarbonyl)indolin-3-yl)acetate (80) 
 
To a solution of 79 (900 mg, 3.2 mmol) and Et3N (1.7 mL, 9.5 mmol, 3.0 eq.) in CH2Cl2 (7 mL) 
under an argon atmosphere, DMAP (7.7 mg, 63 µmol, 2 mol%) was added. The solution was cooled 
to 0 °C, and cyclopropyl acyl chloride (323 µL, 3.5 mmol, 1.1 eq.) was added. The mixture was 
stirred at 0 °C for 10 min and at rt for 2 h. EtOAc was added (50 mL), and the mixture was washed 
with brine (1 x 30 mL). The organic layer was dried over Na2SO4, filtered, and concentrated under 
reduced pressure. Purification by flash column chromatography (SiO2; pentane/CH2Cl2 1:1 ® 9:1) 
afforded 80 (775 mg, 70%) as an off-white amorphous solid. 
1H NMR (400 MHz, CDCl3): δ = 8.05 (br. s, 1H), 7.31 (dd, J = 8.6, 2.0 Hz, 1H), 7.27 (s, 1H), 4.62–
4.46 (m, 1H), 4.27–4.13 (m, 2H), 3.98 (dd, J = 10.3, 6.1 Hz, 1H), 3.90–3.75 (m, 1H), 2.81 (dd, J = 
16.6, 4.6 Hz, 1H), 2.59 (dd, J = 16.6, 9.8 Hz, 1H), 1.82–1.66 (m, 1H), 1.28 (t, J = 7.1 Hz, 3H), 
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1.15–1.07 (m, 2H), 0.94–0.86 ppm (m, 2H); 13C NMR (101 MHz, CDCl3): δ = 172.06, 171.64, 
142.32, 135.48, 131.34, 126.96, 118.58, 115.88, 61.13, 54.77, 39.97, 36.40, 14.36, 13.74, 8.70, 
8.62 ppm; HR-ESI-MS: m/z = 352.0551([M + H]+, calcd. for C16H1979BrNO3+: 352.0543), 
354.0530([M + H]+, calcd. for C16H1981BrNO3+: 354.0522). 
 
(5-Bromo-3-(2-hydroxyethyl)indolin-1-yl)(cyclopropyl)methanone (81) 
 
To a solution of 80 (111 mg, 315 µmol) in anhydrous Et2O (1 mL) at 0 °C under an argon 
atmosphere, MeOH (2 drops) and LiBH4 (2 M in THF, 630 µL, 1.3 mmol, 4.0 eq) were added 
dropwise. The mixture was stirred for 2 h at rt, cooled to 0 °C, and quenched via slow addition of 
MeOH (1.6 mL), followed by careful addition of solid NH4Cl (157 mg) in small portions. The 
resulting mixture was stirred for 1 h at rt, and the solvent was removed under reduced pressure. The 
mixture was re-suspended in EtOAc (30 mL) and washed with brine (1 x 20 mL). The organic layer 
was dried over MgSO4, filtered, concentrated under reduced pressure, and dried in vacuo. The crude 
product was used without further purification in the next step. 
 
(5-Bromo-3-(2-((tert-butyldimethylsilyl)oxy)ethyl)indolin-1-yl)(cyclopropyl)methanone (82) 
 
To a solution of 81 (39 mg, 126 µmol) in DMF (1 mL) at 0 °C under an argon atmosphere, 
TBDMSCl (41 mg, 264 µmol, 2.1 eq.) and imidazole (18 mg, 264 mmol, 2.1 eq.) were added. The 
mixture was warmed to rt and stirred for 2 h. EtOAc (20 mL) was added, and the organic phase was 
washed with brine (2 x 10 mL). Purification by flash master chromatography (SiO2; EtOAc in 
cyclohexane 0 ® 100%) afforded 82 (42 mg, 80%) as an off-white amorphous solid. 
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1H NMR (400 MHz, CDCl3): δ = 8.06 (br. s, 1H), 7.32–7.23 (m, 2H), 4.39 (t, J = 9.6 Hz, 1H), 
4.12–3.94 (m, 1H), 3.76 (t, J = 5.9 Hz, 2H), 3.63–3.44 (m, 1H), 2.08–1.93 (m, 1H), 1.88–1.60 (m, 
2H), 1.14–1.07 (m, 2H), 0.90 (s, 9H), 0.88–0.83 (m, 2H), 0.07 ppm (d, J = 4.8 Hz, 6H); ESI-MS: 
m/z = 424.0([M + H]+, calcd. for C20H3179BrNO2Si+: 424.1), 426.0([M + H]+, calcd. for 
C20H3181BrNO2Si+: 426.1). 
 
2-(5-Bromo-1-(cyclopropanecarbonyl)indolin-3-yl)ethyl Acetate (83) 
 
A solution of 81 (40 mg, 129 µmol), Ac2O (14 µL, 142 µmol, 1.1 eq.), and DMAP (0.1 mg, 2 mol%) 
in pyridine (2 mL) under an argon atmosphere was stirred at rt for 16 h. The mixture was 
concentrated under reduced pressure, re-suspended in EtOAc (20 mL), and washed with an aq. 1 M 
HCl solution (10 mL). The organic layer was dried over MgSO4, filtered, and concentrated under 
reduced pressure. Purification by flash master chromatography (SiO2; EtOAc in cyclohexane 0 ® 
40%) afforded 83 (38 mg, 83%) as an off-white amorphous solid. 
1H NMR (400 MHz, CDCl3): δ = 8.12–7.92 (m, 1H), 7.29–7.20 (m, 2H), 4.38 (t, J = 9.0 Hz, 1H), 
4.25–4.07 (m, 2H), 3.95 (dd, J = 9.5, 6.0 Hz, 1H), 3.56–3.40 (m, 1H), 2.21–2.08 (m, 1H), 2.05 (s, 
3H), 1.95–1.81 (m, 1H), 1.79–1.62 (m, 1H), 1.16–1.02 (m, 2H), 0.95–0.81 ppm (m, 2H); ESI-MS: 
m/z = 352.0([M + H]+, calcd. for C16H1979BrNO3+: 352.1), 354.0([M + H]+, calcd. for 
C16H1981BrNO3+: 354.1). 
 
N
Br
O
O
O
 181 
7. LIST OF ABBREVIATIONS 
°C  degrees Celsius  
4EPB1 eukaryotic initiation factor 4E-binding protein 1 
ABL1 abelson murine leukemia viral oncogene homolog 1  
AC adenylate cyclase 
Ac acyl 
AFC Ac-LLY-7-amino-4-trifluoromethylcoumarin  
AMBRA activating molecule in BECN1-regulated autophagy protein 1 
AMPK 5’-AMP-activated protein kinase 
aq. aqueous 
Ar aryl 
ATG autophagy-related 
Bcl-2 B cell lymphoma 2  
Boc t-butyloxycarbonyl 
BSA bovine serum albumin 
calcd. calculated 
CAPN1 catalytic subunit of calpain-1 
CAS Chemical Abstracts Service 
cat. catalytic 
CETSA cellular thermal shift assay  
COMAS  Compound Management and Screening Center   
COMU (1-cyano-2-ethoxy-2-oxoethylidenaminooxy)dimethylamino-
morpholino- carbenium hexafluorophosphate 
CQ chloroquine 
CREB cAMP response element-binding protein  
DAG diacyl glycerol  
DARTS drug affinity responsive target stability  
DCC dicyclohexyl-carbodiimide  
DDQ ,3-dichloro-5,6-dicyano-1,4-benzoquinone  
DIPEA N,N-diisopropylethylamine 
DMAP 4-dimethylamino pyridine  
DMF  dimethyl formamide  
DMSO  dimethyl sulfoxide   
DSF differential scanning fluorimetry  
EDC 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide  
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eGFP enhanced green fluorescent protein  
EPAC exchange protein directly activated by cAMP 
equiv. equivalents 
ER endoplasmic reticulum 
FCG forward chemical genetics 
FDA Food and Drug Administration  
FP fluorescence polarization  
GABARAP gamma-aminobutyric acid receptor-associated protein 
GDH, GLUD glutamate dehydrogenase  
GEF guanine nucleotide exchange factor  
GFP green fluorescent protein  
GPCR G-protein coupled receptor 
HINT-1 histidine triad nucleotide binding protein 1  
HIP haploinsufficiency profiling  
HPLC  high performance liquid chromatography   
HR high resolution 
HT hydroxytryptamine 
Hz Hertz 
IC50 half maximal inhibitory concentration 
IGD in-gel digest 
IP3 inositol 1,4,5-trisphosphate 
J  coupling constant  
KG α-ketoglutarate  
LC liquid chromatography 
LC3 light chain 3 
LOPAC library of pharmaceutically active compounds  
MAPK mitogen-activated protein kinase  
MKK mitogen-activated protein kinase kinase 
MS mass spectrometry 
mTOR mammalian target of rapamycin  
NBS N-bromosuccinimide  
NHS N-hydroxysuccinimide  
NMM N-methyl-morpholine 
NMR  nuclear manetic resonance 
OBD on-bead digest 
PAGE polyacrylamide gel electrophoresis 
PBS phosphate-buffered saline 
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PE phosphatidylethanolamine  
PEG polyethylene glycol  
PHD prolyl hydroxylase 
PI3K phosphoinositide 3-kinase  
PI3P phosphatidylinositol 3-phosphate  
pin pinacol 
PIP2 phosphatidylinositol 4,5-bisphosphate 
PK pyruvate kinase 
PKA, PKB, and PKC protein kinase A, B, and C 
PLC phospholipase C 
PyBOP benzotriazol-1-yl-oxytripyrrolidinophosphonium 
hexafluorophosphate  
qPCR quantitative polymerase chain reaction  
RAF rapidly accelerated fibrosarcoma  
RAS rat sarcoma 
resp. respectively 
RHEB RAS homolog enriched in brain 
rt room temperature 
RTK receptor tyrosine kinase 
SAR structure–activity relationship 
SDS sodium dodecyl sulfate  
SEA Similarity Ensemble Approach  
SH3GLB1 endophilin-B1 
SILAC stable isotope labeling with amino acids in cell culture  
siRNA Small interfering RNA  
SIRT4 sirtuin 4 
SMM small-molecule modulator 
T3P propylphosphonic anhydride  
TBAF tetrabutylammonium fluoride  
TBDMS t-butyldimethylsilyl 
TBS tris-buffered saline 
TCEP tris(2-carboxyethyl)phosphine 
TCF/LEF T-cell factor/lymphoid enhancer factor  
TEAB triethylammonium bicarbonate 
TFA trifluoroacetic acid 
TFEB transcription factor EB  
THF  tetrahydrofuran  
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TMT10 neutron-encoded isobaric mass tagging reagents 
TPP thermal proteome profiling  
TSA thermal shift assay  
TSC tuberous sclerosis 
TXNL1 thioredoxin-like protein 1  
ULK1 unc-51 like autophagy activating kinase 1  
UVRAG UV radiation resistance-associated gene protein 
VCS valosin-containing protein  
VPS34 vacuolar protein sorting 34 (class III PI3K) 
WIPI WD repeat domain phosphoinositide-interacting protein 
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